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Menstruation and implantation are characterized by increased inflammatory mediator
expression, leukocyte infiltration and stromal oedema. While the sex steroids,
oestrogen and progesterone, are crucial to the control of endometrial function the
molecular mechanisms involved remain unclear. The NFkB pathway is involved in
the regulation of genes associated with the inflammatory and immune response.
Progesterone has been found to inhibit this pathway by several mechanisms but there
is currently little data regarding the role of the NFkB pathway in human
endometrium. The aims of this research project have been to investigate the NFkB
pathway, and mediators that interact with it, in endometrium. Additionally,
progesterone control of the pathway intermediates has been studied.
NFkB pathway intermediates were identified in endometrium and decidua. The
mRNA expression profiles of the inhibitory protein, IkBcc, and an upstream kinase,
TANK binding kinase 1, suggest that the pathway is activated during menstruation.
Additionally, intermediates involved in the NFkB activating pathway are
differentially regulated in first trimester decidua. The pathway that mediates
proinflammatory signalling (MEKK1-IKKP) to NFkB is downregulated in decidua
consistent with the local immunosuppression that occurs during pregnancy. In
contrast, intermediates involved in morphogenic signalling (NIK-IKKa) to NFkB are
increased. This suggests a role in the expression of molecules crucial to successful
pregnancy. The T47D cell line expresses high levels of progesterone receptor and
was used as a cell model to study the effects of progesterone on the NFkB pathway.
IkBcc mRNA expression was found to be increased by progesterone while other
pathway intermediates were unaffected by progesterone over the timecourse
investigated.
CD40 is a proinflammatory signalling molecule that activates NFkB. CD40 was
detected in the perivascular region of endometrium. Previously, it has been reported
that chemokine expression is upregulated in this region premenstrually and the
detection of CD40 in this area suggests a role in the control of inflammatory mediator
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expression during menstruation. Messenger RNA expression for CD40 and its
ligand, CD40L, was increased in decidua suggesting a role similar to that of NIK-
IKKa. Secretory leukocyte protease inhibitor (SLPI) is an anti-inflammatory and
antimicrobial molecule that also has inhibitory effects on the NFkR pathway. SLPI
was localized to the glandular epithelium of endometrium from the mid-late secretory
phase and was also detected in first trimester decidua. SLPI may provide
antimicrobial protection at the time of implantation and during pregnancy. The
detection of NFkB pathway intermediates, the CD40-CD40L system and SLPI in
human endometrium supports a role for interacting control mechanisms in the
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1.1 The Endometrium and Menstrual Cycle
The human endometrium is a dynamic tissue capable of supporting the implantation
and development of an embryo. In order to provide this support the tissue undergoes
a series of cyclical changes which prepare it for potential implantation. In the
absence of pregnancy the endometrium is shed during menstruation and then
regenerates during the next menstrual cycle. The endometrium consists of two layers,
the basalis and the functionalis. Morphological changes during the menstrual cycle
only occur in the functionalis and it is this layer which is shed during menstruation.
Regeneration of the endometrium occurs from the basalis after menstruation. This
sequential shedding, regeneration and differentiation is driven by the ovarian sex
steroids.
1.1.1 The Ovarian Cycle
Cyclical ovarian follicle development and hence, sex steroid production, occurs under
the control of the hypothalamic hormone, gonadotrophin releasing hormone, and the
pituitary gonadotrophins, follicle stimulating hormone (FSH) and luteinizing
hormone (LH) (Johnson and Everitt, 2000). At the beginning of each cycle there is
relaxation of inhibitory mechanisms allowing the increased secretion of FSH from
the pituitary. Under the influence of FSH a cohort of antral follicles begins to
undergo preovulatory development. One of the follicles will become dominant and
will eventually ovulate. This follicle begins to secrete oestrogens exerting an
inhibitory effect on the pituitary. As a result, FSH secretion decreases to a level that
will not support the growth of the other follicles. As the dominant follicle further
develops, oestrogen levels continue to rise. Once a threshold level is reached positive
feedback on the pituitary occurs resulting in the LH surge which is responsible for
ovulation. Under the control of LH the theca and granulosa cells of the follicle
luteinize forming the corpus luteum. It is the corpus luteum that is responsible for the
high levels of oestrogen and particularly, progesterone, in the luteal phase of the
cycle. Negative feedback upon the pituitary is maintained by these high
concentrations of sex steroids. In the absence of conception and embryonic signals,
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the corpus luteum degenerates and sex steroid production decreases. This relaxes the
negative inhibition allowing FSH secretion to increase and the cycle to recommence.
This cyclical production of oestrogen and then, progesterone, (Figure 1) by the
ovarian follicle and corpus luteum is reflected by changes to the morphology of the
endometrium (Johannisson, et al., 1982). These endometrial changes have now been
well documented: firstly, by Noyes et al (1950) and more recently by others (Buckley
and Fox, 1989; Strauss III and Gurpide, 1991). It should also be noted that the
leukocyte populations in endometrium undergo cyclical changes and have a role in
endometrial function (King, et al., 1998; Loke and King, 1995). This is discussed in
detail in section 1.2.1.
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Figure 1: Concentrations of sex steroids and pituitary gonadotrophins in the
circulation during the menstrual cycle (a). Oestradiol (E2) and progesterone (P4).
(b). Follicle stimulating hormone (FSH) and luteinizing hormone (LH). Data
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1.1.2 The Proliferative Phase
The proliferative phase of the menstrual cycle occurs under the influence of
increasing oestradiol levels from the developing follicle. The early proliferative phase
lasts from approximately day 4 to day 7 of a 28 day cycle and is characterized by the
regeneration of the endometrium after menstruation. The glands are narrow and
straight, the surface epithelium is thin and the stroma compact. During the mid and
late proliferative phase (day 8 to day 10; day 11 to day 13) there is continued growth
of glands and stroma with the glands becoming tortuous as ovulation approaches.
1.1.3 The Secretory Phase
After ovulation, under the influence of progesterone, proliferation ceases and there is
differentiation of the endometrium. The early secretory phase lasts from ovulation
until day 18. The first sign that ovulation has occurred is the appearance of
subnuclear vacuoles in the glandular epithelium (day 16). These vacuoles push the
nuclei to the centre of the cells resulting in the alignment of nuclei. This is
accompanied by increased tortuousity of the glands. In the mid secretory phase (day
19 to day 23) the secretory activity of the glands becomes apparent with maximal
secretion around day 20 and stromal oedema peaks around day 22/23. In the late
secretory phase (day 24 to day 28) there is differentiation of spiral arterioles.
Perivascular stromal cells become more apparent as their cytoplasm increases in
volume and their nuclei enlarge. These are predecidual cells and on day 25
predecidual change also begins under the surface epithelium forming a solid sheet of
tissue. This decidual change will occur throughout the endometrium in the event of
pregnancy. If pregnancy does not occur, glandular secretion becomes exhausted and
the glands have a saw-toothed appearance. Growth of the endometrium ceases and
dehydration results in shrinkage. Infiltration of leukocytes begins to occur around
day 26. Focal necrosis becomes apparent and menstruation begins (day 1).
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1.1.4 Mechanisms of menstruation
Menstruation occurs when the demise of the corpus luteum causes circulating levels
of oestradiol and progesterone to fall and involves the sloughing of the superficial
layer of the endometrium (Cameron, 1992). This occurs haphazardly: some areas are
shed while others are being repaired. Menstruation occurs only in humans, Old
World monkeys, anthropoid apes and two non-primate species, the elephant shrew
(Elephantus myuras jamesoni) and some bats (e.g. Glossophaga sorcinina). It is
believed that menstruation is necessary as a result of stromal changes (e.g. decidual
cell reaction, stromal oedema, vascular development, leukocyte infiltration) which, in
menstruating primates, occur in the secretory phase of the cycle, under the influence
of progesterone and regardless of whether a blastocyst is present. This may provide a
maternal protective mechanism which counteracts the aggressive implantation which
occurs in these species (Finn, 1987; Finn, 1996). Due to the terminal differentiation
of the stroma during the menstrual cycle menstruation must occur, in the absence of
pregnancy, in order to allow regeneration of the endometrium. Menstruation does not
occur in mammals with less aggressive implantation. For example, in rodents the
trophoblast adheres to the luminal epithelium but does not invade the endometrium.
The trophoblast phagocytoses the epithelial cells leaving the blastocyst inside the
endometrial stroma. Once this has happened the blastocyst becomes invasive and
stromal changes occur. It is thus unnecessary for these mammals to menstruate as the
stromal reaction occurs only in the presence of pregnancy. However, when a
hormone primed mouse uterus is stimulated with a drop of oil (mimicking the
trophoblast) and the progesterone source withdrawn, a menstruation-like response
occurs (Finn and Pope, 1984).
The mechanisms currently considered to be involved in menstruation were first
described by Markee (1940) in his experiments on the rhesus monkey. These
experiments involved the intraocular transplantation of endometrium allowing it to be
observed during menstruation. It was found that prior to menstruation regression of
the endometrium occurred. Striking changes were also noted in the endometrial
blood vessels. The arteries that supply the endometrium are straight when in the
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basalis region but become coiled when they enter the functionalis. As the secretory
phase of the menstrual cycle progressed the spiral arteries became increasingly coiled
until circulation slowed and stasis occurred due to the increased resistance
encountered in the vessels. About 4 to 24 hours premenstrually, vasoconstriction of
the spiral arteries was found to occur. This caused the functionalis to become anoxic
and resulted in bleeding. Leukocyte infiltration accompanied menstruation.
Vasoconstriction of the basal part of the arteries then occurred terminating bleeding.
The vascular changes found to be associated with menstruation have led to current
theories that vasoactive substances present in the endometrium are likely to be
involved in the menstrual process. Prostaglandins (PGs) are lipid mediators that are
produced from arachidonic acid via the cyclo-oxygenase enzymes, COX-1 and COX-
2. Lipid substances were first discovered in the menstrual fluid by Pickles (Pickles,
1957) and there is now much evidence suggesting a role for PGs in menstruation
(Baird, et al., 1996). First, PGE2, a vasodilator, and PGF2a , a vasoconstrictor, have
been detected in the menstrual fluid. The vasoconstrictive actions of PGF2a imply a
role in the vascular events that precede menstruation. The ratio of PGE2: PGF2a is
found to be increased in the menstrual fluid of women suffering from menorrhagia
(Cameron, et al., 1987; Rees, et al., 1984) and administration of COX inhibitors
reduces blood loss suggesting that aberrant expression of the vasodilator PGE2 causes
increased bleeding (Fraser, 1992). Second, in vitro culture studies suggest that in the
secretory phase of the menstrual cycle the endometrium has a greater capacity to
synthesize PGs although progesterone inhibits actual release (Abel and Baird, 1980).
As a result, when progesterone is withdrawn (i.e. premenstrually) endometrial
prostaglandin production reaches maximal levels. Finally, the prostaglandin
synthesizing and metabolizing enzymes (COX-2 and prostaglandin dehydrogenase;
PGDPI) have been found to be under hormonal control. Progesterone stimulates the
activity of PGDH thus increasing prostaglandin metabolism and activity is high in the
secretory phase (Casey, et al., 1980). Recently, progesterone has been found to
upregulate PGDFI expression at the transcriptional level (Greenland, et al., 2000).
This is consistent with the culture data described above. High levels of PGDH are
usual in first trimester decidua. However, when RU486 (an anti-progestogen) is
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administered to women PGDH expression falls, particularly around blood vessels
(Cheng, et al., 1993b). Expression of COX-2, while present in the glandular
epithelium throughout the menstrual cycle, is increased in the perivascular region
upon premenstrual progesterone withdrawal (Critchley, et al., 1999; Jones, et al.,
1997). While the epithelium is the major site of prostaglandin production in
endometrium (Lumsden, et al., 1984) it is the synthesis of prostaglandins in close
proximity to blood vessels that is likely to be most relevant to menstruation. A
simultaneous increase in COX-2 and decrease in PGDH expression upon
progesterone withdrawal is likely to result in increased PG production in the
proximity of the blood vessels.
More recently, studies on the role of vasoactive mediators in menstruation have
focused on a group of 21 amino acid peptides, the endothelins (Marsh, et al., 1996).
They are cleaved from precursor (pro- and preproendothelins) proteins and to date,
three endothelins have been identified, endothelin-1 (the most potent vasoconstrictor
known), 2 and 3. The endothelins act via two G-protein coupled receptors, ETA and
ETb. Endothelin-1, 2 and 3 mRNA (O'Reilly, et al., 1992) and protein (Cameron, et
al., 1993) have been detected throughout the menstrual cycle in human endometrium.
The proteins have been reported to be localized to the glandular and luminal
epithelium (Cameron, et al., 1993; Salamonsen, et al., 1992) with endothelin-1 also
present in the stroma and in some endothelial cells (Ohbuchi, et al., 1995;
Salamonsen, et al., 1992). Endothelin-1 protein (Ohbuchi, et al., 1995) and mRNA
(Economos, et al., 1992) levels have been found to increase in the premenstrual-
menstrual phase suggesting a role in menstruation. Also, the mRNA (Kubota, et al.,
1995; O'Reilly, et al., 1992) and protein (Collett, et al., 1996) for ETA and ETb have
been detected in endometrial samples. These studies have reported that the ratio of
ETa:ETb varies throughout the menstrual cycle with an increase in the expression of
ETb in the secretory and menstrual phases. ETA has been localized to the
endometrial stroma with maximal expression during the proliferative phase. ETb
immunoreactivity was found to increase in the glandular epithelium of the basalis and
the functionalis regions in the early secretory and late secretory phases, respectively.
The receptor was localized to both the epithelium and the stroma in the menstrual
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phase (Collett, et al., 1996). It has been suggested that the endothelins may act via the
ETb receptor to cause vasoconstriction during menstruation.
An alternative theory explaining the events surrounding menstruation involves the
production of matrix metalloproteinases (MMPs) ( Salamonsen, 1998; Salamonsen
and Woolley, 1999). There are several major subgroups of MMPs: the collagenases
(e.g. MMP-1), the gelatinases (MMP-2 and 9), the stromelysins (MMP-3, 10 and 11)
and the membrane-type MMPs. MMPs are secreted as inactive zymogens, which are
activated by proteases, and together, the MMPs are capable of degrading the
extracellular matrix. Tissue inhibitors of MMPs (TIMPs) are endogenous inhibitors
that act by forming 1:1 complexes with the MMP. The suggestion that MMPs are
involved in menstruation resulted from the observation that small lesions are present
in the luminal epithelium of endometrium prior to any blood loss. This is followed
by rapid degeneration of the functionalis region resulting in the exposure of open
blood vessels (Ludwig and Spornitz, 1991). Also, the basal lamina, which supports
decidualized cells and endothelium, degenerates prior to bleeding (Roberts, et al.,
1992). Expression of MMPs is consistent with a role in menstruation with increased
expression of proMMP-1 and proMMP-3 mRNA in the perimenstrual phase
(Hampton and Salamonsen, 1994). Another study reported similar upregulation of
mRNA for several MMPs (particularly MMP-1, MMP-3, MMP-9 and MMP-10)
during menstruation while TIMP-1 mRNA expression remained constant throughout
the menstrual cycle (Rodgers, et al., 1994). Additionally, progesterone withdrawal
has been found to increase MMP release in in vitro culture of endometrial stromal
cells (Lockwood, et al., 1998; Salamonsen, et al., 1997). No effect of progesterone
withdrawal was found on TIMP release suggesting that an increased ratio of
MMP:TIMP may be involved in menstruation (Salamonsen, et al., 1997). Increased
expression of MMPs as a result of progesterone withdrawal has also been reported in
a non-human primate model of menstruation (Brenner, et al., 1996). This study
suggested that in vivo progesterone withdrawal acts indirectly, via locally produced
cytokines, to upregulate MMPs. Various mediators such as tumour necrosis factor
a (TNFa), interleukin-1 (IL-1) and prostaglandins have been suggested as potential
regulators of MMP expression. The infiltrating lymphoid cells which are present
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prior to menstruation have been suggested to be one source of these mediators
(Salamonsen and Woolley, 1996). Although MMPs are clearly involved in the tissue
breakdown involved in menstruation their activation is likely to be several steps
downstream of the initial vasoconstriction events reported by Markee.
1.1.5 Decidualization and Implantation
Successful implantation requires the simultaneous development of the endometrium
to a receptive state and the embryo to blastocyst stage. The endometrium is
receptive to implantation only for a few days in each menstrual cycle (the
implantation window). This time is between day 20 and 24 in the human (Harper,
1992). The implantation window falls in the mid-late secretory phase (section 1.1.3)
and at this time the endometrium is characterized by the presence of pinopodes on the
luminal epithelial cells. These are thought to withdraw fluid from the uterine lumen
allowing close contact between the epithelial cells and the developing embryo
(Martel, et al., 1989). Nuclear channel systems and giant mitochondria are also
apparent in the glandular and luminal epithelium around this time. The function of
these features is unclear but involvement in secretory events and energy provision has
been suggested (Li, et al., 1994). As detailed in section 1.1.3, the transformation of
endometrium to decidua begins in the secretory phase of the cycle under the
influence of progesterone. This differentiation of the endometrium is critical to the
establishment of pregnancy and there are characteristic changes in all compartments
of the endometrium (King, 2000; Loke and King, 1995). First, secretion from the
glandular epithelium is maximal during the implantation window with production of
various hormonally regulated proteins including progesterone-associated endometrial
protein (also known as glycodelin, placental protein 14, lactoglobulin, a-2
microglobulin, pregnancy-associated a-2 globulin, a uterine protein) and albumin.
In decidua, the glands in the upper two thirds of the tissue become atrophied and are
non-secretory while those in the lower third continue secretory activity. Second, as
detailed above, the stroma also shows predecidual change that develops fully in the
event of implantation. This stromal differentiation begins around the spiral arterioles
and beneath the surface epithelium with the cells becoming plump and glycogen rich.
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Also, extracellular matrix (ECM) proteins are distributed around each stromal cell
with the decidual ECM being particularly rich in laminin and fibronectin. Stromal
cells are responsible for the secretion of al pregnancy-associated endometrial protein
(also known as placental protein 12, insulin-like growth factor binding protein-1) and
prolactin. The precise roles of these proteins, and those secreted by the glandular
epithelium, is unclear although immunosuppressive activities, regulation of
trophoblast growth and fetal effects have been suggested (Strauss III and Gurpide,
1991). Finally, increased coiling of the spiral arterioles begins in the secretory phase
and continues in decidua. Large granular lymphocytes are the main leukocyte
population in first trimester decidua and these are described in section 1.2.1. The
functions of decidua are not fully understood although it is thought that it may have a
role in controlling the invasion of trophoblast into the maternal tissue and also, in
regulating immune events during pregnancy.
After fertilization the zygote undergoes successive cleavage events forming a morula
which enters the uterine lumen around 72-96 hours post fertilization. The blastocyst
forms on day 5 and comprises an inner cell mass with an outer layer of
trophectoderm. Hatching from the zona pellucida occurs around 1-2 days prior to
penetration of the endometrium and at this time, the peripheral cytotrophoblast
differentiates into syncytiotrophoblast. Human chorionic gonadotrophin begins to be
produced by the embryo preventing the demise of the corpus luteum.
Implantation occurs in three stages: apposition, adhesion and invasion. The
apposition stage occurs when the hatched blastocyst is present in the uterine lumen
and in close, but not direct, contact with the luminal epithelium. Between days 6-7
postfertilization adhesion of the blastocyst to the uterine epithelium occurs. This
involves direct interaction of the trophectoderm with the epithelium. After this
attachment, the trophoblast invades the endometrium. The trophoblast cells penetrate
through the surface epithelium into the uterine stroma. Some of the cytotrophoblast
cells extend through the syncytiotrophoblast and invade the decidua. These cells fuse
forming the cytotrophoblast shell which surrounds the inner surface of the
implantation site and anchors the placenta to the decidua. The extravillous
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trophoblasts also invade the decidual spiral arterioles and become incorporated into
the vascular wall, changing its plasticity. This allows a continuous blood supply to
the fetus and isolates it from the pulsatility of the maternal circulation. (Aplin, 1991;
Edwards, 1995; Pijnenborg, et ah, 1981; Tabibzadeh and Babaknia, 1995).
Implantation clearly involves a tightly orchestrated series of events which requires
the controlled expression of a variety of molecules (Giudice, 1999; Simon, et ah,
1996; Tabibzadeh and Babaknia, 1995). First, prior to attachment to the endometrial
epithelium, signalling between the developing blastocyst and the endometrium is
necessary. This is likely to occur via soluble mediators. For example, leukaemia
inhibitory factor (LIF) is a cytokine that has been shown to be crucial for
implantation in mice. LIF expression is maximal in mouse endometrium on the day
of implantation (Bhatt, et al., 1991) and the LIF knockout mouse, while
demonstrating normal ovulation and fertilization, had failed implantation (Stewart, et
ah, 1992). In humans, LIF expression is also found to be maximal during the
implantation window with expression being primarily in the glandular epithelium at
this time (Charnock-Jones, et al., 1994). The precise role of LIF in human
implantation is unknown but involvement in blastocyst-endometrial communication
is likely and effects on trophoblast differentiation have been demonstrated
(Nachtigall, et al., 1996). The role of the IL-1 system in implantation will be
discussed in section 1.2.2.
Integrins are likely to be involved in the adhesion phase of implantation promoting
the formation of contacts between the endometrial epithelium and the trophectoderm.
The integrins are heterodimeric, transmembrane glycoproteins that have an
extracellular domain that binds extracellular matrix components (e.g. fibronectin,
laminin) and an intracellular domain that interacts with cytoskeletal proteins. The
integrins are composed of an a and |3 chain. The human endometrium, like other
tissues, has been found to constitutively express some integrins but also displays
several only during the implantation window (Lessey, et al., 1992). Expression of
a4(3i, av(33 and aiPi has been reported to correlate with the time of implantation
(Lessey, et al., 1994; Lessey, et al., 1992; Tabibzadeh, 1992). Indeed, aberrant
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integrin expression may be involved in infertility. Lack of avP3 expression has been
associated with both classical luteal phase defect (Lessey, et al., 1992) and
unexplained infertility (Lessey, et al., 1995).
The invasion of the endometrium by trophoblasts also involves the expression of
various integrins e.g. as cytotrophoblasts migrate through the endometrium there is a
switch from OC6P4 to otipi and aspi expression (this means that as the cytotrophoblast
moves into the decidua it has an increased capacity to bind to fibronectin, a major
component of decidualized stroma) (Burrows, et al., 1993; Damsky, et al., 1992). In
addition to this, trophoblasts secrete MMPs and serine proteases that are involved in
the tissue degradation that occurs during implantation. The invasive human
trophoblast has been found to secrete MMP9 and MMP2 (Shimonovitz, et al., 1994)
during the first trimester. Both of these MMPs degrade collagenase IV which is the
main component of the uterine basal membrane. Human decidua produces TIMPs, in
particular TIMP3, which are involved in the limitation of MMP action (as described
in section 1.1.4) and therefore, regulation of trophoblast invasiveness (Higuchi, et al.,
1995).
1.2 Inflammatory events in endometrium
Both implantation and menstruation are associated with inflammatory-like events
(Finn, 1986; Kelly, 1994). Leukocyte infiltration of the endometrium, increased
inflammatory mediator expression and oedema have been reported to occur during
these processes.
1.2.1 Leukocytes in endometrium
Leukocytes are present in endometrium throughout the menstrual cycle constituting
approximately 8.2% of the stromal cells in the proliferative phase with this figure
rising to 31.7% in first trimester decidua (Bulmer, et al., 1991). Lymphoid
aggregates are present in the basalis region of endometrium throughout the menstrual
cycle and contain T cells and B cells surrounded by a halo of macrophages. T cells
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are also found scattered in the endometrial stroma and in an intraepithelial location
while B cells are rarely found outwith lymphoid aggregates. Macrophages constitute
about 20% of the leukocytes present in endometrium and are present throughout the
cycle with a small increase premenstrually. A scavenger role during menstruation has
been suggested. In decidua macrophages are found at the implantation site often in
contact with extravillous trophoblast (Bulmer, et ah, 1988; Loke and King, 1995).
Large granulated lymphocytes (LGL; endometrial natural killer (NK) cells) are also
present in endometrium. These cells differ from classical NK cells in that they are
CD56++CD16" whereas classical NK cells are CD56"CD16+. The LGLs are present in
low numbers in the proliferative phase and increase in the mid secretory phase with
numbers peaking in the late secretory phase (i.e. they are present during the
implantation window). In pregnancy the cells constitute approximately 70% of the
leukocytes in first trimester decidua and are present until the 2nd trimester with
numbers subsequently declining (Loke and King, 1995). Proliferation of the LGLs
within the endometrium has been shown by investigation of the proliferation marker,
Ki67 (Kammerer, et ah, 1999), and migration from the circulation is also possible
(Marzusch, et al., 1993). Progesterone is crucial for the appearance of these cells as
in the absence of pregnancy the cells undergo apoptosis a few days prior to
menstruation. The function of uterine LGLs is unclear but may involve a role in
implantation and placentation (King, 2000; King, et al., 1998; Loke and King, 1995).
Prior to menstruation there is an influx of eosinophils (Jeziorska, et al., 1995) and
neutrophils (Poropatich, et al., 1987) into the endometrium and these cells are likely
to be involved in the tissue breakdown involved in menstruation. Figure 2 details the








Figure 2: Leukocyte populations in human endometrium (prol = proliferative phase;
sec = secretory phase) and first trimester decidua. Data and illustration adapted from
Loke and King, 1997.
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Although progesterone is crucial to the presence of LGLs in the endometrium and
progesterone withdrawal is involved in the infiltration of neutrophils and eosinophils
premenstrually it is likely that these effects are indirect as progesterone receptors
have not been detected in these cells (King, et ah, 1996). Instead it is likely that the
effects of progesterone and its subsequent withdrawal are mediated via locally
produced molecules.
1.2.2 Inflammatory mediator expression in endometrium
Chemokines are cytokines which have chemotactic activity. They have four
cysteines and two disulphide bonds (Figure 3) and are divided into two main groups
dependent on the position of their first two cysteines. CXC chemokines (a-
chemokines; first two cysteines separated by one amino acid) are chemoattractant
mainly for neutrophils although those that do not contain an N terminal glutamic
acid-leucine-arginine motif attract lymphocytes. In contrast, the CC chemokines ((3-
chemokines) attract monocytes, basophils, eosinophils and T-lymphocytes.
Interleukin-8 (IL-8), growth-related oncogene a (GROa), GRO(3 and GROy belong
to the CXC group while monocyte chemoattractant protein 1 (MCP1), macrophage
inflammatory protein la and 1(3 (MIPla/(3) and regulated upon activation, normal T
cell expressed and secreted (RANTES) are representative of the CC chemokines
(Luster, 1998; Rollins, 1997). Chemokines act via 7 transmembrane spanning G-
protein coupled receptors (Murphy, 1996).
26




IL-8, a representative CXC chemokine, is a potent neutrophil chemoattractant and
activator (Yoshimura, et al., 1987). It is produced by several cell types including
monocytes (Walz, et al., 1987), T lymphocytes (Gregory, et ah, 1988), fibroblasts
(Larsen, et al., 1989b), endothelial cells (Strieter, et al., 1988) and epithelial cells
(Elner, et al., 1990). In addition to a neutrophil chemotactic role IL-8 has been
implicated in T cell chemotaxis (Larsen, et al., 1989a), angiogenesis (Koch, et al.,
1992) and mitogenesis (Tuschil, et al., 1992; Yue, et al., 1994).
In a reproductive context IL-8 has been found to be produced by cultured endometrial
epithelial and stromal cells (Arici, et al., 1993), amniotic fluid (Laham, et al., 1993)
and choriodecidual cells (Kelly, et al., 1992). It is believed to be involved in the
mechanism of cervical ripening. IL-8 production is found to increase in the cervix at
the time of ripening (Kelly, et al., 1992; Sennstrom, et al., 1997) and, in synergy with
PGE2, is believed to be responsible for the recruitment of neutrophils (Colditz, 1990;
Rampart, et al., 1989). The entry of neutrophils into the cervix is thought to have a
role in the breakdown of collagen (via neutrophil collagenase) causing cervical
softening (Junqueira, et al., 1980). In endometrium a similar synergistic action
between IL-8 and PGE2 has been suggested. IL-8 has been reported to be present in
the endometrial glandular epithelium (Arici, et al., 1998) and in a perivascular
location (Critchley, et al., 1994; Jones, et al., 1997) although, more recently, the
mRNA has been localized mainly to the perivascular area (Milne, et al., 1999).
Progesterone control of IL-8 in endometrium is likely as culture studies have shown
that progesterone decreases IL-8 secretion by endometrial explants (Kelly, et al.,
1994). This is consistent with reports of increased expression of perivascular IL-8
premenstrually (Jones, et al., 1997) and in a progesterone withdrawal model
(Critchley, et al., 1999). The expression of COX-2 is also found to increase
perivascularly in the premenstrual phase (Jones, et al., 1997) and the expression of
these molecules is coincident with the influx of neutrophils reported prior to
menstruation.
MCP-1, a CC chemokine, is produced by several cell types including fibroblasts
(Yoshimura and Leonard, 1990), endothelial cells (Sica, et al., 1990), smooth muscle
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cells (Cushing, et al., 1990) and monocytes (Yoshimura, et al., 1989). It is
chemotactic mainly for monocytes (Rollins, 1991) but is also involved in T cell
(Carr, et al., 1994) and NK cell (Allavena, et al., 1994) chemotaxis and in basophil
activation (Bischoff, et al., 1992). Similar to IL-8, MCP-1 has been found to be
secreted by cultured endometrial epithelial and stromal cells (Arici, et al., 1995) and
is coexpressed with IL-8 and COX-2 in the endometrial perivascular cells (Jones, et
al., 1997). MCP-1 is also thought to be involved in premenstrual leukocyte
recruitment as expression increases in the perivascular region upon progesterone
withdrawal (Critchley, et al., 1999; Jones, et al., 1997). This is in keeping with
reports of progesterone mediated suppression of MCP-1 secretion in human
endometrial stromal cells (Arici, et al., 1999), choriodecidual cells and the T47D
breast cancer cell line (Kelly, et al., 1997).
In addition to the chemokines, many other cytokines have been shown to be
important in endometrial physiology (Tabibzadeh, 1991). The roles of the highly
pleiotropic cytokines, TNFa and IL-1, will be discussed with further descriptions of
inflammatory molecule expression in human endometrium shown in Table 1.
TNFa has wide ranging actions including control of the inflammatory response (Old,
1985), monocyte chemotaxis (Ming, et al., 1987) and angiogenic effects (Frater-
Schroder, et al., 1987). The expression of TNFa in endometrium has been described
by several groups. While it is clear that the endometrial glandular epithelium is the
major site of expression, the regulation of TNFa throughout the menstrual cycle is
controversial. First, Hunt et al (1992) reported both epithelial and stromal expression
of TNFa to increase during the proliferative phase, decrease in the early secretory
phase and then increase in the mid-late secretory phase. In contrast, Philippeaux et al
(1993) found weak expression in the glandular epithelium and arteries in the
proliferative phase with strong expression in the secretory phase. Tabibzadeh
(1995b) described increasing TNFa production throughout the cycle with a peak
during menstruation. Although there are differences between these results they have
all described high expression of TNFa in the late secretory phase. However, a recent
study has suggested that TNFa expression is low at the beginning and end of the
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menstrual cycle with maximal expression in the mid-late proliferative and early-mid
secretory phases (Tabibzadeh, et ah, 1999). Cell culture experiments have also
produced conflicting findings. It has been suggested that TNFa release from
epithelial cells derived from late proliferative endometrium is greater than from cells
derived from other cycle stages (Laird, et ah, 1996). However, a second study
reported that TNFa release was maximal from epithelial cells derived from late
secretory endometrium (Tabibzadeh, et al., 1999). Due to these disparate findings the
role of TNFa in endometrium is also unclear. Regulation of DNA synthesis in the
early proliferative phase (Hunt, 1993) and cell differentiation and tissue remodelling
during implantation (Terranova, et ah, 1995) have been suggested as possible
functions. Tabibzadeh (1996; 1995b) has suggested that the reported increase in
TNFa expression in the late secretory phase is consistent with a role in menstruation
due to the ability of the cytokine to induce apoptosis and compromise vascular
integrity. Steroid hormone control of TNFa expression has been described with
progesterone suppression of TNFa production reported in activated mouse
macrophages (Miller and Hunt, 1998) and in human endometrial epithelial cells
derived from the secretory phase of the cycle (Laird, et ah, 1996). Oestradiol
withdrawal has also been found to upregulate TNFamRNA expression in the
epithelial cells of a human endometrial cancer grown in nude mice (Tabibzadeh, et
ah, 1999).
The IL-1 system is comprised of IL-la and (3, IL-1 receptor antagonist (IL-lra) and
the two IL-1 receptors, type I and II (IL-lRtI and IL-lRtll; only IL-1 Rtl is
functional). IL-1 was originally thought to be a product of macrophages but it is now
clear that it is produced by many cell types including fibroblasts, endothelial cells and
smooth muscle cells (Ibelgaufts, 1994). Both forms of the IL-1 receptor can bind IL-
la and P while IL-lra binds only to IL-1 Rtl. The IL-1 system has been detected in
human endometrium and is thought to have potentially important roles in
implantation and menstruation. IL-ip has been detected in the endometrial
endothelium, isolated stromal cells (Simon, et ah, 1993a) and epithelium (Tabibzadeh
and Sun, 1992) with expression reported to increase in the secretory phase of the
cycle (Simon, et ah, 1993a). IL-1 Rtl is expressed by endometrial epithelial cells,
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particularly those of the luminal epithelium, with expression again increasing in the
secretory phase (Simon, et al., 1993a; Simon, et ah, 1993b)]. IL-lra is also expressed
by endometrial epithelial cells with highest expression in the luminal epithelium. In
contrast to IL-1 (3 and IL-lRtI, IL-lra expression is decreased in the secretory phase
(Simon, et al., 1995). The expression of both IL-1 and its receptor in the secretory
phase suggests a role in the mechanisms involved in implantation. In support of this,
IL-1 production by preimplantation embryos has been detected (Sheth, et al., 1991)
and the IL-1 system is present in early implantation sites (Simon, et al., 1994a).
Also, administration of human recombinant IL-1 ra to mice has been used to block
signal transduction via IL-lRtl. This was found to prevent attachment of embryos to
endometrium (Simon, et al., 1994b). In vitro IL-1 has also been found to stimulate
the production of other molecules involved in implantation such as LIF (Arici, et al.,
1995), IL-6 (Laird, et al., 1994) and PGE2 (Tabibzadeh, et al., 1990). In addition to
a role in implantation, the wide-ranging ability of IL-1 to induce expression of other
inflammatory mediators (e.g. IL-8, MCP-1, TNFa) along with stimulation of MMP
production is consistent with a role in menstruation.
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1.3 Regulation of inflammatory mediator expression in endometrium
The primary means of control of inflammatory mediator expression in endometrium
is via the effects of the steroid hormones. As described earlier (Figure 1) the
hormones, oestradiol and progesterone, are produced in a cyclical manner. The
hormones, in common with all steroids, act via binding to intracellular receptors
belonging to the steroid receptor superfamily. The receptors for both oestrogen (ER)
and progesterone (PR) belong to this family. In the absence of hormone the receptors
are inactive and are present in complexes containing other proteins such as heat
shock protein 90. In the event of hormone binding the receptor dissociates from the
complex and can bind to specific hormone response elements in DNA thus altering
gene expression. (Carson-Jurica, et al., 1990). The PR and the glucocorticoid
receptor (GR) bind to the same consensus sequences (glucocorticoid/progesterone
response element; GRE/PRE) and it is thought that, in the uterus, progesterone has
local immunosuppressive effects similar to the systemic effects of the
glucocorticoids. Also, nonconsensus sequences (negative GRE = nGRE; these differ
from typical GRE and have gene repressive function) exist which allow binding of
the PR or GR to suppress gene transcription. It should also be noted that, when
present in high concentrations, steroid hormones can act via non-genomic
mechanisms e.g. modulation of ion channel function (for review see Revelli, et al.
(1998)).
The progesterone receptor was first identified in the chick oviduct and mammalian
uterus in the 1970s (Leavitt and Blaha, 1972; Milgrom, et al., 1970; Sherman, et al.,
1970) and it is now apparent that the human progesterone receptor exists in two
forms, PRa and PRb (Horwitz and Alexander, 1983; Lessey, et al., 1983). Both
forms are transcribed from a single gene under the influence of separate promoters
(Kastner, et al., 1990). PRb is the larger isoform with 164 additional amino acids at
the N terminus; other than this the proteins are identical. Both forms of PR are
activated by progesterone but they are thought to have differing functions. PRb is the
more transcriptionally active isoform (Wen, et al., 1994) and in settings where both
the A and B forms are present PRa can act as a dominant repressor of PRb function
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(Tung, et al., 1993; Vegeto, et al., 1993). This suggests that in cells where there is an
abundance of PRa the responsiveness to progesterone may be reduced and that the
ratio of PRa: PRomay determine the cellular response to the hormone. PRAhas also
been shown to inhibit the function of the glucocorticoid, mineralocorticoid, androgen
and oestrogen receptors (McDonnell and Goldman, 1994; McDonnell, et al., 1994;
Wen, et al., 1994).
The oestrogen receptor also exists in two forms: ERa (Green, et al., 1986) and
ER(3 (Kuiper, et al., 1996; Mosselman, et al., 1996). In vitro both proteins are
functional and both bind oestradiol with a high affinity (Kuiper and Gustafsson,
1997; Mosselman, et al., 1996).
1.3.1 Oestrogen and progesterone receptor expression in endometrium
Several studies have described the immunohistochemical distribution of the
oestrogen and progesterone receptors throughout the menstrual cycle (Critchley, et
al., 1993; Lessey, et al., 1988; Snijders, et al., 1996). These studies have shown that
ER levels in both endometrial epithelium and stroma increase throughout the
proliferative phase peaking at the time of ovulation. Levels then decline in both
compartments during the secretory phase. This is consistent with the view that
oestrogen positively regulates its receptor while progesterone suppresses ER
expression. PR is shown to increase in epithelium and stroma during the proliferative
phase (under the influence of oestrogen). During the secretory phase PR expression
decreases in the epithelium but persists in stromal cells, particularly those in the
perivascular region (Wang, et al., 1998). In pregnancy PR remains in the
perivascular and stromal cells while ER is absent. Both ER and PR are absent from
epithelium (Perrot-Applanat, et al., 1994).
Recently, the distribution and cycle dependence of the two PR isoforms has been
described by further immunohistochemical studies (Mote, et al., 1999; Wang, et al.,
1998). These studies have shown that, while PRA and PRB are coexpressed in
glandular epithelium and stroma in the proliferative phase, mainly PRA is present in
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the stroma in the secretory phase and early pregnancy. This suggests that PRA is the
isoform responsible for decidualization and other stromal events influenced by
progesterone. Also, the localization of both PR isoforms to the predecidual cells
around the spiral arterioles suggests that progesterone withdrawal effects may be
profound in these cells (Wang, et al., 1998). This would be in keeping with the
upregulation of IL-8, MCP-1 and COX-2 reported in these cells in the premenstrual
phase. Both PR isoforms are reported to decrease in epithelium in the secretory
phase. However, PRB is reported to be present in the mid secretory phase and it is
suggested that this isoform may be responsible for the progestogenic effects which
cause glandular secretion (Mote, et al., 1999).
The localization of ERa and ER(3 proteins in the endometrium has also recently been
reported. Both ERa and ER(3 have been detected in glandular epithelium, stroma and
perivascular cells. Decreased expression of ER(3 in glands in the functionalis region
has been documented in the late secretory phase. ER(3 is also present in the
endometrial endothelium and it is suggested that this receptor may mediate steroid
effects on the endometrial vasculature (Critchley, et al., 2000). A further study
detailed the localization of mRNA for the two isoforms by in-situ hybridization
(Matsuzaki, et al., 1999). ERa mRNA was expressed by glandular epithelial and
stromal cells. This expression decreased in both cell types in the functionalis layer
during the secretory phase of the cycle although stromal cells near secretory glands
continued to express ERa mRNA. This was consistent with immunohistochemical
results. ER(3 mRNA was expressed predominantly by the glandular epithelium with
only faint stromal staining. Again, decreased expression was apparent in the
secretory phase of the cycle. This study suggested that oestrogenic effects on the
endometrium are likely to occur mainly via the ERa isoform although glandular
effects may also involve ER(3.
Although the steroid hormones exert a fundamental influence on the regulation of
inflammatory mediator expression in endometrium the precise molecular mechanisms
involved remain unclear. The promoter regions for several cytokines do not express
GRE/PRE suggesting that progesterone cannot act directly to suppress expression
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and, equally, progesterone withdrawal cannot directly influence upregulation (McKay
and Cidlowski, 1999). Also, the focal expression of many inflammatory mediators
indicates that a more subtle mechanism is involved in their expression. Cross-talk
between the steroid hormone signal transduction pathways and other pathways is
probable. The nuclear factor kappa B (NFkB) signal transduction pathway is likely
to be involved in such interactions.
1.3.2 Nuclear factor kappa B (NFkB)
NFkB is a transcription factor involved in the inflammatory and immune response
(Baldwin, 1996; Siebenlist, et ah, 1994). It was first identified in B cells as a nuclear
factor which bound to the immunoglobulin K enhancer (Sen and Baltimore, 1986)
and subsequently, it has been established that NFkB binding sites are present in the
promoter regions of genes such as IL-1, IL-6, class I MHC and COX-2. Table 2
details molecules relevant to endometrial function which are regulated by NFkB.
NFkB belongs to the Rel family of transcription factors which all contain an
approximately 300 amino acid Rel homology domain. This is involved in DNA
binding, dimerization with other Rel proteins and binding with inhibitor of NFkB
(IkB) protein family members. There are currently several members of the
NFKB/Rel family of transcription factors: c-Rel, NFkBI (p50/pl05), NFkB2
(p52/pl00), Rel A (p65), Rel B and the Drosophila protein, dorsal. These proteins
form both homo- and heterodimers with the classic NFkB heterodimer consisting of
p50 and p65. NFkB binds to the consensus sequence 5'-GGGPuNNPyPyCC-3" thus
activating gene transcription. It should be noted that NFkB rarely acts alone when
regulating gene transcription. Instead, there is likely to be complex interactions
between NFkB and other transcription factors (for review see McKay and Cidlowski
(1999)). As indicated above, there is cross-talk between steroid hormones and NFkB
(described in section 1.3.6) and activator protein 1 (AP-1), another transcription
factor involved in the immune response, often acts in synergy with NFkB.
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Table 2: Examples of NFkB regulated inflammatory molecules. Those molecules
which are also shown in Table 1 are highlighted in red. It can be seen that many of
the genes induced by NFkB are expressed by human endometrium.
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Gene induced by NFkB Reference
COX-2 (Adcock, et al., 1997)
eotaxin (Matsukura, et al., 1999)
Granulocyte/macrophage colony
stimulating factor (GM-CSF)
(Adcock, et al., 1997)
IFNy (Sica, et al., 1997)
IL-lp (Hiscott, et al., 1993)
IL-6 (Gruss, et al., 1992)
IL-8 (Mukaida, et al., 1990)
iNOS (Chao, et al., 1997)
Interferon regulatory factor 1 (IRF-1) (Liu, et al., 1999)
ikba (Sun, et al., 1993)
MCP-1 (Ueda, et al., 1994)
MlP-la (Grove and Plumb, 1993)
MMP-l/MMP-9
(Bond, et al., 1998; Vincenti, et al., 1998;
Yokoo and Kitamura, 1996)
RANTES (Manni, et al., 1996)
TNFa (Shakhov, et al., 1990)
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NFkB is held inactive in the cytoplasm by endogenous inhibitors belonging to the
IkB family (Baeuerle and Baltimore, 1988; Baeuerle, et ah, 1988). These proteins
are also responsible for inhibiting the DNA binding of NFkB. Initially, two IkB
proteins were identified, IkBoc(MAD-3) and IkB(3 (Zabel and Baeuerle, 1990).
Subsequently, other family members have been found including IkBb, IkBy, Bcl-3
and the Drosophila protein cactus. Additionally, the Rel proteins pi05 and pi00 can
act as inhibitors of NFkB. The IkB proteins contain ankyrin repeats (33 amino acid
sequences, originally found in the erythrocyte protein ankyrin) which are responsible
for their interaction with the Rel domain of NFkB and it is now apparent that IkB
retains NFkB in the cytoplasm by masking its nuclear localization sequence. Recent
crystallographic studies have confirmed that loops between the ankyrin repeats
contain the residues crucial for NFkB binding and that Rel A undergoes a
conformational change, masking DNA binding residues, when bound to IkBoc
(Huxford, et ah, 1998; Jacobs and Harrison, 1998). Differential binding of the IkB
proteins to the various NFkB dimers is observed with IkBoc binding preferentially to
p50-p65 and p50-c-Rel heterodimers (Thompson, et ah, 1995). Differential targeting
of iKBaand IkB(3 has also been reported with IkB(3 targeted only by a subset of
NFkB stimulators. While the presence of multiple NFkB and IkB proteins is
acknowledged, the following discussion of the signalling pathway will focus mainly
on the classic NFkB (p50/p65) heterodimer and IkBoc.
1.3.3 The NFkB signal transduction pathway - The IKK complex
The NFkB signal transduction pathway, as described in the following sections (1.3.3
and 1.3.4), is illustrated in Figure 4. Upon stimulation of the cell, IkBcc becomes
phosphorylated (Beg and Baldwin, 1993) on Ser 32 and 36 (Brockman, et al., 1995;
Brown, et ah, 1995) and then ubiquinated on Lys 21 and 22 (Scherer, et ah, 1995)
with subsequent dissociation from NFkB. This allows the release of free NFkB
which travels to the nucleus where it can regulate gene expression while free IkBcc is
rapidly degraded via a proteasome dependent pathway. Crucially, one gene
upregulated by NFkB is IkBcc allowing replenishment of the IkB stock and self-
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limitation of NFkB activation (Sun, et al., 1993). The pathway leading to IkBoc
phosphorylation has recently been identified (for reviews see Hatada, et al., 2000;
Israel, 2000; Mercurio and Manning, 1999; Stancovski and Baltimore, 1997; Zandi
and Karin, 1999).
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Figure 4: The NFkB signal transduction pathway. An extracellular signal activates
the transcription factor, NFkB, via a series of protein kinase. The result is
phosphorylation of the inhibitor, IkBoc, followed by translocation of NFkB to the
nucleus. IkB kinase a (IKKa) is believed to mediate morphogenic signalling to
NFkB and NFkB inducing kinase (NIK) is thought to preferentially phosphorylate
this kinase (Pathway A). In contrast, IkB kinase (3 (IKK(3) is believed to be primarily
involved in proinflammatory signalling to NFkB and is preferentially phosphorylated
















1.3.3a Identification of IKKa and IKKP
In 1996 it was reported that an IkB kinase (IKK) complex had been purified from the
cytoplasm of unstimulated HeLa cells (Chen, et ah, 1996). The complex was found
to phosphorylate IkBoc at the relevant Ser residues in vitro. Following this, two
kinases were detected in a similar IKK complex (this complex was purified from
cells which had been stimulated with TNFa) with the subsequent identification of
IKKa (also known as IKK-1; conserved helix-loop-helix ubiquitous kinase) and
IKKP (IKK-2) (DiDonato, et ah, 1997; Mercurio, et al., 1997; Regnier, et ah, 1997;
Woronicz, et ah, 1997; Zandi, et ah, 1997). The proteins were found to be
approximately 50% homologous, both had N terminal kinase domains and contained
a leucine zipper domain and a helix-loop-helix motif. These domains have been
found to be involved in interactions between the kinases and other molecules in the
IKK complex. IKKa and IKK(3 are believed to associate both as heterodimers and
homodimers in vitro (Mercurio, et al., 1997; Woronicz, et al., 1997; Zandi, et al.,
1998; Zandi, et al., 1997). In vivo Woronicz et al reported the presence of
heterodimers (Woronicz, et al., 1997) while Mercurio et al detected both
heterodimers and IKKp homodimers (Mercurio, et al., 1999). Mutations in the
leucine zipper domain of the kinases has been shown to prevent dimerization
(Woronicz, et al., 1997; Zandi, et al., 1997) and the helix-loop-helix motif is thought
to mediate interactions with other molecules in the IKK complex (Zandi, et al.,
1997). Mutational studies have also shown that both the kinase domain and the
leucine zipper motif of IKKp are needed for interactions with iKBa (Woronicz, et al.,
1997).
Both IKKa and IKKP activity is reported to cause phosphorylation of IxBa on Ser
32 and Ser 36 (mutant forms of IKBa are not phosphorylated with the same
efficiency ) (DiDonato, et al., 1997; Mercurio, et al., 1997; Woronicz, et al., 1997).
Subsequently, experiments transfecting IKKa and IKKP into insect cells have shown
direct phosphorylation of IkB by both kinases (Zandi, et al., 1998). This study also
demonstrated that the kinases preferentially phosphorylate IkB proteins that are
bound to NFkB rather than free IkB. This is consistent with the physiological
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substrate for the IKK complex being NFkB complexed IkB. Activators of NFkB
(e.g. IL-1, TNFa) induced IKK kinase activity with kinetics similar to those seen for
phosphorylation of IkBoc (DiDonato, et ah, 1997; Mercurio, et ah, 1997; Zandi, et ah,
1997) while perturbation of kinase expression or activity provided further evidence
that these kinases are involved in NFkB activation. Overexpression of IKKa
(DiDonato, et ah, 1997) and IKK(3 (Woronicz, et ah, 1997) caused increased
activation of NFkB by IL-1 and TNFa. In contrast, kinase inactive mutants of IKKa
or IKKp and antisense RNA against IKKa inhibited NFkB activation by IL-1 and
TNFa (DiDonato, et ah, 1997; Mercurio, et ah, 1997; Woronicz, et ah, 1997).
Several studies have reported incomplete inhibition of NFkB activation by kinase
inactive mutants (Mercurio, et ah, 1997; Zandi, et ah, 1998; Zandi, et ah, 1997).
1.3.3b Differential functions of IKKa and IKK(3
Although both IKK proteins have been shown to be capable of NFkB activation it is
becoming apparent that the proteins have differing activities. IKK(3 is reported to be
the more active kinase (Mercurio, et ah, 1997; Woronicz, et ah, 1997) and it is also
able to phosphorylate IkB(3 equally well on both Ser 19 and 23 (Woronicz, et ah,
1997). IKKa preferentially phosphorylates Ser 23 (Regnier, et ah, 1997). Recent
reports have also suggested that the proteins have different functions (for review see
May and Ghosh (1999)). Two groups have generated IKKa deficient mice with both
reporting abnormal fetal development (Flu, et ah, 1999; Takeda, et ah, 1999). The
mice showed abnormal limb development, shortened heads and snouts with no
external ears and shiny, rather than the normal wrinkled, skin. The skeletal
development of the limbs was found to be normal but they remained tightly folded.
Differentiation of keratinocytes was prevented and there was hyperplasia of the
epidermis. Hu et al also reported abnormal development of the sternum and
vertebrae. Fibroblasts and thymocytes derived from the mutant embryos had a
normal NFkB activation response to stimulation with IL-1 and TNFa and it was
assumed that this is mediated via IKK(3. These studies suggest that IKKa is not, as
originally believed, critical to NFkB activation by proinflammatory signals but
49
instead, is involved in early development and the transmission of morphogenic
signals to NFkB (see Pathway A, Figure 4).
The role of IKK(3 has also been investigated and it has been found that IKK(3
deficient mice die as embryos due to apoptosis in the liver. These mice can be
rescued by inactivation of the gene for TNFa receptor 1 suggesting that the cells
apoptose as a result of unchallenged activation of pro-apoptotic pathways by TNFa.
Normally, NFkB would also be activated and this would have anti-apoptotic effects.
Fibroblasts derived from the IKK(3 deficient mice showed reduced NFkB activation
upon stimulation by IL-1 and TNFa (Li, et ah, 1999). Similar results have been
reported by Tanaka et al (1999). The role of IKK(3 has also been investigated by
Delhase et al (1999). In this study the activation of IKK activity by upstream kinases
was investigated using mutational studies. It was found that elimination of two
phosphorylation sites within the activation loop (T loop) of IKK(3, but not IKKa,
prevented IKK activation by proinflammatory cytokines or the upstream kinases,
NFkB inducing kinase (NIK) and mitogen activated protein kinase/ERK kinase
kinase-1 (MEKK1; ERK, extracellular regulated kinase). It is thought that when
IKK(3 becomes activated (due to stimulation by proinflammatory molecules) it may
activate IKKa although this is not essential for NFkB activation. Also, IKKf) is
involved in negative regulation of IKK activity via autophosphorylation of C terminal
residues (Delhase, et al., 1999). These results suggest that IKK(3 is the main kinase
involved in proinflammatory signalling to NFkB (see Pathway B, Figure 4) and this
is consistent with reports that the anti-inflammatory agents aspirin and salicylate
inhibit only IKKfl (Yin, et al., 1998).
1.3.3c Additional components of the IKK complex
Further components of the IKK complex have also been described. IKKy (or IKK
associated protein-1) has been identified by two groups (Mercurio, et al., 1999;
Rothwarf, et al., 1998) and has been found to be the human homologue of the mouse
NFkB essential modulator (NEMO) discovered by Yamaoka (Yamaoka, et al., 1998).
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IKKy has been detected in two forms IKKy 1 and 2 (Rothwarf, et al., 1998) and is
thought to have two coiled-coil motifs and a leucine zipper. IKKy can interact with
both IKKa and IKK(3 in cotransfection studies but can only stably interact with
IKKfh IKKy antisense experiments have shown inhibition of IKK activity upon
stimulation with IL-1 or the upstream kinases, NIK and MEKK1. Additionally,
inhibition of p65 nuclear translocation upon TNFastimulation was reported
(Rothwarf, et ah, 1998). Mutant versions of IKKy or molecules lacking the IKK(3
binding site also inhibit NFkB activation (Mercurio, et ah, 1999). IKKy is identical
to a previously identified protein, FIP3, which can interact with the TNFareceptor
complex and immunocytochemical studies have shown that the C-terminal portion of
IKKy translocates to the cell membrane upon stimulation with TNFa (Mercurio, et
ah, 1999). This led the authors to suggest that IKKy may act as a scaffolding protein
allowing interaction of IKK(3 containing IKK complexes with upstream components
of the NFkB activation pathway (e.g. the TNFa receptor complex). Another likely
scaffolding component of the IKK complex, IKK-complex-associated protein (IKAP)
has also been identified (Cohen, et ah, 1998). IKAP was found to interact with NIK,
IKKa and IKK(3 with greatest affinity for NIK. Endogenous NIK and IKK(3 were
found to exist in a complex with IKAP and it was suggested that IKAP promotes an
interaction between the IKK complex and the upstream activating kinase, NIK.
1.3.4 The NFkB signal transduction pathway - Upstream of the IKK complex
Several kinases have been implicated in the phosphorylation of the IKK complex.
The mitogen activated protein kinase kinase kinase enzymes, NIK and MEKK1, have
both been identified as kinases involved in NFkB activation (see Figure 4). NIK was
identified due to its ability to bind to TNF receptor associated factor 2 (TRAF2)
which is a protein crucial for NFkB activation by TNFa(Malinin, et ah, 1997). It
has also been reported to interact with TRAF6 (Song, et ah, 1997). Expression of a
kinase inactive NIK mutant blocked activation of NFkB due to TNFa and IL-1
stimulation (Malinin, et ah, 1997). MEKK1 was identified as an NFkB activating
kinase by similar experiments (Lee, et ah, 1997; Lee, et ah, 1998; Nemoto, et ah,
1998) . It has been reported that NIK and MEKK1 preferentially phosphorylate
IKKa and IKK(3, respectively (Ling, et al., 1998; Nakano, et ah, 1998) (see Pathways
A & B, Figure 4). MEKK2 and 3 have also been shown to be capable of stimulating
IKK activity and activation of NFkB (Zhao and Lee, 1999).
The TNF and IL-1 receptors connect to the NFkB activation pathway through the
actions of several proteins. Upon binding of IL-1 to the IL-1 Rtl a complex is formed
between IL-1R accessory protein, myeloid differentiation factor 88 and a
serine/threonine kinase, IL-1 receptor associated kinase (IRAK). IRAK dissociates
from the receptor and has been found to interact with TRAF6. TRAF6 then interacts
with the protein kinases, transforming growth factor (3 activated kinase 1 (TAK1) and
TAK1 binding protein 1, resulting in NIK activation (Cao, et al., 1996; Ninomiya-
Tsuji, et al., 1999; Wesche, et ah, 1997). In the case of TNF receptor 1 (TNFR1), the
binding of TNFa results in the oligomerization of death domains present in the
cytoplasmic regions of the receptor. This allows recruitment of several proteins
including TNFR-associated death domain protein, TRAF2 and receptor-interacting
protein (Hsu, et ah, 1996; Hsu, et ah, 1995; Rothe, et ah, 1994). As detailed above
TRAF2 is thought to associate with NIK.
A TRAF-binding protein, TRAF family member associated NFkB activator (TANK;
or TRAF interacting protein), reported to inhibit the activation of NFkB by
TNFa (via competition with TRAFs for binding sites on the cytoplasmic tail of the
TNFR2), has also been found to be involved in an NFkB activation pathway. An
IKK-like kinase, TANK binding kinase 1 (TBK1), interacts with TANK in a TBK1-
TANK-TRAF2 complex. This interaction with TRAF2 allows signalling to NFkB
via the NIK-IKK pathway (Pomerantz and Baltimore, 1999). Interestingly, TBK1 is
48% homologous to an inducible IKK which has been identified in mouse
macrophages (Shimada, et ah, 1999).
It should be noted that the elucidation of the NFkB signalling pathway has focused
mainly on stimulation by IL-1 and TNFa. However, activation by most other stimuli
is believed to occur via the IKK complex.
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1.3.5 Activators of NFkB
As described above NFkB is activated by IL-1 and TNFa. Further stimuli
relevance to the female reproductive system are described in Table 3.
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Table 3: Examples of molecules thought to activate the NFkB signal transduction
pathway. Several of these molecules (shown in red) are expressed by human
endometrium and are also detailed in Table 1. Others (e.g. HIV-1) are sexually
transmitted diseases suggesting that NFkB activation may be involved in the




(Browatski, et al., 2000; Gallois, et al.,
1998)
GM-CSF (Oster, et al., 1992)
Herpes simplex virus 1 (Patel, et al., 1998)
HIV-1 (Bachelerie, et al., 1991)
IFNy (Narumi, et al., 1992)
IL-la/p (Osborn, et al., 1989)
Integrins
e.g. (Bhullar, et al., 1998) avP3
(Udagwa, et al., 1996) CX4P1
FIF (Gruss, et al., 1992)
Fipopolysaccharide (FPS) (Richardson, et al., 1991)
Macrophage-colony stimulating factor (Oster, et al., 1992)
pge2 (Muroi and Suzuki, 1993)
TNFa (Osborn, et al., 1989)
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1.3.5a The CD40-CD40 Iigand system
CD40, a member of the TNF receptor superfamily, was originally detected on the
surface of B cells (Stamenkovic, et al., 1989) and has a role in the activation,
proliferation and differentiation of these cells when activated by its ligand, CD40
ligand (CD40L/wCDl 54), found on the surface of T cells (Graf, et ah, 1992).
Subsequently, it has been discovered that both CD40 and CD40L are expressed on
the surface of multiple cells types. CD40 has been reported to be present on
monocytes (Alderson, et al., 1993), fibroblasts (Fries, et al., 1995) and dendritic
(Freudenthal and Steinman, 1990), endothelial (Hollenbaugh, et al., 1995) and some
epithelial cells (Galy and Spits, 1992). In addition to T cells, CD40L is expressed on
eosinophils (Gauchat, et al., 1995), basophils, mast cells (Gauchat, et al., 1993),
activated platelets (Henn, et al., 1998), NK cells (Carbone, et al., 1997) and
macrophages (Mach, et al., 1997).
In non-haematopoietic cells the CD40-CD40L system has been found to be involved
in proinflammatory signalling and activation of the pathway has been reported to
stimulate cytokine release by several cell types. Upregulation of cytokines including
IL-1, IL-6, IL-8, IL-10, TNFa and MlP-la upon crosslinking of CD40 on monocytes
has been shown (Caux, et al., 1994; Kiener, et al., 1995). Similarly, activation of
CD40 has been found to increase production of IL-6 and IL-8 by fibroblasts from
several sites (e.g. orbital, lung) (Sempowski, et al., 1997a; Sempowski, et al., 1998).
COX-2 and PGE2 are also upregulated by CD40 stimulation of lung fibroblasts
(Zhang, et al., 1998). In endothelial cells CD40 is involved in the increased
expression of adhesion molecules including vascular and intercellular adhesion
molecules (VCAM-1 and ICAM-1) (Hollenbaugh, et al., 1995; Karmann, et al.,
1995). These results suggest a role for the CD40 system in control of inflammatory
mediator expression and leukocyte migration during inflammatory events. Prior to
the results presented in this thesis there were no reports detailing CD40 expression
and action in the endometrium.
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CD40 is an activator of NFkB signal transduction (Berberich, et al., 1994). It is also
involved in modulation of nonreceptor tyrosine kinase activity, phosphorylation of
phospholipase Cy2, activation of phosphatidylinositol-3-kinase and stimulation of the
Janus kinase - signal transducer and activator of transcription (JAK-STAT) pathway
(Faris, et ah, 1994; Hanissian and Geha, 1997; Ren, et ah, 1994; Schoenberger, et ah,
1998). The molecular pathways leading from CD40 to NFkB activation are believed
to be similar to those described for TNFa. CD40 has been reported to associate with
TRAF2 (Rothe, et ah, 1994), TRAF3 (Hu, et ah, 1994), TRAF5 (Ishida, et ah, 1996b)
and TRAF6 (Ishida, et ah, 1996a). Recently, it has been shown that the N and C
terminal portions of the CD40 cytoplasmic tail interact differentially with the TRAFs.
The N terminus interacts with TRAF6 while the other 3 TRAF molecules associate
with the C terminus. Mutation of threonine 254 in the C terminus prevents binding
of TRAFs to this part of CD40 (Hu, et ah, 1994). Similarly, it has now been
established that mutation of a glutamate residue in the N terminus prevents binding of
TRAF6. The coupling of CD40 to NIK via these adapter molecules has also been
investigated. The use of dominant negative NIK mutants (mutant protein that
prevents the wild type copies of the protein from performing their normal function)
has shown that TRAF2 and TRAF5 activate NFkB via stimulation of NIK while
TRAF6 acts mainly via a different, unidentified pathway (Tsukamoto, et ah, 1999).
This suggests that signalling from CD40 can activate NFkB by at least two different
mechanisms (Figure 5).
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Figure 5: CD40-CD40L activation of NFkB. CD40 activates NFkB by at least two
distinct pathways. (1). TRAF 2 and 5 interact with the C terminal region of the CD40
cytoplasmic tail (C) and are involved in signal transduction to NFkB via stimulation
ofNIK. (2). TRAF 6 interacts with the N terminus of the cytoplasmic tail (N) and is
involved in NFkB activation via an unidentified pathway.
58
59
1.3.6 Inhibitors of NFkB
Glucocorticoids, the anti-inflammatory steroid hormones, inhibit the activity of
NFkB and it is thought that it is partly via this action that they suppress the
production of inflammatory mediators such as IL-1 and IL-8. The suppression of
NFkB occurs via several mechanisms (McKay and Cidlowski, 1999). First,
glucocorticoids have been shown to increase the mRNA and protein levels of IkBcc
(Auphan, et ah, 1995; Scheinman, et ah, 1995a). This will cause the increased
retention of NFkB in the cytoplasm. Second, the GR has been shown to directly
interact with the p65 subunit of NFkB resulting in mutual inhibition (Caldenhoven, et
al., 1995; McKay and Cidlowski, 1998; Ray and Prefontaine, 1994; Scheinman, et
al., 1995b). This interaction is thought to involve the Rel homology domain of p65
and the DNA binding domain of the GR. The observation that overexpression of p65
does not prevent GR mediated repression of GR expression (McKay and Cidlowski,
1998) suggests that the mutual inhibitory effects may occur by indirect mechanisms
such as competition for a common cofactor. As mentioned earlier, progesterone has
local immunosuppressive effects similar to those of glucocorticoids. Progesterone
has also been reported to interact with the NFkB pathway. Increased IkBoc gene
expression in the presence of progesterone has been reported in the T47D cell line
and in mouse macrophages (Miller and Hunt, 1998, Wissink, 1998) and direct
interactions between p65 and the PR have also been reported (Kalkhoven, et al.,
1996; McKay and Cidlowski, 1998). However, there were discrepancies between
these studies with only Kalkhoven et al reporting mutual inhibition; McKay et al
found only inhibition of PR by p65. The reduced level of inflammatory mediator
expression in the secretory phase of the menstrual cycle and pregnancy may be
mediated in part by progesterone suppression of the NFkB pathway. Additionally,
progesterone withdrawal premenstrually may release inhibition of NFkB allowing
upregulation of inflammatory molecules. Progesterone inhibition of the NFkB
pathway is demonstrated in Figure 6.
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Figure 6: Progesterone interactions with the NFkB pathway. Progesterone increases
the expression of the endogenous inhibitor, IkBcx. The progesterone receptor can
interact with NFkB preventing binding to DNA either (A) directly or (B) via




1.3.6a Secretory leukocyte protease inhibitor (SLPI)
SLPI (also known as antileukoprotease) is an 11.7kDa cysteine rich protein expressed
by neutrophils (Bohm, et ah, 1992), macrophages (Jin, et ah, 1997) and epithelial
cells (Abe, et ah, 1991). It has been found associated with mucosal surfaces such as
lung and cervix (Franken, et ah, 1989) and has been characterized as a crucial
neutrophil elastase inhibitor in lung. SLPI has also been reported to have inhibitory
effects on another neutrophil protease, cathepsin G, and the pancreatic enzymes,
trypsin and chymotrypsin (Thompson and Ohlsson, 1986). Several disease states are
characterized by proteolytic tissue damage (e.g. cystic fibrosis, asthma) and SLPI
has been used as a potential treatment for such conditions (Birrer, 1995). In addition
to its role as a serine protease inhibitor, SLPI has several other functions that suggest
that it may have a more generalized protective effect at mucosal surfaces. SLPI has
been reported to have antibacterial, antiviral and antifungal effects (Tomee, et ah,
1998). SLPI has antibacterial actions against Escherichia coli and Staphylococcus
aureus in vitro suggesting that it has bactericidal effects on both Gram negative and
positive micro-organisms (Hiemstra, et ah, 1996). SLPI also has antibacterial effects
against micro-organisms found on skin (Wiedow, et ah, 1998). The mechanism by
which SLPI has these actions is unclear but it has been suggested to bind to bacterial
mRNA and DNA (Miller, et ah, 1989). Also, it is possible that the cationic nature of
SLPI may be involved as higher salt concentrations inhibit its bactericidal activity
(Hiemstra, et ah, 1996). Interestingly, SLPI has two domains that show high
homology to each other. The C terminal domain is responsible for the protease
inhibitory effects (Eisenberg, et ah, 1990; Kramps, et ah, 1990) while the N terminus
has been shown to be involved in the bactericidal effects of the molecule (Hiemstra,
et ah, 1996). The N terminal domain is also thought to be responsible for anti-fungal
effects (Tomee, et ah, 1997). The fungi, Aspergillus fumigatus and Candida albicans,
are killed by SLPI when they are metabolically active. Antiviral effects have also
been demonstrated with SLPI, present in saliva, reported to reduce the infection of
monocytes with HIV-1 (McNeely, et ah, 1995).
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SLPI also acts to inhibit various proinflammatory events. For example, in mouse
macrophages transfection of SLPI results in suppression of LPS effects (NFkB
activation, TNFaand nitric oxide production) (Jin, et ah, 1997). SLPI also
suppresses MMP production in human monocytes (Zhang, et al., 1997). This
occurred via a downregulation of COX-2 expression and hence, PGE2 production.
The mechanism by which SLPI decreases COX-2 expression is not clear but
inhibitory effects on NFkB activation have been reported (Jin, et al., 1997; Lentsch,
et al., 1999). It has been suggested that SLPI inhibits NFkB via an elevation of
IkB(3protein (Lentsch, et al., 1999). Additionally, a SLPI receptor has been
identified on human monocytes (McNeely, et al., 1997).
SLPI expression is reported to be upregulated by LPS, IL-6 and IL-10 in mouse
macrophages (Jin, et al., 1998) and by phorbol, 1-myristate, 13-acetate (PMA), IL-1(3
and TNFa in bronchial epithelial cells (Maruyama, et al., 1994; Sallenave, et al.,
1994). IFNy has also been suggested to regulate SLPI expression via IRF-1 although
high levels of IRF-1 causes suppression of SLPI levels (Nguyen, et al., 1999).
Several of these mediators can activate NFkB and it has been suggested that SLPI
may be an NFkB responsive gene (Nguyen, et al., 1999). The increased expression
of SLPI by proinflammatory mediators may ensure the presence of protective
molecules at inflammatory sites. SLPI secretion is also increased by glucocorticoids
in airway epithelial cells (Abbinante-Nissen, et al., 1995). Consistent with this
progesterone has been reported to increase SLPI secretion by cervical explants
(Denison, et al., 1999a).
SLPI is, therefore, an anti-inflammatory molecule that is able to inhibit the NFkB
pathway. Additionally, SLPI is likely to be upregulated by activators of NFkB and
also, by anti-inflammatory steroids such as progesterone. Although SLPI has been
detected in human seminal plasma (Franken, et al., 1989) and cervical mucosa
(Casslen, et al., 1981) previous reports have been unable to detect the molecule in
human endometrium (Casslen, et al., 1981; Franken, et al., 1989).
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1.4 Hypothesis and Aims
Previous studies on the mechanisms involved in the inflammatory-like events
associated with menstruation and implantation have focused on the role of molecules
such as chemokines, matrix metalloproteinases and vasoactive agents. While the
expression of such molecules is thought to be controlled primarily by the steroid
hormones, oestradiol and progesterone, the molecular mechanisms involved have yet
to be defined.
The NFkB pathway, due to its involvement in proinflammatory signalling and
suppression by progesterone, is likely to be involved in the inflammatory events in
endometrium. Although progesterone has been found to suppress the NFkB pathway
at several levels there is no data detailing its effects on the expression of intermediate
molecules involved in the signalling pathway. Similarly, there is little information
regarding the role of NFkB in the endometrium. However, comparison of Tables 1, 2
and 3 shows that many of the inflammatory mediators involved in endometrial
function are either regulated by NFkB or interact with the NFkB pathway. High
progesterone levels, such as those found in the secretory phase and early pregnancy,
would be expected to repress signalling via the NFkB pathway (Figure 7a). This
would contribute to the immunosuppressive effects necessary for successful
implantation and pregnancy. In contrast, progesterone withdrawal premenstrually
would result in relaxation of inhibitory mechanisms and allow NFkB activation
(Figure 7b). This would allow upregulation of inflammatory mediator expression.
Although steroid hormones would exercise control over potentially NFkB mediated
events in endometrium the production of local mediators would provide a more subtle
mechanism of control (partly via feedback loops). For example, the presence of
NFkB activators (e.g. CD40) or inhibitors (e.g. SLPI) in endometrium would provide
another level of regulation of the pathway. Many mediators, which have been
identified as regulators of NFkB, have previously been identified in endometrium
(e.g. IL-1). However, as stated above, neither CD40 nor SLPI had been successfully
detected in human endometrium prior to the work described in this thesis. The role
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of CD40 in upregulation of inflammatory mediators in various cell types suggests
that it could play a similar role in menstruation. The expression of CD40L on bone
marrow derived cells would provide a mechanism by which leukocytes infiltrating
endometrium premenstrually could activate CD40 and upregulate inflammatory
molecules. SLPI, as detailed above, is an anti-inflammatory molecule and, if
expressed by endometrium, would be expected to contribute to the
immunosuppressive events surrounding pregnancy. Figure 7 details the hypothesized
involvement of the NFkB pathway, CD40 and SLPI in endometrial physiology.
The aims of this research project are thus:
1. To investigate progesterone control of molecules involved in the NFkB pathway.
2. To investigate the expression and regulation of these molecules in human
endometrium and first trimester decidua.
3. To investigate the expression of the NFkB activator, CD40 and its ligand, in
human endometrium and first trimester decidua.
4. To investigate the expression of the NFkB inhibitor and antibiotic agent, SLPI, in
human endometrium and first trimester decidua.
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Figure 7: Hypothesized role of NFkB in human endometrium. (A). Progesterone
will maintain suppression of NFkB during the secretory phase and pregnancy. The
presence of anti-inflammatory molecules such as SLPI will contribute to this role.
(B). Progesterone withdrawal (e.g. prior to menstruation) will result in NF kB
activation resulting in the upregulation of chemokines, prostaglandins and MMPs.
























All materials used in the work described in this thesis are detailed in Appendix 1.
2.1 Human uterine tissue collection
Endometrial biopsies were collected from women (median age 40, range 24-51; no
previous pregnancy n=l, previous pregnancy n=60) undergoing gynaecological
procedures for benign conditions including hysterectomy (for dysfunctional uterine
bleeding and prolapse) and laparoscopic sterilization. Biopsies were collected with
an endometrial suction curette (Pipelle, Laboratoire CCD, Paris, France) or
alternatively, full thickness endometrial samples were obtained. These included
superficial and basal endometrium plus the endometrial-myometrial junction. All
women described regular menstrual cycles (25-35 days) and had not received any
form of hormonal treatment in the 3 months preceding biopsy. Biopsies were dated
according to the patient's reported last menstrual period (LMP) and only included for
analysis if the histological dating according to published criteria (Noyes, et al., 1950)
and circulating sex steroid concentrations were consistent with the LMP. Serum was
separated (by centrifugation at 3000 rpm for 7 min) from venous blood samples
collected at the time of biopsy and oestradiol (E2) and progesterone (P4)
concentrations were measured by radioimmunoassay.
First trimester decidua (8-10 weeks gestation) was obtained from patients (median
age 25.5, range 16-38; no previous pregnancy n=12, previous pregnancy n=15)
undergoing suction termination of pregnancy. Prior to the termination, biopsies were
collected by curettage of the uterine wall away from the site of implantation.
Trophoblastic villi were also collected during the procedure. Decidua parietalis
(without trophoblast) was confirmed by examination of haemotoxylin and eosin
stained sections and cytokeratin immunolocalization confirmed the absence of
infiltrating trophoblast cells (see 2.3.7). Additionally, trophoblast samples were
included in all quantitative PCR studies that examined mRNA expression in
endometrium and decidua (detailed in Chapters 3-5). In all cases trophoblast mRNA
expression was similar to, or less than, that of first trimester decidua. This provided
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further reassurance that decidual mRNA levels were unlikely to reflect trophoblast
contamination. Table 4 details biopsies included in this study.
Tissue samples were collected in RPMI 1640 medium and additionally, biopsies were
fixed in 10% neutral buffered formalin (NBF) overnight at 4°C, stored in 70%
ethanol and then wax embedded. Also, biopsies to be used in immunohistochemistal
studies (section 2.3) were placed in Hanks Balanced Salt Solution supplemented with
0.7% HEPES buffer and microwaved on high power for 12 seconds. After
microwaving, biopsies were transferred to cold phosphate buffered saline (PBS)
containing 10% sucrose for 15-30 minutes (as described by Slayden, et al. (1995)).
Biopsies were then embedded in OCT freezing compound in tin foil moulds, snap
frozen in liquid nitrogen and stored at -70°C. Biopsies to be used in PCR studies
were immersed in Tri reagent or Ultraspec and then treated as detailed in section 2.2.
Written informed consent was received from all patients prior to biopsy collection
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2.2 RNA extraction and reverse transcription-polymerase chain reaction (RT-
PCR)
2.2.1 RNA extraction
RNA was extracted from tissue and cells using either Ultraspec or Tri reagent. The
protocol for use of Tri reagent is detailed below. Tissue was immersed in 1 ml of Tri
reagent and then homogenized; cells were harvested and then resuspended in 1ml of
Tri reagent. This was followed by a 5 minute incubation period at 4°C. 200pl of
choroform was then added and samples were mixed by inversion. After a further 5
minute incubation, samples were centrifuged at 14000 rpm for 15 minutes at 4°C.
This allowed the sample to separate into 3 phases. The upper, aqueous phase
contained RNA with the remaining phases containing DNA and protein. The
aqueous layer was removed to a fresh tube and 500pl of 100% isopropanol was
added. After thorough mixing the samples were incubated at -20°C for a minimum
of 60 minutes. This was followed by centrifugation at HOOOrpm for 10 minutes at
4°C. The resulting supernatant was removed leaving a pellet containing RNA. This
was washed in 1 ml of 70% ethanol by brief vortexing followed by centrifugation at
14000 rpm for 5 minute at 4°C. Ethanol was removed and the pellet was resuspended
in an RNA storage solution. Samples were stored at -70°C for further use. The
protocol for Ultraspec use was identical to this with the exception of one further wash
in ethanol.
The optical densities of the RNA samples were measured at 260 and 280nm in order
to determine purity and the concentration of RNA present. A 260:280 value of
around 1.8 indicates a pure RNA sample. Concentrations of RNA were calculated
using the following formula:
260 value x dilution of RNA x 40 = RNA concentration (ng/pl)
For use in RT-PCR all RNA samples were diluted to lOOng/pl.
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2.2.2 Reverse transcription
All RNA samples were reverse transcribed using random primers with MgCh
(5.5mM), dNTPs, random hexamers (2.5pM), RNAase inhibitor (0.4U/pl) and
multiscribe reverse transcriptase (1 ,25U/jlx1). The mix was aliquoted into individual
tubes (8pl/tube) and template RNA was added (2pl/tube of 100ng/pl RNA). Mineral
oil was added and samples were incubated for 60 minutes at 25°C, 45 minutes at
48°C and then at 95°C for 5 minutes.
2.2.3 Quantitative Polymerase Chain Reaction
The quantitative PCR method used allows the measurement of PCR product via the
detection of release of a fluorescent reporter dye. The technique uses forward and
reverse primers to the sequence of target DNA along with a probe that recognizes a
sequence present between the annealing sequences of the two primers. The probe is
labelled with two fluorescent dyes: a 5' reporter dye (all amplicons except 18S use
FAM; 6-carboxyfluorescein) and a 3' quencher dye (TAMRA; 6-
carboxytetramethylrhodamine). In the intact state the quencher dye, because of its
proximity, suppresses the fluorescence of the reporter dye. When the target
sequence is amplified during a PCR reaction the probe is cleaved by AmpliTaq Gold
(which has Y shape structure and polymerization dependent 5'-3' nuclease activity
(Holland, et ah, 1991)). This results in the separation of the two dyes so that the
quencher dye can no longer suppress the reporter fluorescence. Hence, the
fluorescence is increased allowing measurement of the amount of PCR product.
(Figure 8). Fluorescence is detected only if the target sequence for the probe is
amplified during the reaction thus preventing the detection of non-specific
amplification.
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Figure 8: Quantitative polymerase ehain reaetion. Stage 1 shows polymerization of
primers and probe to template complementary DNA (cDNA). At this stage
flourescence is low as the quencher dye (TAMRA) suppresses the fluorescence of the
reporter dye (FAM). As the primer is extended along the template the probe is first
displaced (stage 2) and then cleaved by the actions of Taq polymerase (stage 3). This
separates the reporter dye from the suppressive effects of the quencher. The
fluorescence increases and this allows measurement of the amount of PCR product






























Measurement of both ribosomal 18S and specific amplicon levels in the same PCR
well is possible as dyes emitting fluorescence of different wavelengths are
incorporated into the two probes. 18S levels remain constant (relative to the amount
of complementary DNA (cDNA) present) thus allowing changes to specific amplicon
levels to be measured. The reporter dye present on the 18S probe is VIC (chemical
name unavailable) although initial studies used JOE (2,7-dimethoxy-4,5-dichloro-6-
carboxyfluorescein) labelled probe.
Quantitative PCR was used to measure levels of IkBoc, IKKa, IKK(3, IKKy, MEKK-
1, NIK, TBK1, IL-8, COX-2, CD40, CD40 ligand, SLPI and PR in the cDNA
samples. A reaction mix was made containing Taqman buffer, MgCf (5.5mM),
dATP (200p,M), dCTP (200pM), dGTP (200|uM), dUTP (400pM), ribosomal 18S
forward and reverse primers and probe (all at 50nM), specific amplicon forward and
reverse primers (both 300nM), probe (200nM), AmpErase UNG (0.01U/pl) and
Amplitaq Gold DNA polymerase (0.025U/p,l). The mixture was then aliquoted into
separate tubes for each cDNA sample. 1 pl/replicate of cDNA was added to each
tube. After mixing, 23jal of sample were added to the wells on a PCR plate. Each
sample was added in triplicate Wells were sealed with optical caps and the PCR
reaction run on ABI Prism 7700 using standard conditions.
Three steps were taken to ensure that there was not genomic DNA contamination of
PCR samples. A no template control (containing water) and an RNA sample which
had not undergone reverse transcription were included in triplicate in each PCR run.
Additionally, P-actin levels were measured in all RNA samples (without reverse
transcription). Any sample which had a p-actin measurement below an arbitrary
level of 27 (i.e. 3 standard deviations from the mean of all samples) was excluded.
Therefore, two endometrial samples were excluded from analysis. Figure 9 shows
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Figure 9: (3-actin levels in all RNA samples that were subsequently used for RT-
PCR. The PCR cycle number at which fluorescence release reached a threshold level
is shown for each sample. Any sample with a (3-actin measurement below 27
(indicating likelihood of DNA contamination) was excluded from the study. This
meant that two samples were excluded from analysis (shown by red arrow on graph).
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The linearity of the response to specific cDNA was determined by serial dilution.
The concentrations of primers and probes were diluted up to 64 times using a
standard pool of RNA. The log of ng total RNA was plotted against ACt units and
the gradients of the lines through these points were less than 0.1. Figure 10 shows a
representative validation plot. Within assay variation of the PCR measurement of
specific amplicon in cDNA was calculated from six replicates (relative standard
deviation; see Table 5).
Primers and probes were designed (using the PRIMER express program) to ensure
successful hybridization with the template cDNA and efficient amplification.
BLAST (Basic Local Alignment Search Tool) searches were used to determine the
presence of sequences in the scientific databases that are similar to those amplified by
each set of primers. The results of these searches showed that, in all cases, the primer
and probe sets used were unlikely to amplify an inappropriate template. The results
of BLAST searches give an expect value (E) which shows the number of hits
expected to be found by chance when searching a database. If the E value is equal to
1 this indicates that 1 sequence is expected to match that of interest by chance. The E
values along with the sequences of primers and probes are shown in Table 5.
PCR data was analyzed using the formula 2~aaCT (CT is the cycle number at which the
PCR signal crosses a threshold; ACT is the difference between the CT values for the
specific amplicon and 18S; AACT relates the ACT value of each sample to that of an
internal control). This normalizes the amount of target mRNA to the amount of 18S
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Figure 10: Validation of secretory leukocyte protease inhibitor (SLPI) PCR primers
and probe. Validation was performed for each set of primers and probes used in this
research project and this figure is representative of these experiments. The delta Ct
values (difference between the CT values for SLPI and 18S; CT is cycle number at
which fluorescence release reaches a threshold value) are plotted against the log ng
total RNA present. For successful validation the gradient of the line of best fit must
be less than 0.1. In this case the equation of the line was: y=0.029x + 5.103.
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Immunohistochemistry was performed in order to detect NIK, IKKa, CD40, Thy-1,
CD la, SLPI and cytokeratin proteins in tissue biopsies. All protocols were optimized
to determine appropriate conditions for maximum immunostaining. Protocols are
summarized in Table 6.
Throughout this thesis the term 'perivascular' is used to describe the presence of cells
and proteins in the region associated with the endometrial vasculature. Endothelial,
fibroblast and smooth muscle cells are present in this area. This term has been used
to describe similar cell/protein localization in previous studies (Critchley, et al., 1999;































































Table6:Detailsprotocolsusedforimmunohi toch micalinves igationfproteiexpr onre o uctivesues. MW=microwaveantigenretrievals ep.Allincubatio sw thpr maryan ibodiesrov rnightt4°Cwitthxcep ionft cytokeratinantibody(1hour37°C).
2.3.1 NIK
NIK immunohistocheinistry was performed on paraffin sections (5pm). These were
dewaxed in histoclear and rehydrated in descending grades of alcohol. After washing
in PBS a microwave antigen retrieval step was performed. Sections were heated in
0.01 M sodium citrate (pH 6) on full power for 10 minutes and were then incubated
for 20 minutes in the oven. After further washing in PBS endogenous peroxidase
activity was blocked with 3% hydrogen peroxide in distilled water for 10 min at room
temperature. Sections were washed for 10 min in PBS and then diluted normal goat
serum was applied to all tissue sections for 20 min in a humidified chamber at room
temperature. Tissue sections were incubated overnight at 4°C with 50pl of rabbit
anti-NIK antibody (1:200 dilution in goat serum). The primary antibody was
substituted with an equimolar concentration of rabbit immunoglobulin (IgG) in
negative control sections. After the primary antibody incubation, sections were
washed between each stage for 10 min in PBS + Tween. Sections were incubated
with biotinylated goat-anti rabbit IgG and then with an avidin-biotin peroxidase
detection system (ABC; both for 60 min at room temperature). The peroxidase
substrate diaminobenzidine, which forms a brown precipitate on contact with the
antigen-antibody complex, was used to identify positive staining. Sections were
counterstained with Harris's haemotoxylin, dehydrated in ascending grades of
alcohol and mounted from xylene in Pertex.
2.3.2 IKKcc
This protocol was identical to that for NIK immunolocalization with the exception
that the primary antibody was anti-IKKa <hluted 1:800 in goat serum) and
incubations with the secondary antibody and ABC were for 40 minutes only.
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2.3.3 CD40
CD40 immunostaining was performed on frozen tissue sections (5p.m). These were
lightly fixed in NBF for 10 min at room temperature. After washing in PBS an
endogenous peroxidase block was carried out and the remainder of the protocol was
similar to that of NIK (section 2.3.1). The non-immune block used normal horse
serum. The primary antibody was mouse anti-CD40 (G28-5; diluted 1:4 in horse
serum) and equimolar mouse IgG was applied to negative control sections (overnight
at 4°C). Sections were sequentially incubated with biotinylated horse-anti mouse IgG
and ABC (both 60 minutes, room temperature). The protocol was completed as for
NIK.
2.3.4 Thy-1
Thy-1, a molecule expressed on fibroblasts, was immunolocalized using an identical
protocol to that for CD40 with the exception that the primary antibody was for Thy-1
(1:10 dilution in horse serum). The negative control sections were incubated with
mouse IgG at a concentration of lp.g/ml. The Thy-1 antibody was in a culture
supernatant and so, the antibody concentration could not be determined. Hence, the
concentration of mouse IgG was not matched to that of anti-Thy-1.
2.3.5 CDla
Immunolocalization of the dendritic cell marker, CDla, was performed on paraffin
sections and the protocol was similar to that of NIK. A microwave antigen retrieval
step was necessary prior to the endogenous peroxide block. The non-immune block
used normal horse serum and the primary antibody was anti-CDla (1:50 dilution in
horse serum). The concentration of antibody was unknown so the mouse IgG could
not be concentration matched. It was used at a concentration of 2(xg/ml. Sections
were sequentially incubated with biotinylated horse-anti mouse IgG and ABC (both




SLPI immunohistochemistry was performed on paraffin sections. After this stage the
protocol was similar to that of NIK. There was no antigen retrieval step. The
primary antibody was goat anti-SLPI (1:400 in horse serum) and negative control
sections were incubated with equimolar concentrations of goat IgG. After overnight
incubation at 4°C, the sections were treated with biotinylated horse-anti goat IgG and
then, ABC (both for 60 min at room temperature). The protocol was then completed
as above.
2.3.7 Cytokeratin
Cytokeratin immunolocalization was performed to confirm the absence of infiltrating
trophoblast cells in decidual biopsies. Cytokeratin is present in endometrial epithelial
cells but any additional immunoreactivity indicates the presence of trophoblast cells.
Any biopsies found to have such contamination were excluded from the study.
Immunolocalization of cytokeratin used paraffin sections and the protocol was
similar to that of NIK. However, no antigen retrieval step was necessary. The
primary antibody was mouse anti-cytokeratin (1:60 in horse serum). Negative
control sections were incubated with equimolar concentrations of mouse IgG. It
should be noted that incubation with the primary antibody was for 1 hour at 37°C.
Sections were then treated with biotinylated horse-anti mouse IgG and ABC (both for
60 min at room temperature). The protocol was completed as described above.
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2.3.8 Scoring of immunohistochemistry
Location and intensity of NIK and IKKa immunostaining was measured using a
semi-quantitative scoring system. A score of 0 indicated no immunoreactivity; 1
faint immunoreactivity; 2 strong immunoreactivity and 3 very strong
immunoreactivity. Sections were scored by two observers (blind to the stage of
menstrual cycle). This scoring system is a standard method used in previous studies
(Critchley, et ah, 1998b; Jones, et ah, 1997; Wang, et ah, 1998).
2.4 In vitro culture
2.4.1 Tissue Culture
Tissue was cultured on sterilized polypropylene capillary matting in RPMI 1640
supplemented with 10% fetal calf serum, penicillin (50|ig/ml), streptomycin
(50pg/ml) and gentamycin (5pg/ml; complete medium). Endometrium and decidua
were cultured in the presence of oestradiol (10"8M) and any additional treatments
(detailed in chapters 3-6) were added. Tissue was incubated for 24 hours and then
culture medium was removed for subsequent inclusion in enzyme linked
immunosorbent assays (ELISAs). Tissue was weighed after incubation and all assay
measurements were corrected for weight. Tissue that was to be collected for RNA
extraction was immersed in Tri reagent immediately after culture and processed as
detailed in section 2.2.
2.4.2 Cell Culture
HeLa and Ishikawa cells were cultured in 24 well cultured plates; T47D and MFE
cells were cultured in 25cm3 culture flasks. All cells were cultured at a concentration
of 2xl03cells/ml in complete medium. After passaging cells were incubated for 24
hours to allow adherence to the well/flask. Treatments were added and cells were
incubated for an appropriate time (detailed in chapters 3-6). Culture supernatants
were then removed for subsequent inclusion in ELISAs. In the event that cells were
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collected for RNA extraction (see section 2.2), Tri reagent was added directly to
culture wells and then harvested. Cells in culture flasks were trypsinized, centrifuged
to form a pellet (2000 rpm, 3 min) and then resuspended in Tri reagent.
2.5 Enzyme linked immunosorbent assays (ELISA)
IL-8 and SLPI protein concentrations in culture supernatants were determined by
ELISA. The protocol for the IL-8 ELISA has been previously described (Denison, et
al., 1997).
2.5.1 IL-8 ELISA
Plates were passively coated overnight at 4°C with lOOpl/well of capture antibody
(4p,g/ml). After incubation, plates were washed in water and 100pl/well of blocking
solution was added. After 30 min at room temperature the solution was flicked out
and plates were air dried and stored at 4°C. Prior to use, plates were washed in water.
Standards were diluted in ELISA buffer (top standard 500pg/ml). lOOjilAvell of
standard or sample was added. Plates were sealed and incubated overnight at 4°C.
Plates were washed 4 times in wash buffer and then detection antibody (50ng/ml)
was added at lOOpl/well. Incubation was for 90 min on a plate shaker at room
temperature. Plates were washed as above. 100pl/well of streptavidin peroxidase
(1:1000 dilution) was added and plates were incubated for 20 min on a plate shaker at
room temperature. Plates were washed as above. 200pl/well of substrate was added.
Plates were left for 20 min, quenched with 50|il/well of 2N sulphuric acid and then
read on a plate reader at 450nm.
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2.5.2 SLPI ELISA
Assay plates (96 well) were coated with 0.025pg/ml recombinant SLPI in PBS and
1% 400mM carbonate buffer. lOOpl was added to each well. Plates were left for 60
min at room temperature. Blocking was carried out with 400pl/well
blocking/protecting solution for 30 min. Plates were washed (wash buffer). 150|xl of
standard/sample and 50pl of anti-SLPI (2|ig/ml; diluted in ELISA buffer) were
added to each well. A non specific binding well (200|il buffer only) and two Bo wells
(150pl buffer; 50pl anti-SLPI) were included on each plate. Standards were added in
triplicate and their concentration range was from 0.098-50ng/ml. Incubation was on
a plate shaker at room temperature for 2 hours. Plates were washed. 100pl/well of
peroxidase labeled anti-sheep/goat IgG Fab fragments raised in donkey (1:1000
dilution of stock in ELISA buffer) was added. Incubation was on a shaker as before.
Plates were washed. 200pl substrate was added to each well. After 2-10 minutes
wells were quenched with 50pl/well 2N sulphuric acid. Plates were read in a plate
reader at 450nm.
2.6 Statistical analysis
All statistical analysis performed in this research project used Statview 3.0.
Statistical tests used are described in individual chapters. Throughout this thesis
statistical differences are indicated on graphs by the use of letters (shown above the
relevant bars). For example, in Figure 14 the letter 'a' indicates that IkBcc mRNA
expression in perimenstrual endometrium is significantly different to that in the
proliferative phase. P values relating to the letters used are shown in the top right of
each figure.
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The endometrium is a major target tissue of progesterone and the hormone is crucial
to successful implantation and pregnancy. Its presence during the secretory phase of
the menstrual cycle is vital to the development of the endometrium in preparation for
implantation. For example, as a consequence of progesterone production, glandular
secretory activity ensues, pinopodes develop and production of chemokines such as
MCP-1 and IL-8 is suppressed (Jones, et al., 1997; Martel, et ah, 1989). The
presence of the hormone is also required for the stromal decidualization that occurs in
the late secretory phase and further, in early pregnancy. Equally, progesterone is
critical to the maintenance of pregnancy once established. It causes
immunosuppression at a time when inflammatory and immune events would be
detrimental to the development of the fetus (Siiteri and Stites, 1982). This occurs via
several mechanisms, some of which may be indirect. For instance, suppression of
inflammatory mediator expression and modulation of T cell activity may be induced
by cytokine release from endometrial cells that possess the progesterone receptor.
The withdrawal of progesterone at the end of the menstrual cycle is a crucial event in
the initiation of the proinflammatory events associated with menstruation.
Endothelins and prostaglandins mediate vasoconstrictive events (Cameron, 1992) and
upregulation of proinflammatory molecules such as IL-8, MCP-1 and COX-2 occurs
upon progesterone withdrawal (Critchley, et al., 1999; Jones, et al., 1997).
Leukocytes infiltrate the tissue (Jeziorska, et al., 1995; Poropatich, et al., 1987) and
tissue degradation occurs under the influence of MMPs (Lockwood, et al., 1998;
Salamonsen and Woolley, 1999).
Although progesterone production and its subsequent withdrawal are the key
processes involved in implantation/pregnancy and menstruation the precise molecular
mechanisms by which it mediates its actions are unclear. The NFkB pathway has
been implicated in the production of many inflammatory molecules e.g. IL-8,
MMPs, COX-2 (Adcock, et al., 1997; Mauviel, et al., 1992; Vincenti, et al., 1998)
and several such molecules are involved in endometrial function. However, there is
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little data regarding the role of NFkB in endometrium although it has been reported
to be involved in the upregulation of LIF and IL-6 associated with implantation
(Laird, et al., 2000). As detailed previously, progesterone (and other steroid
hormones) suppresses the NFkB pathway at several levels and it has been suggested
that this may be involved in reproductive function (van der Burg and van der Saag.,
1996). Cross-talk between these pathways in endometrium is likely. Suppression of
NFkB by progesterone would be consistent with the immunosuppressive effects of
progesterone that occur during the secretory phase of the cycle and in pregnancy. In
contrast, progesterone withdrawal premenstrually may release inhibition of the
pathway and would allow activation of NFkB. This may contribute to the
inflammatory events surrounding menstruation.
This chapter details the expression and possible regulation of NFkB pathway
intermediates in human endometrium and first trimester decidua. Additionally, the
effects of NFkB inhibition on inflammatory molecule expression by endometrial
epithelial cells are discussed.
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3.2 Methods
3.2.1 Human uterine tissue collection
Endometrial (n=32), decidual (n=6) and trophoblast (n=5) samples were collected as
detailed in section 2.1. Biopsies utilized in this chapter are detailed in Table 7.








First trimester decidua 6
Trophoblast villi 5
Table 7: Details biopsies used in the studies presented in Chapter 3.
Biopsies used in the RT-PCR studies (detailed below) were treated as three groups:
perimenstrual, proliferative and secretory phases. The term 'perimenstrual' is used to
describe biopsies from the premenstrual and menstrual phases of the cycle (Figure
11). Although the histological appearance of premenstrual and menstrual tissue
differs, the circulating levels of oestradiol and progesterone at these times are very
similar (circulating sex steroid concentrations are shown in Figure 12 & 13).
Initiation of menstruation results from the withdrawal of progesterone. Therefore,
investigation of biopsies from the time immediately prior to, and during,


















Figure 11: The perimenstrual phase. In this thesis the term 'perimenstruaT is used
to describe endometrium from the premenstrual and menstrual phases of the cycle.
At these times circulating levels of both oestradiol (E2) and progesterone (P4) are
low. The perimenstrual phase lasts from approximately day 26 to day 5 of the
menstrual cycle and is highlighted by the red line. Data regarding oestradiol and
progesterone levels are adapted from Marshall and Odell, 1989.
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Figure 12: Serum oestradiol (E2) concentrations relating to endometrial biopsies
collected during the perimenstrual (peri), proliferative (prol) and secretory (sec)
phases of the menstrual cycle, 'n' numbers are shown above bars. Paired letters
indicate statistical significance (a:P<0.05).
Figure 13: Serum progesterone (P4) concentrations relating to endometrial biopsies
collected during the perimenstrual (peri), proliferative (prol) and secretory (sec)
phases of the menstrual cycle, 'n' numbers are shown above the bars. Paired letters











































3.2.2 Uterine tissue analyses
3.2.2a RNA extraction and RT-PCR
RNA was extracted from endometrial (n=14), decidual (n=6) and trophoblast (n=5)
biopsies and cDNA was prepared as detailed in general materials and methods, 2.2.1
and 2.2.2.
PCR reactions were performed on these cDNA samples (see 2.2.3). Expression of
mRNA for the following NFkB pathway intermediates was measured: IkBcx, IKKa,
IKKP, IKKy, MEKK1, NIK and TBK1.
3.2.2b Immunohistochemistry
IKKa and NIK proteins were localized in endometrium (n=18) and decidua (n=4)
using the protocols described in 2.3.1 and 2.3.2. Location and intensity of protein
immunolocalization was subsequently scored as detailed in the material and methods
(section 2.3.8).
101
3.2.3 In vitro cell culture studies (cell line)
3.2.3a Cell culture
MFE cells (endometrial epithelial cell line) were cultured as described in 2.4.2.
Treatments were as described in Table 8.
Treatment Concentration used Incubation time




MG132 + IL-1 3pM + lng/ml
SN50 5pg/ml
SN50 + IL-1 5pg/ml + lng/ml
Table 8: Details treatment of the MFE endometrial epithelial cell line.
MG132 and SN50 both inhibit the activation of NFkB. MG132 is a peptide aldehyde
proteasome inhibitor. Inhibition of proteasome activity prevents degradation of IkBoc
causing retention of NFkB in the cytoplasm (Bush, et ah, 1997). SN50 is a cell
permeable peptide which carries the nuclear localization sequence of the NFkB p50
subunit and so, prevents the translocation of NFkB into the nucleus (Lin, et al.,
1995).
3.2.3b RNA extraction and RT-PCR
After incubation RNA was extracted and cDNA prepared. COX-2, IL-8 and IkBcc
mRNA levels were measured in these cDNA samples by quantitative PCR (see 2.2).
102
3.2.3c IL-8 ELISA
Culture supernatants from the above cell culture experiments were collected for
subsequent inclusion in IL-8 ELISAs (see 2.5.1).
3.2.4 Statistical analysis
PCR (tissue only) results were analyzed using analysis of variance (ANOVA)
(Statview 3.0). Individual differences were assigned using Fisher's protected least
squares differences (PLSD) test. Immunohistochemical semi-quantitative scoring
results were analysed using non-parametric statistics. Differences between
immunoreactivity in different endometrial compartments (e.g. glands, stroma)
throughout the menstrual cycle were assessed using the Kruskall-Wallis method.
Variations in immunoreactivity in equivalent compartments in the functionalis and
basalis regions of endometrium from the same tissue sections (e.g. glands in
functionalis vs glands in basalis) were determined using the Wilcoxin rank test.
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3.3 Results
3.3.1 Uterine tissue analyses
3.3.1a Progesterone withdrawal (menstruation) and high progesterone levels
(pregnancy) have differential effects on NFkB pathway intermediates mRNA
levels
IkBcc mRNA levels are increased in perimenstrual endometrium relative to other
cycle stages (Figure 14; P<0.01). In addition, a trend towards increased IkBoc levels
in secretory relative to proliferative endometrium is noted. There is a further increase
in first trimester decidua and this is significantly higher than levels in the
proliferative phase (Figure 14; P<0.05).
The molecules involved in activation of NFkB are found to be differentially
expressed in decidua. NIK expression is increased in first trimester decidua
compared to endometrium from all cycle stages (Figure 15; P<0.001). In contrast,
MEKK1 mRNA levels are decreased in first trimester decidua relative to
endometrium (Figure 17; decidua/perimenstrual and decidua/secretory P<0.05;
decidua/proliferative PO.Ol).
Amounts of IKKa mRNA are found to be increased in first trimester decidua (Figure
16; decidua/perimenstrual P<0.05; decidua/secretory P<0.01) while IKK(3 mRNA
levels are decreased in decidua relative to endometrium from the perimenstrual phase
(Figure 18; P<0.05). Messenger RNA expression of the scaffolding protein, IKKy, is
decreased in first trimester decidua relative to endometrium from the secretory phase
of the cycle (Figure 19; P<0.05).
Messenger RNA for TBK1, a kinase with homology to an inducible IKK, is
expressed at higher levels in endometrium from the perimenstrual phase when
compared to biopsies from the secretory phase (Figure 20; P<0.05).
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peri prol sec dec tb
tissue biopsy type
Figure 14: IkBcx mRNA expression in perimenstrual (peri), proliferative (prol) and
secretory (sec) endometrium, decidua (dec) and trophoblast (tb). All sample PCR
measurements are related to an internal control (proliferative endometrial sample)
and these ratio are presented in the figure (y axis = ratio to calibrator), 'n' numbers









































Figure 17: MEKK1 expression in perimenstrual (peri), proliferative (prol) and
secretory (sec) endometrium, decidua (dec) and trophoblast (tb). All sample PCR
measurements are related to an internal control (proliferative endometrial sample)
and these ratio are presented in the figure (y axis - ratio to calibrator), 'n' numbers
are shown above bars. Paired letters indicate statistical significance (a and e:P<0.05;
b, c, d and f:P<0.01).
Figure 18: IKK(3 mRNA expression in perimenstrual (peri), proliferative (prol) and
secretory (sec) endometrium, decidua (dec) and trophoblast (tb). All sample PCR
measurements are related to an internal control (proliferative endometrial sample)
and these ratio are presented in the figure (y axis = ratio to calibrator), 'n' numbers






































































3.3.1b Localization of NIK and IKKa in human endometrium and first
trimester decidua
Both NIK (Figure 21 a&b) and IKKa (Figure 22 a&b) proteins were present
predominantly in the glandular epithelial cells of endometrium from all stages of the
menstrual cycle. Endothelial immunostaining was also observed in some blood
vessels. Little stromal staining was present and was only observed in the stroma
adjacent to the luminal epithelium.
No significant changes to immunolocalization of the proteins were detected during
the menstrual cycle. There was a trend towards decreased IKKa stromal
immunoreactivity in the late secretory phase but this was likely to be due to the
sloughing of the surface endometrium associated with menstruation. A trend towards
increased expression of IKKa in the functionalis layer of the endometrium was also
observed. This was apparent for all compartments at all stages of the cycle but was
only significant for the stroma in the proliferative phase (P<0.04).
In first trimester decidua both proteins were localized in the glandular epithelium.
Moderate IKKa immunoreactivity was observed in the decidualized stromal cells and
in the endothelium of some blood vessels. NIK was also localized to the
decidualized stromal cells although immunoreactivity was faint. NIK was absent
from the decidual endothelium. Figures 21 c&d and 22 c&d show NIK and IKKa
immunolocalization in first trimester decidua, respectively.
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Figure 21: Immunohistochemical localization of NIK in human endometrium and
first trimester decidua. Pictures are shown at two magnifications (x20 and x40). (a
and b). Secretory endometrium. NIK is present in the glandular epithelium and
endothelial cells. Little immunoreactivity is present in the stroma. Arrows show
location of endothelium, (c and d). First trimester decidua. Immunoreactivity is
present in the glandular epithelium with faint immunostaining present in decidualized
stromal cells, (e). Negative control. Primary antibody replaced with rabbit
immunoglobulin at equimolar concentration. Scale bars=100pm. Scale bar in (d)
also relates to (b); scale bar in (e) relates to (a) and (c).
113
Ill*
Figure 22: Immunohistochemical localization of IKKa in human endometrium and
first trimester decidua. Pictures are shown at two magnifications (x20 and x40). (a
and b). Proliferative endometrium. IKKa immunoreactivity is present in the
glandular epithelium and endothelial cells. Little immunoreactivity is present in the
stroma (only adjacent to luminal epithelium - not shown). Arrows show location of
endothelium, (c and d). First trimester decidua. Immunoreactivity is localized
mainly to the decidualized stromal cells and is also present in the glandular
epithelium. Some endothelial immunoreactivity is also present (not shown), (e).
Negative control. Primary antibody replaced with rabbit immunoglobulin at
equimolar concentration. Scale bars=100pm. Scale bar in (d) also relates to (b);
scale bar in (e) relates to (a) and (c).
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3.3.2 In vitro cell culture studies (endometrial epithelial MFE cells)
3.3.2a The effects of the NFkB inhibitors, SN50 and MG132, on IL-8, COX-2
and IkBcx mRNA expression
The data described below represents the mean values from two separate experiments.
All treatments were for 24 hours. Treatment of MFE cells with IL-1 caused IL-8
mRNA expression to be raised 3 fold above control values. However, this was not
prevented by the addition of the NFkB inhibitors, SN50 and MG132. MG132 alone
increased IL-8 mRNA by 140 fold with a further increase of 2.4 fold in the presence
of IL-1. SN50 alone had little effect on IL-8 expression but, in the presence of IL-1,
mRNA levels were raised 100 fold. (Figure 23).
COX-2 mRNA expression changed in a similar fashion although the effects of the
inhibitors were reduced. An increase of 2 fold was observed upon treatment with IL-
1 alone. MG132 alone, and with IL-1, caused increases of 17 and 37 fold,
respectively. Again, treatment with SN50 alone had little effect. Treatment with IL-
1 and SN50 caused an 11 fold increase in COX-2 mRNA expression. (Figure 24).
As expected IL-1 caused an increase in IkBoc expression. This was not reduced by
treatment with either SN50 or MG132. Neither of these inhibitors affected IkBcc
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control IL-1 MG132 MG132/IL-1 SN50 SN50/IL-1
treatment
Figure 25: iKBa mRNA expression in MFE cells. The results of two separate
experiments are shown (Exp 1 = Experiment 1; Exp 2 = Experiment 2). Data are
presented as the fold increase in IkBoc mRNA expression relative to control levels.
Cells were treated with the NFkB inhibitors, MG132 and SN50, in the absence and
presence of interleukin-1 (IL-1). All treatments were for 24 hours. As only two
experiments were performed statistical analysis was not possible.
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3.3.2b The effects of the NFkB inhibitors, SN50 and MG132, on IL-8 protein
expression
The IL-8 protein expression profile (Figure 26) in the presence of IL-1 and the NFkB
inhibitors was similar to that of the mRNA. IL-1 increased IL-8 protein expression 2
fold compared to control values. MG132 alone increased protein levels 43 fold with
a further increase of 1.7 fold in the presence of IL-1. SN50 alone, and in the presence
of IL-1, caused a 3 and 18 fold upregulation of IL-8 protein expression, respectively.
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control IL-1 MG132 MG132/IL-1 SN50 SN50/IL-1
treatment
Figure 26: IL-8 protein expression in MFE cells. The results of two separate
experiments are shown (Exp 1 = Experiment 1; Exp 2 = Experiment 2). Data are
presented as the fold increase in IL-8 protein expression relative to control levels.
Cells were treated with the NFkB inhibitors, MG132 and SN50, in the absence and
presence of interleukin-1 (IL-1). All treatments were for 24 hours. As only two
experiments were performed statistical analysis was not possible.
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3.4 Discussion
In endometrium, high progesterone levels are associated with immunosuppressive
effects while progesterone withdrawal premenstrually initiates the inflammatory
events associated with menstruation. The molecular mechanisms that allow
progesterone to mediate immunosuppression and, its withdrawal, to precipitate
inflammatory-like events are unclear. The NFkB pathway regulates the expression
of several molecules involved in menstruation and implantation and is also inhibited
by progesterone. The results presented in this chapter suggest that intermediate
molecules in the NFkB activation pathway (see Chapter 1, Figure 4) are differentially
regulated during the cycle and the results accord with a modulating role of
progesterone.
Menstruation - A role for NFkB?
IkBoc is the key molecule involved in the activation of NFkB. The phosphorylation
of IkBo, by upstream kinases occurs in the presence of an appropriate stimulus. IkBcc
is then ubiquitinated and degraded by the proteasome allowing free NFkB to enter
the nucleus where it regulates gene transcription. Expression of IkBcc is upregulated
by NFkB activation allowing self-limitation of inflammatory actions (Sun, et ah,
1993). Additionally, the steroid hormones, dexamethasone and progesterone, exert
some of their anti-inflammatory effects by upregulating IkBoc expression (Auphan, et
ah, 1995; Scheinman, et ah, 1995a; Wissink, et ah, 1998).
Figure 27 details the role of the NFkB pathway in menstruation. Expression of IkBoc
mRNA is greater in perimenstrual endometrium than in endometrium from other
stages of the cycle. Upregulation of IkBoc as a result of high progesterone levels is
not possible at this time as progesterone concentrations have declined due to the
demise of the corpus luteum (see Figure 13). Instead, it is likely that activation of
NFkB during menstruation results in increased IkBcc expression. NFkB activation is
likely to occur as progesterone concentrations fall premenstrually, relieving the
inhibition of the pathway. This would be likely to mediate, at least partly, the
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upregulation of inflammatory molecules such as IL-8, MCP-1 and COX-2 which has
been reported to occur premenstrually and in a model of progesterone withdrawal
(Critchley, et ah, 1999; Jones, et ah, 1997). Each of these molecules has been
reported to be upregulated by NFkB in other systems (Adcock, et ah, 1997; Martin, et
ah, 1997; Mauviel, et ah, 1992). NFkB also contributes to the regulation of other
molecules which are involved in menstruation e.g. MMPs, IL-1, TNFa (Hiscott, et
ah, 1993; Shakhov, et ah, 1990; Vincenti, et ah, 1998). In addition, the increased
production of inflammatory mediators during menstruation is likely to further
activate NFkB. For example, endothelin-1, PGE2and IL-1 are known stimuli of the
pathway (Gallois, et ah, 1998; Muroi and Suzuki, 1993; Osborn, et ah, 1989). As
detailed previously, NFkB activation is preceded by IkBcc ubiquitination. Ubiquitin
immunoreactivity is reported to increase in the endometrial glandular epithelial cells
in the late secretory phase (Bebington, et ah, 1999). However, this is unlikely to be
related to increased ubiquitination of IkBoc (and, hence, NFkB activation) as the
ubiquitin was detected in the nuclei, rather than the cytoplasm, of the cells.
Activation of NFkB during menstruation is also suggested by the observation that
mRNA expression of the IKK-like kinase, TBK1, is increased in the perimenstrual
phase relative to the secretory phase. This kinase is 48% homologous to an inducible
IKK identified in mouse macrophages (Pomerantz and Baltimore, 1999). Its mRNA
expression profile in endometrium suggests upregulation as a result of progesterone
withdrawal and implies a role in menstruation. Alternatively, the increased
production of inflammatory mediators such as IL-1 during menstruation may
stimulate TBK1 expression. This would be consistent with induction of the mouse
inducible IKK by IL-1 and LPS (Shimada, et ah, 1999).
In the secretory phase of the cycle progesterone receptor expression is maintained in
the endometrial stromal cells, particularly those in the perivascular region (Wang, et
ah, 1998). This suggests that the effects of progesterone withdrawal on the NFkB
pathway will occur primarily via actions on these cells. The perivascular cells
express several chemokines and their close proximity to the blood vessels suggests
that they are likely to have a role in the vascular events involved in menstruation. The
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immunolocalization of IKKa and NIK in endometrium shows that these elements of
the NFkB cascade are not present in the fibroblast cells of the perivascular region
(although they are present in endothelium). Immunohistochemical studies focusing
on the expression of IKK(3 and TBK1 are necessary to determine if these kinases are
present in the perivascular region and also, to clarify the effects of progesterone
withdrawal on the potential expression of these kinases by the perivascular cells.
When menstruation ceases NFkB activity is likely to be reduced. This might occur
as a result of increasing oestradiol concentrations (ER has also been reported to
interact with NFkB (McKay and Cidlowski, 1998)) and also, sloughing of the tissue
involved in the inflammatory response.
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Figure 27: The NFkB pathway in the perimenstrual phase. Prior to menstruation
progesterone levels decline rapidly and this is likely to release progesterone-mediated
inhibition of the NFkB pathway. The resultant activation of the pathway is likely to
contribute to the proinflammatory mechanisms associated with menstruation. In the
perimenstrual phase, IkBoc mRNA expression is increased suggesting that NFkB is
activated at this time. Also, mRNA expression of an IKK-like kinase, TBK1, is




Pregnancy - Suppression of NFkB activity?
As detailed above progesterone has local immunosuppressive actions during
pregnancy. During this time NFkB would be expected to be inhibited to prevent an
inappropriate inflammatory response which would be detrimental to the fetus.
However, high progesterone levels exert differential effects on the expression of
NFkB pathway intermediates in first trimester decidua. This is highlighted in Figures
28 and 29.
The IKK complex is responsible for the phosphorylation of IkBcx and consists of two
protein kinases, IKKa and IKKP, and the scaffolding protein, IKKy. IKKa and
IKKP have been reported to have different functions with IKKa thought to be
involved in mediating morphogenic signals to NFkB (Hu, et al., 1999; Takeda, et ah,
1999) while IKKP is primarily involved in proinflammatory signalling (Delhase, et
al., 1999; Li, et al., 1999). This suggests that the two kinases may also have
divergent roles in endometrium. This is supported by the observation that IKKa
mRNA expression is higher in first trimester decidua than in endometrium whereas
IKKP levels are decreased in decidua. NIK and MEKK1, two kinases shown to
interact with the IKK complex, are thought to preferentially phosphorylate IKKa and
IKKP, respectively (Ling, et al., 1998; Nakano, et al., 1998). Interestingly, these
kinases are differentially regulated in endometrium similar to their target proteins.
Expression of NIK mRNA is increased in decidua relative to endometrium while
MEKK1 mRNA levels are downregulated. Messenger RNA expression of the
scaffolding protein, IKKy, is significantly lower in decidua relative to secretory phase
endometrium. IKKy is thought to interact primarily with IKKP (Rothwarf, et al.,
1998) and so the decreased levels in decidua may be linked to the reduced expression
oflKKp.
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Figure 28: Differential expression of mRNA for NFkB pathway intermediates in
first trimester decidua relative to secretory endometrium. Data is presented as the log
of decidual mRNA expression:secretory mRNA expression. Both NIK and IKKa are
expressed at a greater level in decidua than in endometrium. In contrast, MEKK1
and IKK(3 are decreased in decidua. IKRy mRNA expression is also reduced in
decidua while IkBoc and TBK1 are increased, 'n' numbers are shown above bars
(number of decidua/number of secretory endometrium). Statistical analysis relating
to expression of NFkB intermediates throughout the menstrual cycle and in first
trimester decidua is presented in Figures 14-20.
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Figure 29: The NFkB pathway in early pregnancy. In the presence of the high
progesterone levels of early pregnancy there is differential expression of intermediate
molecules in the NFkB pathway. The expression of NIK and IKKa (Pathway A) is
upregulated in decidua while the expression of MEKK1 and IKK(3 (Pathway B) is
reduced. The MEKKl-IKKp pathway is thought to mediate proinflammatory signals
to NFkB and activation of this pathway is likely to be detrimental to the fetus. In
contrast, the NIK-IKKa pathway may be involved in decidual growth and

























The apparent differential regulation of the signalling pathways to NFkB has several
implications. First, as proinflammatory signalling to NFkB is believed to occur via
IKK(3 it is interesting that this kinase and MEKK1, its activating kinase, are
decreased in first trimester decidua (Figure 29, Pathway B). This suggests that the
proinflammatory signalling pathway to NFkB is inhibited during pregnancy and is
consistent with the local immunosuppressive effects of progesterone. Second, the
increased expression of IKKa and NIK (Figure 29, Pathway A) suggests that
signalling to NFkB is not universally inhibited by progesterone. Although
proinflammatory mechanisms are suppressed during pregnancy, decidua is the source
of many molecules which are thought to be beneficial to pregnancy e.g. COX-2, GM-
CSF (Jokhi, et al., 1994; Psychoyos, et ah, 1995). These can be upregulated by NFkB
activation (Adcock, et al., 1997). Also, the NFkB pathway may be involved in the
growth and differentiation processes that occur in first trimester decidua with
upregulation of NFkB reported to occur during decidualization in the rat (Thienel, et
al., 2000).
IKKa and NIK proteins were detected in endometrium and decidua by
immunohistochemistry. Both were detected primarily in the glandular epithelium of
endometrium. Expression of IKKa and NIK protein in endometrium did not vary
during the menstrual cycle and this is consistent with mRNA levels. In decidua both
proteins were also present in the decidualized stromal cells. The immunolocalization
of IKKa and NIK proteins in the stromal cells of decidua, but not endometrium, is in
keeping with the increased mRNA expression of IKKa and NIK in first trimester
decidua. The only previous study investigating NFkB activity in endometrium
detected the p65 (Rel A) subunit of NFkB in glandular epithelium (and stroma) and
suggested that it had a role in the upregulation of LIF and IL-6 during the
implantation window (Laird, et al., 2000). The identification of IKKa and NIK in
these cells confirms that some upstream molecules in the NFkB signalling pathway
are also present. In addition to involvement in LIF and IL-6 expression, NFkB may
be involved in the production of several other molecules by the glandular epithelium
e.g. TNFa, prostaglandins (Lumsden, et al., 1984; Tabibzadeh, et al., 1995b). IKKa
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and NIK are also expressed by the endothelial cells of endometrium. Angiogenesis is
involved in menstruation and implantation (Rogers, et ah, 1992; Smith, 1998) and
NFkB activation has a role in modulating the expression of angiogenic factors by
endothelial cells (Yoshida, et ah, 1997). Also, NFkB has been reported to upregulate
expression of adhesion molecules such as VCAM-1 and so, may have a role in
leukocyte infiltration of the endometrium (Iademarco, et ah, 1992).
The effects of progesterone on endometrial IkBcc expression remain unclear.
iKBamRNA expression is greater in the secretory phase than in the proliferative
phase. There is a further increase in expression in decidua. These increases are
coincident with the increasing concentrations of progesterone which occur in the
secretory phase and the subsequent maintenance of these levels in early pregnancy.
This suggests that progesterone may increase IkBoc levels in decidua and may be
inhibiting NFkB activation by certain stimuli e.g. IKK(3 activity. This is consistent
with the results to be presented in chapter 6 (which show increased expression of
IkBoc in the progesterone receptor expressing T47D cell line as a result of
progesterone treatment) and also, with previous studies (Miller and Hunt, 1998;
Wissink, et ah, 1998). Alternatively, the increased expression of IkBoc mRNA
expression in decidua may occur as a result of NFkB activation via the IKKa-NIK
pathway. The mechanisms by which IKKa and IKK(3 differentially activate NFkB
are currently unexplained. However, one possible explanation is that the kinases may
phosphorylate different forms of IkB-NFkB.
This study has focused on the actions of progesterone on the NFkB pathway in the
uterus. It should be noted that glucocorticoids are regarded as physiological
antagonists of NFkB (McKay and Cidlowski, 1999) and contribute to the regulation
of the NFkB pathway in other sites (for mechanisms of regulation see Chapter 1,
section 1.3.6). The actions of glucocorticoids on the IKK complex and the upstream
kinases have not been fully evaluated and these may differ to the effects of
progesterone in the uterus.
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NFkB and pathophysiological events in endometrium
In addition to potential roles in endometrial physiology the NFkB pathway is likely
to be involved in pathophysiological events. Menstrual problems, such as
dysmenorrhea and menorrhagia, and some types of infertility are related to aberrant
expression of inflammatory mediators. NFkB may contribute to these problems. In
addition, one of the main functions of endometrium is mucosal defence. In this
respect it is similar to tissues such as lung and gut. The NFkB system has a role in
mucosal defence (as recently reviewed in the case of the intestinal epithelium (Jobin
and Sartor, 2000)) and this is likely to be a key function of the pathway in
endometrium. The localization of components of the pathway in the epithelium,
throughout the cycle, supports the concept that NFkB activation is likely to be
involved in the defence against uterine infections.
Production of inflammatory molecules by endometrial epithelial cells - Effects
of NFkB inhibition.
Previously, it has been shown that in primary cultures of endometrial epithelial cells
the NFkB inhibitors, MG132 and SN50, inhibit IL-1 and TNFa induced IL-6 and LIF
production (Laird, et ah, 2000). In the MFE endometrial epithelial cell line the
expression of IL-8 and COX-2 was increased by IL-1 stimulation. However,
simultaneous treatment with MG132 and SN50 did not cause inhibition of this effect.
Instead, there was a dramatic increase in IL-8 and COX-2 expression in the presence
of MG132. A smaller increase occurred under the influence of SN50 and IL-1. IL-8
protein expression was consistent with the mRNA profile. These results are
surprising although there are several possible explanations. First, the proteasome is
involved in the degradation of several proteins (Lee and Goldberg, 1998) and
inhibition may interfere with pathways other than that of NFkB. This may mean that
another pathway involved in the regulation of IL-8 and COX-2 expression has been
affected by MG132 treatment. Second, inhibition of NFkB may decrease the
production of cytokines that reduce IL-8 and COX-2 expression. This would result in
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upregulation of the mediators. Finally, there may be differences between the
cytokine control mechanisms present in the MFE cell line and primary cells.
In summary, the results presented in this chapter describe the presence of the NFkB
pathway in endometrium. A role for the pathway in menstruation (Figure 27) is
suggested by the upregulation of IkBoc and the IKK-like kinase, TBK1, in the
perimenstrual phase. Additionally, differential regulation of the IkBoc kinases, IKKa
and IKK(3, and the upstream kinases, NIK and MEKK1, has been observed in first
trimester decidua (Figure 29). The proinflammatory signalling pathway, MEKK1-
IKKP, is decreased in decidua suggesting suppression of inflammatory mechanisms
at this time. However, upregulation of the NIK-IKKa NFkB activation pathway
occurs indicating that signalling can occur via NFkB in decidua. This is likely to
have a role in modulating expression of factors, such as COX-2, which are crucial to
successful pregnancy.
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4: The CD40-CD40 ligand system in human
endometrium and first trimester decidua
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4.1 Introduction
CD40 and its ligand, CD40L, are involved in proinflammatory signalling via the
NFkB signal transduction pathway (Berberich, et al., 1994). Alternatively, the
system can activate other signal transduction pathways including JAK-STAT
(Hanissian and Geha, 1997). As detailed earlier CD40 is expressed on various cell
types while CD40L is expressed predominantly on bone marrow derived cells.
Fibroblasts from various sites, including lung and gingiva, have been found to
express CD40 (Fries, et al., 1995; Sempowski, et al., 1998). Recent reports have
suggested an important role for the CD40-CD40L system in fibroblast physiology.
Initially, it was thought that fibroblasts were merely inert, structural cells but it has
now been suggested that they interact with cells of the immune system. The CD40-
CD40L system may be an important mediator involved in this (Smith, et al., 1997).
Some types of fibroblast display increased expression of the proinflammatory
cytokines, IL-6 and IL-8, upon engagement of CD40 with CD40L (Sempowski, et al.,
1997a; Sempowski, et al., 1997b; Sempowski, et al., 1998). Additionally, increased
COX-2 expression and hence, PGE2 production, results from stimulation of lung
fibroblasts via this system (Zhang, et al., 1998).
In a reproductive context there is little information regarding the CD40-CD40L
system. Recent work from our laboratory has shown that endometrial, cervical and
myometrial fibroblasts display CD40 in vitro and that upregulation occurs in the
presence of IFNy. These cells display increased expression of the chemokines, IL-8
and MCP-1, and the cytokine, IL-6, upon stimulation with CD40L (King, et al.,
2000b). This is particularly interesting as the role of these molecules in reproductive
tissues has been, at least partly, elucidated. As detailed earlier (Chapter 1, section
1.2.2) both IL-8 and MCP-1 are present in the endometrial perivascular area and are
involved in leukocyte chemotaxis prior to menstruation (Critchley, et al., 1994;
Jones, et al., 1997). IL-8 also has a role in neutrophil chemotaxis during cervical
ripening (Kelly, et al., 1992; Sennstrom, et al., 1997). Additionally, IL-6 is expressed
in the endometrium from the mid-secretory phase onwards with increased expression
as the cycle progresses (Tabibzadeh, et al., 1995a). A role in menstruation has been
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suggested and increased production has recently been associated with cervical
ripening (Sennstrom, et ah, 2000).
The localization of CD40 and CD40L in endometrium, first trimester decidua and
myometrium has not previously been established although CD40 has been detected in
the squamous epithelium of cervical carcinoma (Altenburg, et ah, 1999). The
presence of the CD40-CD40L system on fibroblasts in vivo in these tissues could
provide a link between resident structural cells and infiltrating leukocytes and may be
involved in modulation of inflammatory mediator expression. A role in
pathophysiological events such as dysfunctional bleeding would also be possible.
The results in this chapter detail the protein expression of CD40, and mRNA
expression of both CD40 and CD40L, in endometrium and decidua.
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4.2 Methods
4.2.1 Human uterine tissue collection
Endometrial (n=37), decidual (n=12) and trophoblast (n=4) biopsies were collected as
detailed in 2.1. Non-pregnant myometrium (n=18) was present in full thickness
endometrial biopsies (these are described in Chapter 2, section 2.1) and this was
utilized in immunohistochemical studies. Human first trimester cervical biopsies
(all<63 days gestation) were available from a parallel study supported by the Medical
Research Council (grant no: G9620138 and G9406438) addressing the local effects
of antiprogestogen and prostaglandin administration. Paraffin tissue sections were
available from n=8 'control' cervical biopsies included in the above studies (no
antiprogestogen). Biopsies included in this chapter are detailed in Table 9.






Mid secretory 7 |
Late secretory 3 I
Myometrium (non-pregnant) 18
First trimester decidua 12
Trophoblast villi 4
Cervix (pregnant - first trimester) 8
Table 9: Details biopsies used in the studies presented in Chapter 4.
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4.2.2 Uterine tissue analyses
4.2.2a RNA extraction and RT-PCR
RNA was extracted from endometrial (n=19), decidual (n=5) and trophoblast (n=4)
biopsies and cDNA was prepared. Quantitative PCR was performed in order to
determine amounts of CD40 and CD40L mRNA expression. All protocols are
detailed in section 2.2.
4.2.2b Immunohistochemistry
CD40 was immunolocalized in endometrial biopsies (n=18) from throughout the
menstrual cycle and in first trimester decidua (n=7). CD40 expression was also
investigated in cervix (n=8) and myometrium (n=18). Similarly, the cell surface
glycoprotein, Thy-1 (expressed by fibroblasts), was localized in endometrium (n=4)
and decidua (positive control tissue). CD la (expressed by dendritic cells) was
examined in tonsil (positive control tissue), endometrium (n=4) and cervix (n=3). All
immunohistochemistry protocols are detailed in general materials & methods, 2.3.
4.2.2c CD40L Immunohistochemistry
Standard immunohistochemistry protocols (as detailed in section 2.3) were tested on
frozen and paraffin embedded tissue sections. Antigen retrieval in paraffin sections
was attempted using microwaving, pressure cooking in glycine-EDTA buffer and
trypsin digestion. Endometrial biopsies from several cycle stages and decidual
biopsies (control and from patients administered with RU486 prior to biopsy
collection) were investigated. Tonsil biopsies (positive control) were also examined.
The primary antibody was tested at concentrations ranging from 0.5 to 4 |ag/ml. In
addition, immunolocalization was attempted using a catalyzed amplification
technique (Catalyzed Signal Amplification System Peroxidase, Dako Ltd.,
Cambridge, UK). CD40L transfected cells (Looney cells) were used throughout as a
positive control. Cells were seeded onto 8 well chamber slides (poly-L-lysine
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coated) and after adherence were treated with brefeldin A (10p.g/ml; Sigma, Poole,
UK) for 24 hours. This causes the intracellular accumulation of newly synthesized
proteins due to inhibition of protein transport from the endoplasmic reticulum to the
Golgi apparatus. After incubation with brefeldin A cells were fixed in NBF for 30
minutes at room temperature and then permeablized with Triton XI00 at 37°C. The
slides of CD40L expressing cells were subsequently treated in an identical manner to
tissue sections (although these slides were not included in antigen retrieval steps)
4.2.3 In vitro cell culture studies (cell line)
4.2.3a Cell culture
T47D cells were cultured as described previously (see 2.4.2). Table 10 shows the
treatments administered. Fetal calf serum stripped of steroid hormones was used
throughout.
Treatment Concentration used Incubation time
Control N/A 0, 2, 4, 8 and 24 hours
Progesterone 10"6M 2, 4, 8 and 24 hours
Table 10: Details treatment of the T47D breast epithelial cell line. T47D cells
express high levels of progesterone receptor (see Chapter 6).
4.2.3b RNA extraction and RT-PCR
After the above incubations RNA extraction and RT-PCR were performed as detailed
earlier (section 2.2). CD40 mRNA expression was measured by PCR.
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4.2.4 Statistical analysis
PCR results (tissue only) were analyzed using ANOVA. Individual differences were
assigned using Fisher's PLSD test.
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4.3 Results
4.3.1 Uterine tissue analyses
4.3.1a CD40 and CD40L mRNA expression in endometrium and decidua
Expression of CD40 mRNA was increased in first trimester decidua in comparison to
endometrium from all stages of the menstrual cycle (Figure 30; P<0.001). CD40L
mRNA expression had a similar expression profile with highest levels in decidua
(Figure 31; P<0.0001).
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Figure 30: CD40 mRNA expression in perimenstrual (peri), proliferative (prol) and
secretory (sec) endometrium, decidua (dec) and trophoblast (tb). All sample PCR
measurements are related to an internal control (proliferative endometrial sample)
and these ratio are presented in the figure (y axis = ratio to calibrator), 'n' numbers
are shown above bars. Paired letters indicate statistical significance (a, b, c and
d:P<0.001).
Figure 31: CD40L mRNA expression in perimenstrual (peri), proliferative (prol)
and secretory (sec) endometrium, decidua (dec) and trophoblast (tb). All sample PCR
measurements are related to an internal control (proliferative endometrial sample)
and these ratio are presented in the figure (y axis = ratio to calibrator), 'n' numbers
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4.3.1b Immunolocalization of CD40 in endometrium, decidua, cervix and
myometrium
Positive CD40 immunostaining was detected predominantly in the perivascular
region of endometrial biopsies from all stages of the menstrual cycle (Figure 32a&b).
CD40 was immunolocalized to this region in both superficial and basal endometrium.
The area around the blood vessels that expressed CD40 was several cell layers deep.
Moderate immunostaining was also detected on stromal cells, particularly those in the
basal and subglandular regions of endometrium (Figure 32b). White blood cell and
very faint epithelial immunoreactivity was also observed in some biopsies. No
differences were observed in CD40 immunostaining relative to menstrual cycle stage.
In first trimester decidua strong CD40 immunostaining was apparent in the
perivascular region. Decidualized stromal cells also expressed CD40. (Figure
32d&e).
CD40 immunoreactivity was present in the perivascular cells of cervix (Figure
33a&b) and myometrium (Figure 33d&e). Faint immunostaining was also observed
in fibroblast-like stromal cells. Additionally, CD40 was detected in the basal
epithelium of cervical biopsies.
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Figure 32: Immunohistochemical localization of CD40 in human endometrium and
first trimester decidua. Photomicrographs are at two magnifications. Arrows show
the location of blood vessels. (a). Early secretory endometrium (serum
progesterone: 39.7nmol/L). CD40 immunoreactivity is present in the perivascular
area and in some stromal cells. Only very faint immunostaining is found in the
glandular epithelium, (b). Endometrium. Blood vessels at higher magnification.
CD40 stromal immunolocalization is shown (s). (c). Endometrium. Negative
control. Primary antibody replaced with mouse immunoglobulin at equimolar
concentrations. (d). First trimester decidua. CD40 is present in the perivascular
cells and in the large decidualized stromal cells, (e). First trimester decidua. Blood
vessels at higher magnification, (f). First trimester decidua. Negative control. Scale
bars=l00p.m. Scale bar in (c) also relates to (b); scale bar in (f) relates to (e).
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Figure 33: CD40 immunolocalization in human myometrium (non-pregnant) and
cervix (first trimester). Photomicrographs are at two magnifications. Arrows show
the location of blood vessels, (a). Cervix (day 65 of gestation). CD40
immunoreactivity is present in the perivascular area, some stromal cells (s) and in the
basal epithelium, (b). Cervix. Blood vessel at higher magnification, (c). Cervix.
Negative control. Primary antibody replaced with mouse immunoglobulin at
equimolar concentrations, (d). Myometrium. CD40 is present in perivascular cells
and in some fibroblast-like stromal cells (s). (e). Myometrium. Blood vessel at
higher magnification, (f). Myometrium. Negative control. Scale bars = 100pm.
Scale bar in (d) also relates to (a); scale bar in (f) relates to (b), (c) and (e).
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4.3.1c Immunolocalization of Thy-1 (expressed by fibroblasts) in endometrium
and decidua
A distinctive pattern of Thy-1 stromal immunostaining was observed in all
endometrial biopsies studied. Stromal cells in the basalis layer exhibited very little
Thy-1 immunostaining (Figure 34a). In contrast, strong immunoreactivity was
present in the stromal cells of the functionalis layer (Figure 34b). Positive Thy-1
immunoreactivity was observed in the perivascular area in both functionalis and
basalis regions (Figure 34a&b). The perivascular region which expressed Thy-1 was,
as for CD40 expression, several cell layers deep.
In first trimester decidua diffuse Thy-1 immunoreactivity was observed in the
decidualized stromal cells and particularly, in the perivascular cells (Figure 34c).
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Figure 34: Thy-1 immunolocalization in human endometrium and first trimester
decidua. Arrows show the location of blood vessels. (a). Basalis endometrium.
Thy-1 is present in the cells surrounding the blood vessels and the glandular
basement membrane but is not present in the stromal cells, (b). Functionalis
endometrium. Thy-1 is present in perivascular cells and throughout the stroma, (c).
First trimester decidua. Immunoreactivity is present in the cells around the blood
vessels and in the large decidualized stromal cells, (d). Negative control. Primary
antibody substituted with mouse immunoglobulin at a concentration of lpg/ml.
Scale bar = 100p.m.
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4.3.Id Immunolocalization of the dendritic cell marker, CDla, in endometrium
Positive CDla immunostaining was observed in human tonsil (positive control
tissue) in cells infiltrating the epithelium (Figure 35a). Similarly, a small number of
cells infiltrating the squamous cervical epithelium displayed CDla immunoreactivity
(Figure 35c). No obvious CDla expression was observed in endometrium (Figure
35b).
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Figure 35: Immunohistochemical localization of the dendritic cell marker, CDla, in
human endometrium, cervix and tonsil, (a). Tonsil (positive control). CDla is
present on dendritic cells infiltrating the epithelium, (b). Endometrium. No
immunostaining was observed, (c). Cervix. Immunoreactivity is present on cells
infiltrating the squamous epithelium, (d). Negative control. Primary antibody





It was not possible to detect CD40L in endometrium using any of the protocols
tested. However, CD40L transfected cells displayed positive immunoreactivity
throughout (Figure 36a). This inability to detect CD40L may be due to the transient
nature of CD40L expression. Alternatively, although immunolocalization was
attempted in biopsies from throughout the menstrual cycle, CD40L may have a very
limited expression window in endometrium.
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Figure 36: CD40L immunolocalization in CD40L-transfected cells, (a). CD40L is
present in the cytoplasm of the cells. Although CD40L is normally expressed on the
cell membrane, treatment with brefeldin A ensures that the cells retain CD40L in the
cytoplasm (see 4.2.2c, immunohistochemistry). (b). Negative control. The primary




4.3.2 In vitro cell culture studies (breast epithelial T47D cell line)
4.3.2a Effects of progesterone on CD40 mRNA expression in T47D cells
Progesterone had no effect on CD40 mRNA expression by T47D cells during the 0-




Figure 37: CD40 mRNA expression in T47D cells. Cells were treated with and
without progesterone for 0-24 hours (x-axis). Data is shown as the ratio of
progesteronercontrol values (y-axis) and the results of two separate experiments are
shown. Progesterone had no effect on the expression of CD40 mRNA in T47D cells.
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4.4 Discussion
The results in this chapter describe the presence of CD40 on the perivascular cells of
endometrium. This finding suggests a role for the CD40-CD40L system in the
regulation of the inflammatory events which are associated with menstruation and
implantation (Finn, 1986; Kelly, 1994). Additionally, CD40 is present in the
perivascular region of cervix and myometrium and may have a role in cervical
ripening and parturition, which are also proinflammatory events.
CD40 has been detected in vitro on fibroblasts from several sites including
endometrium, myometrium and cervix (King, et ah, 2000b). The synthesis of the
chemokines, IL-8 and MCP-1, and the cytokine, IL-6, by these fibroblasts is
increased upon CD40 engagement. In endometrium, MCP-1 and IL-8 expression is
upregulated in the perivascular area premenstrually (Jones, et ah, 1997). Increased
IL-8 mRNA and protein expression is also observed in an in vivo model of
progesterone withdrawal (Critchley, et ah, 1999). The identification of CD40 on the
perivascular cells suggests that activation of this system may be responsible for the
upregulation of these chemokines prior to menstruation. Additionally, COX-2
increases perivascularly in the late secretory phase of the menstrual cycle and after
progesterone withdrawal (Critchley, et ah, 1999; Jones, et ah, 1997) while
perivascular PGE2 is upregulated in decidua after administration of a progesterone
antagonist (Cheng, et ah, 1993a). CD40 activation could also be involved in this as
increased COX-2 and PGE2 expression occurs upon engagement of CD40 on lung
fibroblasts (Zhang, et ah, 1998).
The perivascular region includes endothelial cells, fibroblasts and smooth muscle
cells. The nature of the cell types expressing CD40 in this area is unclear although all
of the above have been reported to express CD40 (Fries, et ah, 1995; Hollenbaugh, et
ah, 1995; Mach, et ah, 1997). However, a recent report (Oliver, et ah, 1999) has
suggested that decidual perivascular cells (predecidual cells) have ultrastructural
characteristics similar to myofibroblasts and has shown immunohistochemically that
these cells express both Thy-1 (a molecule expressed by fibroblasts and smooth
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muscle cells (Dalchau, et al., 1989)) and a marker of smooth muscle differentiation,
a-smooth muscle actin (Darby, et al., 1990). Similar to CD40 expression, Thy-1 is
present on several cell layers around the blood vessels and this suggests that the same
cells express both CD40 and Thy-1. However, colocalization studies are necessary to
confirm that CD40 is expressed on myofibroblasts in the endometrial perivascular
region and also, that these are the cells that express IL-8, MCP-1 and COX-2. In first
trimester decidua, CD40 is expressed in the perivascular region and there is also more
diffuse immunoreactivity present in the decidualized stromal cells. These cells are
believed to form from the proliferation and differentiation of the endometrial stromal
cells and this, decidual change, begins around the spiral arterioles (Loke and King,
1995). As discussed above, the perivascular cells have a phenotype consistent with
that of the myofibroblast and this is also true of the decidualized stromal cell (Oliver,
et al., 1999). The expression of both CD40 and Thy-1 by the perivascular cells of the
endometrium and the decidualized stromal cells is consistent with this report and
suggests that both molecules are expressed by myofibroblasts.
In addition to Thy-1 the expression of the dendritic cell marker, CD la, was
investigated. A previous study has suggested that dendritic cells constitute only a
very minor cell population in endometrium with dendritic-like cells identified in an
epithelial location in only five of thirty endometrial samples (Kamat and Isaacson,
1987). This finding along with the absence of CD la immunoreactivity in the few
endometrial samples investigated in this study suggests that dendritic cells are
unlikely to be a major source of CD40 in endometrium. CD la expression was
observed on cells infiltrating the cervical squamous epithelium and this confirms
previous reported data (Poppe, et al., 1998).
In vitro fibroblast CD40 expression is upregulated by IFNy. In endometrium,
expression of CD40 is also likely to be maintained by the presence of an
inflammatory mediator. T cells associated with endometrial lymphoid aggregates,
present between the bases of glands in the basalis region, have been suggested as a
likely source of IFNy(Tabibzadeh, 1994). If these cells do produce IFNy they may
be responsible for the CD40 stromal staining found in the basalis and subglandular
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regions of endometrium (there is less stromal staining in the functionalis). However,
the reports suggesting that lymphoid aggregates produce IFNy have been disputed in
a study which states that neutrophils are the main source of endometrial
IFNy(Yeaman, et ah, 1998). Neutrophils are closely associated with menstruation
(Poropatich, et al., 1987) and may have a role in regulating CD40 expression via
IFNy release. However, this would be in contrast to the finding that CD40 expression
is menstrual cycle independent.
The activation of CD40 relies on the presence of CD40L expressing cells at the local
site. Although it was not possible to detect CD40L immunohistochemically in this
study, there are several cell types capable of expressing CD40L present in
endometrium. Resident T cells, macrophages and mast cells are present throughout
the menstrual cycle while eosinophils infiltrate the endometrium premenstrually.
Activated platelets also express CD40L (Henn, et al., 1998) and these may be present
in the uterus during bleeding or infection. Additionally, uterine NK cells are present
in the mid-late secretory phase (Jeziorska, et al., 1995; Loke and King, 1995;
Poropatich, et al., 1987). In first trimester decidua, uterine NK cells and
macrophages are present in greatest number (Loke and King, 1995). It is likely that
the function of the CD40-CD40L system in endometrium and decidua involves
mediating an interaction between resident structural cells and infiltrating leukocytes.
There are several potential roles for the CD40 system in endometrium. As detailed
above, CD40 activation may be involved in the upregulation of chemokines by the
perivascular cells in the late secretory phase of the menstrual cycle. This suggests
that CD40 may have a role in menstruation by modulating the systems involved in
leukocyte recruitment. As the activation of CD40 is likely to be dependent upon the
presence of leukocytes it is possible that the system may not be involved in the initial
upregulation of chemokine synthesis. Instead, it may be that the system is part of a
positive feedback loop which, as leukocytes infiltrate the tissue, allows further
chemokine production. This is consistent with the observation that CD40
immunoreactivity is not upregulated in the late secretory phase of the menstrual cycle
(i.e. upon progesterone withdrawal). This was further substantiated by the findings
165
that CD40 mRNA expression did not significantly differ during the menstrual cycle
and also, that progesterone had no effect on CD40 mRNA expression in T47D cells.
This lack of CD40 regulation by progesterone and its subsequent withdrawal suggests
that the pathway is primarily controlled by indirect steroid regulation of the migration
of CD40L-expressing leukocytes into endometrium. It is also likely that CD40 is
involved in the tissue regeneration that occurs during and after menstruation.
Endometrial leukocytes have been suggested to contribute to this via cytokine release
and phagocytosis of debris (Salamonsen, 2000). It is also possible that leukocytes
expressing CD40L would activate CD40-expressing myofibroblasts in endometrium.
Myofibroblasts have contractile activity and are thought to be involved in wound
healing (Schurch, et al., 1992). The actions of the CD40-CD40L system during
menstruation are likely to be mediated, at least in part, by activation of the NFkB
pathway. As described in chapter 3 (section 3.4), NFkB activation in the perivascular
region, as a result of progesterone withdrawal, is most likely to be mediated via the
proinflammatory kinase, IKK{3, or the IKK-like kinase, TBK1 .
In first trimester decidua, CD40 is present in higher levels than in endometrium.
Also, the mRNA expression profile of CD40L suggests that it is present at greatest
levels in first trimester decidua (mRNA levels are very low in endometrium). The
presence of an apparently proinflammatory system in decidua is surprising.
However, the striking similarity between the patterns of CD40 and CD40L mRNA
expression and those of NIK and IKKa is interesting (see chapter 3, section 3.3,
Figures 15&16). This observation suggests that if the CD40 system activates the
NFkB pathway in decidua it may do this via IKKa rather than the proinflammatory
IKK(3. As discussed in chapter 3 the consequences of such differential signalling is
unclear but it may have a role in the growth and differentiation of decidua and the
regulation of molecules such as COX-2 which are vital for successful pregnancy. It
should also be noted that the CD40 system can activate signal transduction pathways
other than that of NFkB and that this may be involved in endometrial and decidual
physiology. The potential roles of the CD40-CD40L system in endometrium and
first trimester decidua are summarized in Figure 38. Possible interactions with the
NFkB pathway are also detailed.
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As described above, CD40 is also present in cervix (pregnant) and myometrium (non¬
pregnant) and is expressed in the perivascular cells of these tissues. This suggests a
role in the proinflammatory events associated with cervical ripening and parturition.
The CD40-CD40L system is likely to be involved in the increased expression of IL-8
in the ripening cervix and in the lower segment myometrium during labour (Kelly, et
ah, 1992; Sennstrom, et ah, 1997; Thomson, et ah, 1999). In the cervix increased IL-
8 production, in synergy with PGE2, results in the recruitment and activation of
neutrophils which is crucial to the ripening process (Colditz, 1990; Rampart, et ah,
1989). Cells capable of expressing CD40L are present in both cervix and
myometrium. Mast cells and eosinophils are present in the ripening cervix and
macrophages are present from late pregnancy onwards (Knudsen, et ah, 1997). In
myometrium, T cells and macrophages are present at the onset of labour. Mast cells
are also present but at lower levels than in the non-pregnant state (Thomson, et ah,
1999).
In addition to a role in physiological reproductive events the CD40-CD40L system
may be involved in pathophysiological problems. As described in chapter 3,
dysfunctional menstrual bleeding is likely to involve the aberrant expression of
uterine molecules. For example, there is reduced expression of oc-smooth muscle
actin in the perivascular region of straight arteries in women suffering from
menorrhagia (Abberton, et ah, 1999). Inflammatory mediators associated with the
perivascular region of endometrium and myometrium (e.g. prostaglandins) may also
be associated with menorrhagia and it seems likely that dysregulation of the CD40
system could be involved. Premature labour is associated with increased expression
of proinflammatory cytokines in the uterine cavity particularly during infection
(Romero, et ah, 1990; Romero, et ah, 1991). The CD40-CD40L system may be
activated during uterine infection and may contribute to the upregulation of cytokines
such as IL-6. Recently, CD40 has been detected in cervical carcinoma with CD40L
present on infiltrating T cells. CD40-CD40L interactions were suggested as a
possible regulator of chemokine expression in carcinoma cells indicating that the
CD40 system may be involved in reproductive cancers (Altenburg, et ah, 1999).
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In summary, this study has identified CD40 on the perivascular cells of the
endometrium and other reproductive tissues. The CD40-CD40L system is likely to
be involved in proinflammatory events in these tissues (e.g. menstruation, parturition)
and in particular, the system is likely to allow interactions between resident structural
cells and infiltrating immune cells (Figure 38a). Regulation of inflammatory
molecule expression by CD40 is likely to occur via the NFkB pathway.
Additionally, the presence of the system in first trimester decidua (Figure 38b)
suggests that it may be involved in the regulation of expression of molecules, such as
COX-2, which are vital for successful pregnancy.
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Figure 38: The role of the CD40-CD40L system in endometrium and first trimester
decidua and potential interactions with the NFkB pathway. (A). In endometrium,
CD40 is expressed on the perivascular cells and is likely to be involved in
upregulation of proinflammatory molecule expression by these cells prior to, and
during, menstruation. This will encourage the migration of leukocytes to the tissue.
These leukocytes are a potential source of CD40L in endometrium. CD40 may be
activated by CD40L-expressing leukocytes and this will result in NFkB activation,
possibly via IKK(3 or TBK1. (B). CD40 is likely to be involved in activation of
NFkB in decidua via the NIK-IKKa pathway. This may contribute to the expression
of inflammatory mediators beneficial to pregnancy. Also, there may be involvement
in the growth and differentiation of decidua. It is unclear which cell types express































5: Secretory leukocyte protease inhibitor (SLPI)




Secretory leukocyte protease inhibitor (SLPI), a critical neutrophil elastase inhibitor
(Thompson and Ohlsson, 1986), is found associated with mucosal surfaces (Franken,
et ah, 1989) and is reported to have antibacterial, antiviral and antifungal effects
(Tomee, et ah, 1998). Additionally, it has more generalized anti-inflammatory
actions suppressing LPS activation of mouse macrophages (Jin, et ah, 1997) and
inhibiting MMP production by human monocytes (Zhang, et ah, 1997). SLPI also
inhibits activation of NFkB and, via this action, is likely to suppress the
inflammatory response (Jin, et ah, 1997; Lentsch, et ah, 1999). SLPI is thus a
pleiotropic molecule protecting against inflammatory insult and infection of mucosal
surfaces in several ways.
In a reproductive context, SLPI has been detected in human cervical mucosa
(Casslen, et ah, 1981), term decidua (Denison, et ah, 1999b) and seminal plasma
(Franken, et ah, 1989). This suggests that SLPI contributes to the mucosal defence
mechanisms present in the female reproductive tract. SLPI has also been localized to
the glandular and luminal epithelial cells of porcine maternal endometrium (Reed, et
ah, 1996). Additionally, the mRNA has been detected in equine and bovine
endometrium during pregnancy (Badinga, et ah, 1994). It has been suggested that
SLPI acts to maintain the uterine-placental border in these species. Expression was
thought to be related to epitheliochorial placentation as SLPI was not detected in the
endometrium of mammals with haemochorial placentation (e.g. rat) (Badinga, et ah,
1994) although this finding is in contrast to the reported presence of SLPI in human
term decidua. Mitogenic effects of SLPI on porcine endometrial epithelial cells have
also been reported suggesting that SLPI may act as an autocrine growth promoter
(Badinga, et ah, 1999).
Previous studies have failed to detect SLPI in non-pregnant human endometrium
(Casslen, et ah, 1981; Franken, et ah, 1989) although SLPI is present in uterine fluid
(Casslen, et ah, 1981). Successful human implantation and pregnancy demands that
there is control of inflammatory responses in the uterus. It seems likely that SLPI
172
may contribute to this via its antibacterial and anti-inflammatory actions. The results
presented in this chapter describe the production of SLPI by endometrium and first
trimester decidua. Regulation of SLPI production by cervical and endometrial cell
lines is also detailed.
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5.2 Methods
5.2.1 Human uterine tissue collection
Endometrial (n=56), decidual (n=24) and trophoblast (n=13) samples were collected
as described in 2.1. In addition, endometrium was collected from women using a
levonorgestrel intrauterine system (LNG-IUS; n=4) for contraception and heavy
menses. The LNG-IUS creates very high local concentrations of progestogen in
endometrium (Pekonen, et ah, 1992) resulting in decidualization (Critchley, et al.,
1998a; Critchley, et al., 1998b). The biopsies utilized in this chapter are detailed in
Table 11.








First trimester decidua 24
Trophoblast villi 13
LNG-IUS 4
Table 11: Details biopsies used in the studies presented in Chapter 5.
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5.2.2 Uterine tissue analyses
5.2.2a Tissue culture
Endometrium (n=38), endometrium from LNG-IUS users (n=4), decidua (n=18) and
trophoblast (n=13) were cultured as described in 2.4.1. The endometrial and decidual
biopsies were cultured in the presence of oestradiol (10"8M); otherwise there were no
additional treatments. Culture medium was stored for subsequent inclusion in SLPI
ELISAs.
Additionally, proliferative endometrial biopsies (n=5) were cultured with or without
progesterone (10~6M) for 24-48hours. After incubation tissue was immediately
immersed in Tri reagent for RNA extraction.
5.2.2b Acid extraction of tissue
SLPI is an acid stable molecule with a high isoelectric point (pi) and therefore more
soluble in weak acid solution. After 24 hour culture, tissue was acid extracted in the
presence of 200pl PBS and 10pl HC1 (IN) for 10 minutes. Neutralization was
achieved by addition of 10pd NaOH (IN) and 50p,l Tris buffer (1M; pH7.2).
Supernatant was collected for subsequent inclusion in SLPI ELISAs.
5.2.2c SLPI ELISA
SLPI concentrations were measured in the supernatants from the tissue culture and




SLPI was localized in endometrium (n=13) and first trimester decidua (n=6) using
the protocol detailed in 2.3.6.
5.2.2e RNA extraction and RT-PCR
RNA was extracted from endometrial (n=14), decidual (n=6) and trophoblast (n=3)
samples immediately after tissue collection as described in 2.2.1. Similarly, RNA
extraction was performed on proliferative endometrial biopsies that had been cultured
for 24-48 hours (see above). cDNA was prepared from all samples and SLPI mRNA
levels were determined by quantitative PCR using the protocols in 2.2.2 and 2.2.3.
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5.2.3 In vitro cell culture studies (cell line)
5.2.3a Cell culture
HeLa and Ishikawa cells were cultured as detailed in 2.4.2. Treatments were as
detailed in Table 12. Culture supernatants were collected for inclusion in SLPI
ELISAs.



















Table 12: Details treatments of HeLa and Ishikawa cell lines. Treatments were all
for 24 hours and SLPI secretion into culture medium was subsequently measured by
ELISA.
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5.2.3b Acid extraction of cells
This was performed as described in section 5.2.2b.
5.2.3c SLPI ELISA
Cell culture supernatants and acid extraction medium were included in SLPI ELISAs
as detailed in 2.5.2.
5.2.4 Statistical Analysis
All PCR and ELISA results in this chapter were analyzed by ANOVA. Individual
differences were assigned using Fisher's PLSD test. The only exception to this was
the experiment shown in Figure 45 (progesterone effect on SLPI mRNA expression
in endometrial explants) which was analyzed using a paired t-test.
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5.3 Results
5.3.1 Uterine tissue analyses
5.3.1a SLPI secretion by endometrium, decidua and trophoblast
First trimester decidua produces 4.411.9 ng SLPI/mg decidua of SLPI. This is
significantly higher than production by either endometrium (from throughout the
menstrual cycle; P<0.001) or trophoblast (P<0.01). These tissues produce
0.410. lng/mg and 0.1i0.04ng/mg, respectively (Figure 39). Endometrial SLPI
secretion is menstrual cycle dependent and peaks in the late secretory phase.
Secretion is 1.210.2ng/mg at this time, compared with 0.210.lng/mg in the
proliferative phase and 0.310.lng/mg in the early/mid secretory phase (Figure 40;
P0.0001). Endometrium from LNG-IUS users secretes 1.4il.0ng/mg of SLPI and
this is comparable to production by late secretory endometrium.
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Figure 39: SLPI production by control endometrium (endo; throughout cycle),
endometrium from levonorgestrel-intrauterine system users (LNG-IUS), first
trimester decidua (dec) and trophoblast (tb). 'n' numbers are shown above bars.
Paired letters indicate statistical significance (a :P<0.001; b:P<0.01).
Figure 40: SLPI production by endometrium from the proliferative (prol), early/mid
secretory (ES/MS) and late secretory (LS) phases of the menstrual cycle. Note that
the scale of the y-axis differs to that of Figure 39. 'n' numbers are shown above bars.











5.3.1b SLPI release from endometrium, decidua and trophoblast during acid
extraction
Endometrial release of SLPI was increased by 10.4 fold by acid extraction (relative to
release into culture medium). Decidual and trophoblast release was increased by 1.5
and 2.1 fold, respectively (Figure 41; endometrium/decidua P<0.03). The result from
one decidual sample was discounted from this analysis as the value was 118.1 (i.e.
101 standard deviations from the mean of the other values).
The increased release of SLPI from endometrium due to acid extraction is greatest
during the early/mid secretory phase of the menstrual cycle. Release is increased by
19.6 fold at this time while release from proliferative and late secretory endometrium
is increased by 5.3 and 2.9 times, respectively (Figure 42: P<0.01). These results
suggests that the majority of SLPI produced by endometrium in the early/mid
secretory phase is not secreted into culture medium.
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Figure 41: SLPI release as a result of acid extraction of endometrium (endo),
decidua (dec) and trophoblast (tb). SLPI release into acid extracted supernatant is
presented as fold increase over secretion into culture medium (y-axis). 'n' numbers
are shown above bars. Paired letters indicate statistical significance (a :P<0.003).
Figure 42: SLPI release as a result of acid extraction of endometrium from the
proliferative (prol), early/mid secretory (ES/MS) and late secretory (LS) phases of the
menstrual cycle. SLPI release into acid extracted supernatant is presented as fold
increase over secretion into culture medium (y-axis). Note that the scale of the y-axis
differs to that of Figure 41. 'n' numbers are shown above bars. Paired letters indicate
statistical significance (a :P<0.001; b:P<0.01).
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5.3.1c Localization of SLPI in endometrium and decidua
SLPI immunoreactivity was present in the glandular epithelium and secretions in
endometrial biopsies from the mid to late secretory phase. In some biopsies positive
immunostaining was also observed in the luminal epithelium. SLPI was present
mainly in glands in superficial areas of endometrium. No stromal staining occurred
(Figure 43b). Very little SLPI immunoreactivity was detected in endometrium from
the proliferative and early secretory phase (Figure 43a).
In first trimester decidua SLPI immunoreactivity was again present in glandular
epithelial cells and secretions. SLPI was also detected in the decidualized stromal
cells of some decidual biopsies (Figure 43c).
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Figure 43: Immunohistochemical localization of SLPI in human endometrium and
first trimester decidua. (a). Proliferative endometrium. No immunoreactivity is
present, (b). Late secretory endometrium. Immunoreactivity is present in the
epithelial cells and secretions of the glands. No immunostaining is observed in the
stroma, (c). First trimester decidua. SLPI immunoreactivity is present in the
glandular epithelium and secretions. Immunostaining is present in stromal cells, (d).
Negative control. Primary antibody is replaced with goat immunoglobulin at
equimolar concentrations. Scale bars = 100p,m.
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5.3.1d SLPI mRNA expression in endometrium and decidua
Decidual samples contained 0.5±0.3 of SLPI mRNA. This was greater than both
proliferative and secretory endometrium which had 0.2±0.04 and 0.4±0.3,
respectively (Figure 44; not significant).
Progesterone treatment of proliferative endometrial biopsies for 24 or 48 hours






prol sec dec tb
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Figure 44: SLPI mRNA expression in endometrium from the proliferative (prol) and
secretory (sec) phases of the menstrual cycle, first trimester decidua (dec) and
trophoblast (tb) (not significant). All sample PCR measurements are related to an
internal control (proliferative endometrial sample) and these ratio are presented in the
figure (y axis = ratio to calibrator), 'n' numbers are shown above bars. No
significant differences were found between SLPI mRNA expression in different
tissue types. It should be noted that trophoblast SLPI mRNA is detectable by PCR
and is present at very low levels. The value of less than 0.01 shown.in this figure
reflects the presence of trophoblast SLPI mRNA relative to an internal control (which






Figure 45: Progesterone effect on SLPI mRNA expression in proliferative
endometrium. Data is presented as the % of SLPI mRNA present in control samples.
Progesterone treatment resulted in a trend towards increased SLPI mRNA expression
in all endometrial explants investigated (n=5; not significant).
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5.3.2 In vitro cell culture studies (cell lines)
Both the cervical (HeLa) and the endometrial (Ishikawa) epithelial cell lines secreted
SLPI under control culture conditions. The cells were treated with various agents
(see Table 12) and SLPI in culture supernatants and acid extracted medium was
measured by ELISA. No significant regulation of SLPI secretion into culture
medium was found for any treatment of HeLa or Ishikawa cells (Figures 46&48).
However, when HeLa cells were acid extracted both dexamethasone and EGF
treatment resulted in upregulation of SLPI release when compared to control values
(Figure 47; P<0.01).
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Figure 46: SLPI production by the HeLa cervical epithelial cell line. Cells were
treated with PGF2a (50ng/ml; PGF2a 50), progesterone (prog), lipopolysaccharide
(LPS), lipoteichoic acid (LTA), IL-6, PGE2, PMA, EGF, indomethacin (indo),
rolipram, dexamethasone & progesterone (dex/prog), PGF2a (350ng/ml; PGF2a 350),
prolactin and dexamethasone (dex). Values are presented as the % of SLPI released
into culture supernatant relative to cells treated under control conditions, 'n'
numbers are shown above bars. No significant differences were found to SLPI
secretion as a result of different treatments.
Figure 47: SLPI release by HeLa cells when acid extracted. Cells were treated as
detailed in Figure 46. Dexamethasone and EGF treatment resulted in increased SLPI
release. Values are presented as the % of SLPI released into acid extracted medium
relative to cells treated under control conditions, 'n' numbers are shown above bars.
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Figure 48: SLPI production by the Ishikawa endometrial epithelial cell line. Cells
were treated with progesterone (prog), LTA, IL-6, PGE2, indomethacin (indo),
PGF2a (350ng/ml; PGF2a 350), prolactin and dexamethasone (dex). Results shown
are from three separate experiments. Values are presented as the % of SLPI released
into culture supernatant relative to cells treated under control conditions. No




SLPI, an antibacterial and anti-inflammatory molecule, has been detected in the
glandular epithelium of human endometrium and first trimester decidua. This is
consistent with the production of SLPI by epithelial cells at other mucosal surfaces
such as lung and cervix (Franken, et al., 1989). The detection of SLPI in
endometrium is in contrast to previous studies which have failed to detect it in
biopsies from both the proliferative and secretory phases of the menstrual cycle
(Casslen, et ah, 1981; Franken, et ah, 1989). SLPI has been reported to be present in
uterine fluid although this was thought to be due to diffusion from the cervix
(Casslen, et ah, 1981). As a result of the work presented here, it now seems likely
that endometrial epithelial cells are the principal source of uterine SLPI.
SLPI secretion by endometrium was found to increase in the mid-late secretory phase
and this was confirmed by both culture and immunohistochemical studies. This
finding may explain why SLPI has not previously been detected in endometrium as in
earlier studies very limited numbers of biopsies were investigated (with only two
from the secretory phase). Acid extraction was performed to ensure that the SLPI
values measured in culture medium were a true representation of SLPI production by
the tissue. Interestingly, acid extraction of endometrium resulted in release of SLPI
at concentrations far greater than those found in culture medium. This effect was
observed mainly during the early-mid secretory phase and suggests that at this time
endometrium is producing more SLPI than it is secreting. It may be that initiation of
endometrial SLPI production begins after ovulation and that SLPI is then released
during the mid-late secretory phase. However, SLPI has been reported to bind to
endometrial extracellular matrix proteins (Reed, et ah, 1997) and may also remain
closely associated with glandular secretory products or the mucosal epithelial cell
surface. Acid extraction in in vitro experiments may cause release of bound SLPI and
reflect more accurately the production of SLPI by endometrium. Decidua,
trophoblast and endometrium from other cycle stages released similar amounts of
SLPI during culture and acid extraction.
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First trimester decidua produced more SLPI than endometrium and trophoblast. SLPI
has previously been detected in term decidua in the large decidualized stromal cells
(Denison, et al., 1999b) while in early pregnancy decidua SLPI is expressed
predominantly in the glandular epithelium with only some stromal cells containing
SLPI. This suggests that as pregnancy progresses the site of SLPI expression
changes from the glandular epithelium to the stromal cells. A similar change of
expression site has been reported in the case of the endothelin B (ETb) receptor. It is
present in the endometrial glandular epithelium becoming apparent in the stromal
cells during menstruation and in decidualized stroma (Kohnen, et al., 1998). As
pregnancy progresses decidual glands atrophy (Buckley and Fox, 1989) and it may be
that the stromal cells begin to produce SLPI in order to maintain decidual function.
SLPI expression is increased in endometrium in the mid-late secretory phase and
further, in first trimester decidua. The amounts of mRNA present are consistent with
this. This expression profile suggests that SLPI may be regulated by progesterone.
The finding that there is a trend towards increased SLPI mRNA expression when
proliferative endometrium is treated with progesterone supports this (although this
did not reach significance). Also, progesterone has been reported to increase SLPI
secretion by cervical explants (Denison, et al., 1999a). Regulation by progesterone
could occur either by a direct action on SLPI gene expression or via an indirect
mechanism. Progesterone has morphological effects on endometrium such as
increasing the glandular surface area and has control over the expression of various
inflammatory mediators. These actions may result in secondary effects such as
increased SLPI production. Regulation of SLPI expression was investigated in
representative cell lines. Progesterone did not cause increased SLPI production by
the Ishikawa endometrial epithelial cell line. However, progesterone receptor
expression by these cells is controversial (Nishida, et al., 1985; personal
communication from Dr Nishida to Dr Kelly, Oct 18, 1994). Co-workers have
detected an increase in SLPI mRNA expression in progesterone treated T47D cells
(progesterone receptor is expressed at high levels; see Chapter 6, Figure 50). In the
HeLa cervical epithelial cell line both dexamethasone and EGF were found to
increase SLPI release upon acid extraction. These findings are consistent with
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previous reports. Glucocorticoids have been reported to upregulate SLPI production
in airway epithelial cells (Abbinante-Nissen, et al., 1995) while EGF treatment of
porcine maternal endometrial explants resulted in increased SLPI mRNA expression
(although this did not reach significance) (Reed, et ah, 1998).
As the increase in SLPI secretion in late secretory endometrium is coincident with
decidualization this may contribute to its upregulation. Endometrium from LNG-IUS
users is decidualized due to the very high local concentration of progestogen which is
1000 times greater than in serum (Pekonen, et ah, 1992). Late secretory
endometrium and endometrium from LNG-IUS users also have similar progesterone
receptor (PR) expression (Critchley, et ah, 1998b). Both have low PR expression
(although levels are maintained in the stroma of endometrium from the late secretory
phase). Culture results show that endometrium from LNG-IUS users produces
similar amounts of SLPI to late secretory endometrium. While this suggests that
decidualization may contribute to SLPI production, confirmation is necessary.
Immunohistochemical investigation of SLPI in endometrium from LNG-IUS users
may clarify this point. Also in the late secretory phase, prior to menstruation,
leukocytes infiltrate the endometrium. As neutrophils are known to be a source of
SLPI (Bohm, et al., 1992) they may contribute to the increased presence of SLPI in
endometrium at this time. However, this is inconsistent with the increased
production of SLPI by decidua and also, immunostaining suggests that the glands are
the major source of SLPI in endometrium.
There are several potential roles of SLPI in endometrium and decidua. These are
summarized in Table 13 and will be discussed in detail in the following text.
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(Badinga, et ah, 1999)
Suppression of
inflammatory mechanisms







profile is similar to
defensin 5
(Tomee, et ah, 1997)
(King, et ah, 2000a)
(Quayle, et al., 1998)
Table 13: Describes potential roles of secretory leukocyte protease inhibitor (SLPI)
in human endometrium.
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Neutrophils infiltrate the endometrium prior to menstruation (Poropatich, et ah, 1987)
and may contribute to tissue breakdown. SLPI is a potent neutrophil elastase
inhibitor and may act to limit the actions of neutrophils in endometrium. However,
this is unlikely as there is increased expression of SLPI by decidua and neutrophils
are rare (King, et al., 1998). Also, SLPI is produced in a superficial location in
endometrium and as this is the area sloughed off during menstruation it is unlikely
that SLPI is preventing tissue breakdown.
Previously, SLPI has been detected in the maternal endometrium of mammals that
have epitheliochorial placentation and it has been suggested that SLPI may maintain
the uterine-placental border in these species by controlling trophoblast invasion
(Badinga, et ah, 1994). The identification of SLPI in human endometrium and
decidua shown here indicates that endometrial SLPI is not unique to mammals that
have epitheliochorial placentation. Also, a role in control of trophoblast invasion in
humans is unlikely as SLPI is found predominantly in the superficial endometrium
whereas the trophoblast invades throughout the decidua and into the inner
myometrium (Aplin, 1991).
SLPI has also been shown to stimulate DNA synthesis by porcine endometrial
epithelial cells suggesting an autocrine growth promoting role (Badinga, et ah, 1999).
Although auto- and paracrine actions of SLPI are likely to occur in human
endometrium, promotion of epithelial cell growth is unlikely as the expression of
SLPI does not coincide with the time of maximal epithelial cell growth (i.e.
proliferative phase). Receptors for SLPI have been detected in human monocytes
although the identity of these is unclear (McNeely, et ah, 1997). Further
characterization of these binding sites and subsequent localization in endometrium
may clarify the potential auto/paracrine roles of SLPI.
Antibacterial, antifungal and antiviral actions of SLPI have been documented
(Tomee, et ah, 1997). The presence of SLPI in the cervix and male genital tract (high
concentrations in semen) has been suggested to offer antimicrobial protection of
these mucous membranes (Ohlsson, et ah, 1995). A similar role for SLPI in human
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endometrium and first trimester decidua is likely. While SLPI may have additional
functions in endometrium (as acknowledged in Table 13 and above text) its
expression around the time of implantation and during pregnancy suggests that it
would be an ideal candidate to offer protection against infection. Intrauterine
infection is thought to be the cause of premature labour in at least 20% of cases
(Romero, et ah, 1989) and natural antibiotics are likely to have a role in controlling
this.
The presence of defensins, which also have antibacterial, antiviral and antifungal
properties, has previously been reported in endometrium. Both defensin 5 and (3-
defensin 1 have been identified in epithelial cells of the endometrium and endocervix
(Quayle, et ah, 1998; Valore, et ah, 1998). Also, defensin 5 has a similar expression
profile to that of SLPI with maximal expression in the secretory phase of the
menstrual cycle (Quayle, et ah, 1998). Interestingly, one area of the SLPI molecule
has 37% homology to the defensins and five cysteines are conserved between the
molecules (King, et ah, 2000a). This area does not coincide with the N terminus of
the SLPI molecule, which is the area reported to be responsible for the antibacterial
actions. The similar expression profiles and protein sequences of SLPI and the
defensins lends further support to an antimicrobial role for SLPI in endometrium.
Several bacteria secrete proteins that degrade SLPI. This suggests that SLPI would
otherwise be harmful to these microbes. Trichomonas vaginalis is a major pathogen
of the lower female genital tract which has been found to secrete cysteine proteases
that can degrade recombinant SLPI under assay conditions (Draper, et ah, 1998). It is
currently unknown if other bacteria, such as those causing sexually transmitted
diseases, have evolved virulence factors protecting against SLPI. It has been
suggested that the presence of uterine bacteria may be associated with irregular
menstrual bleeding (Kristiansen, et ah, 1987; Moller, et ah, 1995). All patients
included in this research project reported regular menstrual cycles and no attempt was
made to distinguish between patients with reported normal and heavy menstrual
bleeding.
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In addition to a possible antimicrobial role, SLPI may have other anti-inflammatory
effects in endometrium and decidua. SLPI has been reported to inhibit the NFkB
signal transduction pathway via increased levels of IkB(3 (Lentsch, et al., 1999). This
is particularly interesting given the antibacterial properties of SLPI. IkB(1 is thought
to be involved in signalling to NFkB only by a small subset of NFkB activators.
IkB(3 is reported to respond to stimulation by LPS and IL-1 but not by TNF or PMA
(Thompson, et ah, 1995). LPS is a major component of the cell wall of Gram
negative bacteria and as such, is likely to be involved in activation of NFkB during
infection. It may be that SLPI acts to limit activation of the pathway by reducing the
NFkB response to LPS via increased levels of IkB(3. Also, expression of SLPI has
been suggested to be increased by NFkB activation (Nguyen, et ah, 1999) and this
may form a negative feedback loop. It is possible that SLPI may inhibit the NFkB
pathway at multiple levels. However, it is currently unknown if SLPI has any effects
on the IKK proteins.
In summary, the antibacterial and anti-inflammatory molecule, SLPI has been
detected in human endometrium and decidua. The temporal expression of SLPI
suggests a role in implantation and pregnancy. As detailed in previous chapters,
progesterone has immunosuppressive actions in the uterus which allow successful
pregnancy to occur. The expression of SLPI, along with other antibacterial agents,
may act to prevent infection at a time when local immune responses are compromised
(Figure 49).
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Figure 49: The potential actions of SLPI in human endometrium and first trimester
decidua. SLPI is likely to mediate a variety of anti-inflammatory actions. In
particular, antimicrobial effects and inhibition of the NFkB signal transduction
pathway are likely. Such actions are necessary to prevent inappropriate inflammatory





















As described in previous chapters the NFkB pathway is involved in the upregulation
of genes involved in the inflammatory and immune response (Baldwin, 1996). These
include proinflammatory cytokines and adhesion molecules. Glucocorticoids are
believed to act as physiological antagonists of NFkB as they suppress the expression
of several proinflammatory genes (McKay and Cidlowski, 1999). Glucocorticoids
act to inhibit the NFkB pathway and indeed, several proinflammatory molecules that
are known to be suppressed by glucocorticoids do not contain glucocorticoid
response elements in their promoter regions (McKay and Cidlowski, 1999). This
suggests an indirect mechanism of downregulation. Cross-talk between the
glucocorticoid and NFkB signal transduction pathways is thought to be involved in
this.
Glucocorticoids interact with NFkB at several levels. Dexamethasone has been
found to increase expression of the key NFkB inhibitory protein, lKBa(Auphan, et
al., 1995; Scheinman, et al., 1995a). Also, the glucocorticoid receptor has been
reported to interact directly with the p65 subunit of NFkB (Caldenhoven, et al., 1995;
McKay and Cidlowski, 1998; Ray and Prefontaine, 1994; Scheinman, et al., 1995b).
This is thought to cause inhibition of the actions of both transcription factors (GR and
NFkB). The precise mechanism of this action is unclear and may involve
competition for a common cofactor. The sex steroid hormone progesterone, which
has immunosuppressive effects in the uterus similar to those of systemic
glucocorticoid effects, also suppresses the NFkB pathway. Again, increased IkBcc
expression and interactions between the progesterone receptor (PR) and NFkB are
reported (Kalkhoven, et ah, 1996; McKay and Cidlowski, 1998; Wissink, et al.,
1998).
Several protein kinases have been implicated in the activation of NFkB. These
include IKKa, IKK(3, TBK1, NIK and MEKK1. The effects of progesterone on these
kinases are unknown and it is possible that the hormone may interact with the NFkB
pathway by modulating expression of one or more of these kinases. Expression of
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the scaffolding protein, IKKy, may also be affected by progesterone. In the context
of this research project the most appropriate cell model to study possible effects of
progesterone would be an endometrial cell line. However, it is difficult to maintain
PR expression in such cells even in the presence of oestradiol. The T47D breast
cancer cell line constitutively expresses the PR (Horwitz, et al., 1982) and, as such,
provides a good cell model to study progesterone effects on the NFkB pathway in
epithelial cells.
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that has been reported to
inhibit the NFkB pathway (Lentsch, et al., 1997; Schottelius, et al., 1999). It acts to
suppress proinflammatory cytokine production and promotes T helper 2 (Th2)
responses (Moore, et al., 1993). Adenosine-3',5'-cyclic monophosphate (cAMP) is
also reported to inhibit NFkB and the Thl response (Chen and Rothenberg, 1994;
Kelly, 1994; Manna, et al., 2000; Neumann, et al., 1995). cAMP can also activate
NFkB in myeloid cells (Serkkola and Hurme, 1993). The actions of IL-10 and cAMP
are relevant to endometrial function as during pregnancy Th2 responses are believed
to predominate while Thl activity is suppressed. The results in this chapter detail the
effects of progesterone on the intermediate molecules of the NFkB pathway in T47D




6.2.1 In vitro cell culture studies (cell line)
6.2.1a Cell culture
Culture of T47D cells was carried out as described in section 2.4.2. MFE and
Ishikawa cells (endometrial epithelial) were also cultured under control conditions for
24 hours. Tables 14-16 detail the treatment of the T47D cells. Fetal calf serum
stripped of steroid hormones was used throughout.
Treatment Concentration used Incubation time
Control N/A 0, 2, 4, 8, 24 hours
Progesterone 10"6M 2, 4, 8, 24 hours
Table 14: Details the treatment of T47D cells in order to investigate the effects of
progesterone on expression of NFkB pathway intermediates over a 0-24 hour
timecourse.
Treatment Concentration used Incubation time
Control N/A 0, 0.5, 2, 4, 24 hours
Forskolin lOpM
0.5, 2, 4, 24 hours
PGE2 + rolipram 10"6M+ lpg/ml
Table 15: Details the treatment of T47D cells cultured to investigate the effects of
forskolin and PGE2 + rolipram on NIK expression over a 0-24 hour timecourse. Both
forskolin and PGE2 + rolipram are cAMP elevating treatments.
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Treatment Concentration used Incubation time




Forskolin + progesterone 10pM + 10"6M
24 hours
Forskolin + IL-10 lOpM + 1 Ong/ml
PGE2 + rolipram 10"6M+ lpg/ml
PGE2 + rolipram +
progesterone
10"6M+ lpg/ml+ 10"6M
PGE2 + rolipram + IL-10 10~6M + lpg/ml + 1 Ong/ml
Table 16: Details the treatments used to examine the effects of IL-10, progesterone
and cAMP elevating agents on NIK mRNA expression.
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6.2.1b RNA extraction and RT-PCR
RNA was extracted from T47D, MFE and Ishikawa cells after 24 hour incubations
under control conditions. Subsequently, reverse transcription was performed and
PCR was used to determine levels of PR mRNA in each of the cell lines. The
primers and probe used to measure PR allowed detection of both PRA and PRB.
Similarly, after the incubations described in Tables 14-16 RNA was extracted from
T47D cells and cDNA was prepared. Messenger RNA expression of the following
components of the NFkB pathway was then measured by PCR: IkBoc, IKKa, IKK[3,
IKKy, TBK1, NIK and MEKK1. Protocols are described in Chapter 2, section 2.2.
6.2.2 Statistical analysis
The results of the experiment detailed in Table 16 were analyzed by ANOVA.
Individual differences were assigned using Fisher's PLSD test.
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6.3 Results
6.3a PR mRNA expression in the MFE and Ishikawa endometrial epithelial cell
lines compared to the T47D breast epithelial cell line
Figure 50 shows that expression of PR (PRa+PRb) mRNA is 1000 fold greater in
T47D cells than in either the MFE or Ishikawa endometrial cell lines. This suggests
that these endometrial cell lines are unsuitable for the study of progesterone effects
on the NFkB pathway and that the T47D cell line is an appropriate cell model for
subsequent experiments. The low expression of PR in the endometrial epithelial cell
lines may be a result of the cells being of too high passage number. The conditions




Figure 50: PR (PRa+PRb) expression in the T47D breast epithelial cell line and in the
Ishikawa and MFE endometrial epithelial cell lines. All PCR measurements are related
to an internal control (MFE cell line sample) and the ratio are presented in the figure (y
axis = ratio to calibrator). T47D cells express far greater levels of PR than either of the
endometrial cell lines. This confirms that the T47D cell line is a suitable cell model for
the investigation of progesterone effects on the NFkB pathway, 'n' numbers are shown
above bars. Paired letters indicate statistical significance (a and b:P<0.01).
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6.3b The effects of progesterone on NFkB pathway intermediate expression in
T47D cells
Figure 51 shows the effects of progesterone treatment on the following NFkB
pathway intermediates: IkBcc, IKKa, IKK(3, IKKy, MEKK1, NIK and TBK1. The
results of two separate experiments are shown and data is presented as the ratio of
progesterone:control values.
The mRNA expression of IkBoc was increased by progesterone at each of the
timepoints investigated. Progesterone treatment had little effect on the expression of



















Figure 51: Progesterone effects on NFkB pathway intermediate mRNA expression
in T47D cells. Data are presented as the ratio of progesterone:control values (y-axis)
at 0, 2, 4, 8 and 24 hours (x-axis). The results of two separate experiments are shown
(1 = experiment 1; 2 - experiment 2). IkBc* mRNA expression is increased at all
timepoints in the presence of progesterone. However, as only two experiments were
performed statistical analysis was not possible. Expression of mRNA for IKKa,
IKKP, IKKy, NIK, MEKK1 and TBK1 is not affected by progesterone at the
timepoints investigated.
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6.3c The effects of forskolin and PGE2 + rolipram on NIK mRNA expression
over a 24 hour timecourse
This experiment was carried out in order to determine an appropriate incubation time
to use in subsequent studies. Throughout the timecourse (0-24 hours) forskolin and
PGE2 + rolipram had little effect on NIK mRNA expression (Figure 52). Hence, 24





Figure 52: NIK mRNA expression in T47D cells in the presence of cAMP elevating
agents. All PCR measurements are related to an internal control (control value at
Ohr) and the ratio are presented in the figure (y axis = ratio to calibrator). Treatment
with forskolin or rolipram + PGE2 (PGE2/rol) had no effect on NIK expression at the
timepoints investigated.
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6.3d The effects of progesterone and IL-10 on NIK mRNA expression in the
presence of agents that increase cAMP levels
The results of these experiments were anomalous and as such, the effects of
progesterone and IL-10 on NIK mRNA expression remain unclear. The results of
three separate experiments suggested that both progesterone and IL-10 reduce NIK
expression in the presence of agents that increase cAMP concentrations. However, a
further three experiments showed no effect of progesterone (these experiments did
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Figure 53: Effects of progesterone and IL-10 on NIK mRNA expression in the
absence and presence of cAMP elevating agents. The results shown in this figure
suggest that progesterone and IL-10 have no effect on NIK expression (ANOVA: not
significant). However, results were anomalous with three experiments showing
progesterone and IL-10 to decrease NIK expression in the presence of forskolin while
a further three experiments (measuring the effects of progesterone only) showed no
effect. Treatments were as follows: control, progesterone (prog), IL-10, forskolin
(forsk), forskolin + progesterone (forsk/prog), forskolin + IL-10 (forsk/IL-10), PGE2
+ rolipram (E2/rol), PGE2 + rolipram + progesterone (E2/rol/prog) and PGE2 +
rolipram + IL-10 (E2/rol/IL-10). 'n' numbers are shown above bars.
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6.4. Discussion
The results presented in this chapter detail the actions of progesterone on the NFkB
pathway in T47D cells. The T47D cell line has high levels of constitutive PR
expression (Horwitz, et ah, 1982) and, as shown here, PR mRNA levels are greater
than in either the MFE or Ishikawa endometrial epithelial cell lines. Thus, the T47D
cell line was used for the studies described in this chapter. Activation of the NFkB
pathway is primarily controlled by phosphorylation-dephosphorylation events and
this is likely to be crucial to efficient activation of the pathway during the immune
response to infection. However, the pathway is also involved in physiological events
such as cell differentiation and it may be that in these circumstances levels of the
pathway intermediates are modulated. Progesterone is maintained at high levels
throughout the secretory phase of the menstrual cycle and during pregnancy and so,
any effects on the NFkB pathway are unlikely to be acute. Therefore, in the T47D
cell model progesterone effects on NFkB intermediates were investigated over a 0-24
hour timecourse. Progesterone was found to increase IkBoc mRNA expression which
would result in the inhibition of NFkB activation. This confirms the results of
previous studies (Miller and Hunt, 1998; Wissink, et ah, 1998). Progesterone was
not found to alter the levels of mRNA for the kinases, IKKa, IKK(3, MEKK1, NIK
and TBK1, or the scaffolding protein, IKKy. It is possible that lengthened exposure
to progesterone may affect these kinases or that their expression/activity is altered by
an indirect mechanism.
The effects of progesterone and interleukin-10 (IL-10) (in the presence of cAMP
elevating agents) on NIK expression were also investigated. IL-10 is an anti¬
inflammatory cytokine. Its actions include suppressing the production of cytokines
such as IL-1, IL-6 and IL-8 and diminution of the T helper 1 (Thl) response (Moore,
et ah, 1993). IL-10 inhibits NFkB activity and is reported to achieve this by initially
inhibiting IKK activity and, after prolonged treatment, via inhibition of DNA binding
of NFkB (Schottelius, et al., 1999). Additionally, preservation of IkBoc protein
expression has been reported and it was suggested that this was due to induction of
gene expression or stabilization of mRNA (Lentsch, et al., 1997). cAMP is involved
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in signalling to protein kinase A as a result of activation by many mediators e.g. PGE.
As for IL-10, cAMP has been reported to inhibit the NFkB pathway. This inhibition
has been suggested to involve downregulation of NFkB, upregulation of
IkBoc expression and inhibition of IkBoc phosphorylation (Chen and Rothenberg,
1994; Manna, et al., 2000; Neumann, et al., 1995). It has also been reported that
cAMP activates NFkB (Serkkola and Hurme, 1993) in myeloid cells although this
appears to depend on the maturity of the cells.
The effects of both IL-10 and cAMP on the NFkB pathway are relevant to
endometrial physiology. For example, in pregnancy it is believed that maternal cell
mediated immunity is suppressed allowing humoral immunity to dominate. This is
thought to involve an increased T helper 2 (Th2) cell activity with a simultaneous
decrease in Thl activity. This hypothesis was based on studies in the mouse
(Wegmann, et al., 1993) but relevance to man has been assumed. Several cytokines
are involved in this bias towards Th2 activity and IL-10 is likely to be a crucial
contributor (via its Thl suppressing actions). PGE, via stimulation of cAMP, is also
involved in suppressing the Thl response (Kelly, 1994). Interestingly, inhibition of
NFkB has been found to impair Thl but not Th2 activity (Aronica, et al., 1999).
Thus, there is scope for interactions between progesterone, cAMP, IL-10 and the
NFkB pathway.
The effects of progesterone and IL-10 on NIK mRNA expression in the presence of
cAMP elevating agents are unclear. The results of three consecutive experiments
showed, on average, a 40% and 50% reduction in NIK mRNA levels as a result of
treatment (in the presence of forskolin) with IL-10 and progesterone, respectively.
Elowever, a further three experiments showed no modulation of NIK mRNA
expression by progesterone. The reasons for these disparate findings are unclear.
However, the original three experiments coincided with a time when the T47D cells
were not growing well. The latter experiments (i.e. those that showed no effect) were
performed at a time when cell growth was normal. This suggests that stage of cell
cycle or some other factor relating to rate of cell growth may have been responsible.
The effects of progesterone and IL-10 suggest cross-talk between the cAMP-protein
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kinase A signal transduction pathway and others. For example, it has been reported
that the presence of 8-bromo-cAMP can potentiate the actions of the progesterone
receptor. The progesterone antagonist RU486 has the actions of a partial agonist in
the presence of 8-bromo-cAMP (Beck, et ah, 1993). The reason for this is thought to
be due to differential recruitment of the corepressors, nuclear receptor corepressor
(NCoR) and silencing mediator for retinoid and thyroid hormone receptor (SMRT).
The presence of 8-bromo-cAMP reduces the interaction ofNCoR and SMRT with the
PR thus potentiating its transcriptional activity (Wagner, et ah, 1998). One possible
mechanism for the results described in experiment 3 is that the reduction in NIK
mRNA by progesterone is due to forskolin potentiating the actions of PR. There are
also possible interactions between IL-10 and cAMP. For example, cAMP has been
found to increase IL-10 synthesis (Eigler, et ah, 1998; Strassmann, et ah, 1994).
In summary, the results detailed above confirm that progesterone increases IkBcc
mRNA expression and is likely to inhibit NFkB via this mechanism. There was no
evidence for actions of progesterone on the upstream kinases in the NFkB pathway.
It is possible that progesterone and IL-10 suppress NIK mRNA expression in the
presence of cAMP elevating agents. Unfortunately, the results presented here are




7.1 Synopsis of results
This thesis presents evidence suggesting that the proinflammatory NFkB signalling
pathway is involved in endometrial function. Expression of NFkB signalling
intermediates was investigated along with that of the NFkB activator, CD40, and the
NFkB inhibitor, SLPI. Progesterone control of the NFkB pathway was also studied.
As detailed previously, activation of the NFkB pathway has been shown to involve
several protein kinases: IKKa, IKK(3, NIK, MEKK1 and TBK1 (see Chapter 1,
Figure 4). IKKa and IKK(3 are held in a complex that also contains a scaffolding
protein, IKKy. The result of activation of these kinases is the phosphorylation and
subsequent degradation of the endogenous inhibitor, iKBa. This allows translocation
of NFkB to the nucleus where activation of gene expression occurs. The expression
of the above intermediates was investigated in endometrium and in T47D cells.
Expression profiles of NFkB pathway intermediates were investigated in
endometrium and first trimester decidua. IKBa and TBK1 mRNA expression was
increased in endometrium from the perimenstrual phase suggesting activation of the
pathway as a result of progesterone withdrawal. This is consistent with reports which
describe inhibitory actions of progesterone on the NFkB pathway (Kalkhoven, et ah,
1996; McKay and Cidlowski, 1998; Wissink, et ah, 1998). As a result of this,
progesterone withdrawal would be expected to release the inhibition, allowing NFkB
activation.
In first trimester decidua, differential expression of intermediates was observed
suggesting that the high progesterone concentrations of early pregnancy may
influence signalling to NFkB. The proinflammatory signalling pathway (MEKK1-
IKK(3) to NFkB was downregulated in decidua while there was increased expression
of NIK and IKKa. These kinases are thought to be involved in morphogenic
signalling to NFkB (Hu, et ah, 1999; Takeda, et ah, 1999). The expression of NIK
and IKKa in endometrium and decidua was examined by immunolocalization. Both
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proteins were expressed primarily in the glandular epithelium and the endothelium of
endometrium. In decidua, immunoreactivity was also detected in the decidualized
stromal cells. Additionally, NFkB activity was investigated in an endometrial
epithelial cell line. The presence of NFkB inhibitors resulted in an unexpected
increase in COX-2 and IL-8 expression. It should be noted that glucocorticoids
regulate the NFkB pathway in sites other than the uterus and may not have the same
effect as progesterone on pathway intermediates. Also, other transcription factors
(such as AP-1) are known to interact with NFkB and these are likely to modulate its
actions in the uterus.
The NFkB activating, CD40-CD40 ligand system was investigated in several
reproductive tissues. CD40 was found to be expressed predominantly in the
perivascular cells of endometrium and decidua (diffuse stromal staining was also
present in decidua). Similar expression was observed in myometrium and cervix.
CD40 expression was found to be progesterone independent as there were no changes
in expression during the menstrual cycle or in T47D cells treated with progesterone.
In endometrium, Thy-1 (expressed by fibroblasts) was also found to be present in the
perivascular cells. This finding is consistent with previous reports of Thy-1
expression in these cells (Oliver, et ah, 1999) and suggests that the source of CD40
expression in endometrium is likely to be myofibroblasts (the earlier study also
detected a-smooth muscle actin expression). It was not possible to measure CD40L
protein expression in the current study. However, investigation of mRNA expression
indicated that both CD40 and CD40L are present at higher levels in decidua than in
endometrium.
SLPI is a neutrophil elastase inhibitor that also has antimicrobial activity and inhibits
NFkB. This anti-inflammatory protein was found to be expressed by endometrium
during the mid-late secretory phase of the menstrual cycle. Secretion was increased
in first trimester decidua. Acid extraction studies indicated that endometrium,
cultured in in vitro studies, may not release all of the SLPI which is produced into
culture medium. SLPI was detected immunohistochemically in the glandular
epithelium of endometrium and decidua and was also expressed in the decidualized
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stromal cells of some first trimester decidual biopsies. These results suggested that
SLPI expression may be under progesterone control. This was confirmed by the
finding that culture of proliferative endometrial explants in the presence of
progesterone resulted in increased SLPI mRNA expression. This is consistent with a
colleague's results showing that progesterone has been found to increase SLPI
mRNA levels in the progesterone receptor expressing T47D cell line. Regulation of
SLPI expression was also investigated in cell lines. Dexamethasone and EGF were
found to increase SLPI production by HeLa cells.
Progesterone regulation of the NFkB pathway was studied in T47D cells. These cells
express the progesterone receptor at far greater levels than the endometrial cell lines
investigated (MFE and Ishikawa) and as such, are an appropriate cell model for the
study of progesterone effects on the NFkB pathway. In keeping with previous
studies (Miller and Hunt, 1998; Wissink, et ah, 1998), progesterone was found to
upregulate IkBcc mRNA expression. This is thought to inhibit NFkB and is likely to
occur as a direct result of increased transcriptional activity. Expression of the protein
kinases and IKKy was not affected by progesterone during the 24 hour timecourse.
However, the results suggest that in the presence of cAMP elevating agents,
progesterone (and IL-10) reduces mRNA expression of NIK. Therefore, it is possible
that, under circumstances where cAMP levels are raised, progesterone may inhibit
NFkB activity via this mechanism. However, the results presented are inconclusive
and further investigation is necessary. The following text discusses the results in the
context of menstruation and early pregnancy.
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7.2 Regulation of inflammatory mediators during menstruation
Menstruation is characterized by an inflammatory like reaction which involves
increased inflammatory mediator expression, leukocyte infiltration and tissue oedema
(Kelly, 1994). The NFkB pathway regulates the expression of several inflammatory
molecules which are involved in menstruation e.g. IL-8, COX-2 (Adcock, et al.,
1997; Mukaida, et al., 1990). The results presented in this thesis support a role for
the NFkB pathway in the events associated with menstruation. The increased
expression of the endogenous inhibitor, IkBoc, in the perimenstrual phase suggests
that NFkB is activated at this time. Premenstrual progesterone withdrawal will
activate NFkB causing upregulation of IkBoc. Also, the IKK-like kinase, TBK1, is
upregulated in the perimenstrual phase indicating that this kinase may be involved in
signalling to NFkB during menstruation. Activation of NFkB prior to, and during,
menstruation is likely to contribute to the upregulation of inflammatory mediator
expression which has been reported to occur at this time. In turn, this will mediate
events such as leukocyte recruitment and tissue degradation.
The results described in this thesis suggest that the CD40-CD40L system may
contribute to NFkB activation during menstruation. The CD40-CD40L system is
likely to be involved in mediating interactions between resident structural cells and
infiltrating leukocytes (Smith, et al., 1997). Such leukocytes are a likely source of
CD40L in endometrium. CD40L has also been reported to be produced by platelets
(Henn, et al., 1998). Previously, it has been shown that CD40 engagement increases
IL-8 production and COX-2 expression in fibroblasts (Sempowski, et al., 1997a;
Sempowski, et al., 1998; Zhang, et al., 1998). The expression of CD40 in the
endometrial perivascular region is consistent with a role in the upregulation of IL-8,
COX-2 and MCP-1 which occurs in this area premenstrually (Critchley, et al., 1999;
Jones, et al., 1997). Regulation of these mediators may occur by CD40 activation of
the NFkB pathway and will contribute to leukocyte recruitment. A role in
endometrial repair processes during menstruation is also likely as leukocytes are
known to be involved in this (Salamonsen, 2000). CD40L-expressing leukocytes may
activate CD40 present on endometrial myofibroblasts. Myofibroblasts are involved
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in wound healing (Schurch, et al., 1992) and therefore it is possible that activation of
these cells could contribute to the repair mechanisms involved in the final stages of
menstruation. The contribution of the NFkB pathway and CD40 to events associated



















7.3 Regulation of inflammatory mediators in early pregnancy
High progesterone levels prevail in pregnancy resulting in local immunosuppression
and anti-inflammatory actions (Siiteri and Stites, 1982). Consistent with this, the
results presented here indicate the downregulation of proinflammatory signalling to
NFkB in early pregnancy. This is demonstrated by the decreased mRNA expression
of MEKK1 and IKK(3 (IKK(3 mediates inflammatory signals). However, in contrast
there is upregulation of NIK and IKKa expression. IKKa has been reported to be
involved in morphogenic signalling to NFkB in mice although the implications of
this are unclear. In decidua, NIK and IKKa may be involved in the differentiation
events that occur as decidualization is completed during early pregnancy.
Alternatively, involvement in regulation of mediator expression (e.g. COX-2) in
decidua is possible. In addition to the upregulation of the NIK-IKKa pathway in
decidua there is also increased mRNA expression of CD40 and CD40L. This system
may have a similar role to that of NIK-IKKa and indeed, may activate this pathway.
Also, as there is a large number of lymphoid cells in first trimester decidua (Loke and
King, 1995) CD40 may be involved in interactions between these cells and decidual
stromal cells.
SLPI may also contribute to the anti-inflammatory processes associated with
pregnancy. SLPI expression is apparent in endometrium at the time of implantation
and in first trimester decidua and its expression is under progesterone control. SLPI
has been reported to have antimicrobial activity and this suggests that it may be part
of the innate defence against infection that is crucial to successful pregnancy. Both
the temporal and spatial expression profile of SLPI is consistent with such a role.
SLPI is also likely to contribute to suppression of proinflammatory mediator
expression via inhibitory actions on the NFkB pathway. It is acknowledged that
there are additional possible roles for SLPI in endometrium including inhibition of
neutrophil actions, control of trophoblast invasion and auto/paracrine effects.
However, the data presented in this thesis is most consistent with a protective role
during pregnancy. The roles of the NFkB pathway, CD40 and SLPI in early
pregnancy are detailed in Figure 55.
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Figure 55: The role of the NFkB pathway, CD40-CD40L system and SLPI in early
pregnancy. The intermediates in the NFkB pathway are differentially regulated in
first trimester decidua. The proinflammatory signalling pathway to NFkB (MEKK-
1 -IKK(3) is downregulated while mediators thought to be involved in morphogenesis
(NIK-IKKa) are increased. This suggests that NFkB may have a role in controlling
expression of mediators that are crucial to pregnancy and also, those involved in
growth and differentiation. The CD40-CD40L system may contribute to this by
activating NFkB via NIK and IKKa. SLPI is an anti-inflammatory molecule that has
an expression profile consistent with an antimicrobial role in pregnancy. It may also
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7.4 Suggestions for Future Study
1. The current study details the effects of progesterone on the NFkB pathway in a
breast cancer epithelial cell line and examines the pathway in whole endometrial
and decidual biopsies. However, as detailed earlier, the endometrial perivascular
cells are the predominant site of progesterone receptor expression in the late
secretory phase of the cycle (Wang, et al., 1998). This suggests that, if NFkB
activation occurs as a direct result of premenstrual progesterone withdrawal, it is
these cells which will be most affected. Several questions should be addressed.
Which NFkB pathway intermediates are expressed by the perivascular cells? Are
these intermediates regulated by progesterone? Is NFkB activated in these cells
premenstrually?
2. CD40 was shown to be present on the endometrial perivascular cells. Previous
studies have suggested that these cells are of myofibroblast lineage and that they
express COX-2, IL-8 and MCP-1 (Critchley, et al., 1999; Jones, et al., 1997;
Oliver, et al., 1999). Are CD40, myofibroblast markers and these inflammatory
mediators coexpressed in the same cells? If so, does engagement of CD40 on
these cells result in increased expression of COX-2, IL-8 and MCP-1? Does
CD40 activate NFkB in the perivascular cells and is this responsible for the
upregulation of mediators?
3. The localization of CD40L expressing cells in endometrium was not possible
during this study. However, the identification of such cells in endometrium and
other reproductive tissues is crucial to our understanding of the role of the CD40-
CD40L system. Which cell types express CD40L?
4. This study has suggested that SLPI has an antimicrobial and anti-inflammatory
role in endometrium and decidua. SLPI binding sites have been detected in
monocytes (McNeely, et al., 1997). Are similar binding sites present in
endometrium and decidua? What are the results of the interaction of SLPI with
these sites?
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5. Similar to menstruation, parturition and cervical ripening are associated with
inflammatory responses. Both are characterized by increased expression of
inflammatory mediators and leukocyte infiltration. This suggests that NFkB
activation may also be involved in these reproductive events. Indeed, it has been
reported that the nuclear localization of the p65 subunit of NFkB increases with
advancing gestation (Gibb, et al., 2000). Also, the finding that CD40 is expressed
by both myometrium and cervix suggests that this system is present and may
contribute to activation of NFkB. Are the various NFkB pathway intermediates
expressed by cervix, myometrium, term decidua and fetal membranes and in
which cell types? Are any of the intermediates upregulated immediately prior to,
or during, parturition or in the case of infections associated with preterm labour?
6. Pathophysiological reproductive events are also likely to involve the NFkB
pathway and systems that interact with it. For example, menstrual problems such
as menorrhagia and dysmenorrhea are associated with abnormal prostaglandin
production. Is there aberrant activation of the NFkB pathway or abnormal
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Appendix 1: General Materials
TISSUE COLLECTION SOURCE
RPMI 1640 medium Sigma, Poole, Dorset, UK
NBF See Appendix 2
Hanks Balanced Salt Solution Life Technologies Ltd., Paisley, UK
HEPES Flow Laboratories, Irvine, UK
Phosphate buffered saline Sigma
Sucrose Sigma
OCT freezing compound Tissue-Tek, Elkhart, USA
RNA EXTRACTION SOURCE
Tri Reagent Sigma
Ultraspec RNA Isolation System Biogenesis Ltd., Poole, UK
chloroform BDH Laboratory Supplies, Poole, UK
isopropanol Sigma-Aldrich Co. Ltd.
ethanol Hayman Ltd., Essex, UK
RNA storage solution Ambion Inc, Austin, Texas, USA
RT-PCR SOURCE




neutral buffered formalin (NBF) see Appendix 2
phosphate buffered saline (PBS) see Appendix 2
PBS + Tween see Appendix 2
hydrogen peroxide BDH
horse/goat serum Vector Laboratories, Peterborough, UK
0.01M sodium citrate see Appendix 2
mouse/rabbit immunoglobulin Vector Laboratories
goat immunoglobulin R&D Systems, Oxford, UK
anti-NIK
Santa Cruz Biotechnologies Inc,
California, USA
anti-IKKcc Santa Cruz Biotechnologies Inc
anti-CD40 Dr. Ed Clark, Seattle, Washington, USA
anti-Thy-1 Clone F15-421-5 (Smith, et al., 1995)




anti-cytokeratin Dako Ltd., Cambridge, UK
biotinylated horse a mouse/ goat
a rabbit/ horse a goat
Vector Laboratories
avidin-biotin complex (ABC)
Elite ABC 6101, Vector Laboratories or
Dako Ltd.
diaminobenzidine Vector Laboratories or Dako Ltd
Harris's haematoxylin
Pioneer Research Chemicals Ltd,
Colchester, UK
histoclear
National Diagnostics, Atlanta, Georgia,
USA
pertex Cellpath pic, Hemel Hempsted, UK
xylene BDH
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TISSUE & CELL CULTURE SOURCE
polypropylene capillary matting Garden Centre







24 well culture plates Corning Costar, High Wycombe, UK
25cm2 culture flasks Corning Costar




epidermal growth factor (EGF) Sigma
forskolin Sigma
indomethacin Sigma





TISSUE & CELL CULTURE SOURCE
Interleukin-6 (IL-6) R&D Systems
lipopolysaccharide (LPS) - E. coli Sigma
lipoteichoic acid (LTA) Sigma
MG132
Biomol Research Laboratories Inc.,
Plymouth Meeting, PA, USA
oestradiol Sigma
phorbol, 1-myristate, 13-acetate (PMA) Calbiochem, Nottingham, UK
progesterone Sigma
prolactin
Gift from Prof. A. McNeilly, Medical
Research Council, Human Reproductive
Sciences Unit, Edinburgh
prostaglandin E2 (PGE2)
Gift from Control Therapeutics, East
Kilbride, UK
prostaglandin F2a (PGF2J




tumour growth factor a (TGFa) Peprotech
tumour necrosis factor a (TNFa) Sigma
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ELISA SOURCE
96 well assay plates Nunc Maxi-Sorp, Gibco, Paisley, UK
recombinant SLPI R&D Systems
anti-SLPI R&D Systems
peroxidase labeled anti-sheep/goat IgG
Fab fragments
Boehringer Mannheim, Lewes, UK
IL-8 standard Toray Industries, Tokyo, Japan
anti-IL-8 detection antibody R&D Systems
anti-IL-8 coating antibody R&D Systems
carbonate buffer see Appendix 2
PBS Sigma
blocking/protecting solution see Appendix 2
wash buffer see Appendix 2
substrate see Appendix 2
2N sulphuric acid BDH
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Appendix 2: Recipes for solutions
All chemicals listed were from Sigma and all dilutions were in distilled water
otherwise stated.
1. Blocking/protecting solution
In 1 litre: 20g polyvinylpyrollidone 2%
5g BSA
lml preservatives Boehringer Mannheim
1.9g EDTA
6.1 g Tris
2. Carbonate coating buffer














lml tetramethyl benzidine : 1ml urea hydrogen peroxide : 10ml sodium acetate
lOOmM sodium acetate






0.5% in 50mM sodium acetate, pH6
5. ELISA wash buffer




Dilute 1:20 to use
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6. Neutral buffered formalin (NBF)




7. Phosphate buffered saline (PBS)
In 1 litre: 5 PBS tablets
pH 7.4-7.6
8. PBS + Tween




9. 0.1M sodium citrate buffer
In 1 litre: 29.4g Tri-sodium citrate BDH
O.lg sodium azide
pH 6
Diluted 1:10 to use
10. Tris buffer
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Presence of secretory leukocyte protease inhibitor in human
endometrium and first trimester decidua suggests an antibacterial
protective role
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Secretory leukocyte protease inhibitor (SLPI) is a neutrophil elastase inhibitor which also has antibacterial
and anti-inflammatory properties. It is found associated with mucosal membranes. Although SLPI has been
reported in the cervix it has not thus far been reported in human endometrium. This study investigates the
presence of SLPI in endometrium, first trimester decidua and trophoblast. Cultured first trimester decidua
was found to produce 4.7 ± 2.0 ng/mg/24 h of SLPI. Endometrium and trophoblast were both found to
secrete significantly lower amounts of SLPI {P < 0.01) although endometrial expression was menstrual cycle
dependent with increased secretion in the secretory phase. Although relatively low concentrations of SLPI
were released from the endometrium during culture, most of the SLPI remained associated with the tissue
and could be recovered with mild acid extraction. This is in agreement with the high isoelectric point (pi) for
SLPI, associated with high solubility at low pH. The main site of SLPI synthesis in endometrium and decidua
was found to be the glandular epithelium. An antibiotic role for SLPI in the endometrium and decidua during
implantation and pregnancy would be consistent with the expression profile and localization of SLPI.
Key words: defensins/endometrium/epithelial glands/natural antibiotics/SLPI
Introduction
Secretory leukocyte protease inhibitor (SLPI) is a 11.7 kDa
cysteine-rich protein found associated with mucosal surfaces,
e.g. lung and cervix (Franken et al., 1989). SLPI is produced
by neutrophils (Bohm et al., 1992), macrophages (Jin et al.,
1997) and epithelial cells (Abe et al., 1991). SLPI is thought
to function mainly as a serine protease inhibitor (serpin) and
has been characterized as a critical inhibitor of neutrophil
elastase in the lung (Thompson and Ohlsson, 1986). There is
evidence to suggest that SLPI has a protective function at
mucosal membranes. SLPI has been shown to kill both
Escherichia coli and Staphylococcus aureus, thus showing
bactericidal activity against gram-negative and gram-positive
bacteria (Hiemstra et al., 1996). Antiviral (McNeely et al.,
1995) and antifungal (Tomee et al., 1997) effects have also
been observed. Secondly, evidence suggests that SLPI acts to
inhibit various proinflammatory systems. For example, in
mouse macrophages SLPI inhibits the actions of lipopoly-
saccharide (LPS) (Jin et al., 1997). Also in human monocytes,
SLPI decreases the production of matrix metalloproteinases
(responsible for extracellular matrix degradation) via suppres¬
sion of a cyclo-oxygenase-2/prostaglandin E2/cAMP pathway
(Zhang et al., 1997). Receptors for SLPI have been identified
in human monocytes (McNeely et al., 1997). Finally, SLPI
inhibits activation of the NFkB signal transduction pathway
(Jin et al., 1997) which is a major inducer of proinflammatory
genes. SLPI is thus a pleiotropic molecule protecting against
inflammatory insult and infection in a variety of ways.
In a reproductive context, SLPI has been detected in human
cervical mucosa (Casslen et al., 1981), term decidua (Denison
et al., 1999) and seminal plasma (Franken et al., 1989). It has
also been localized to the glandular and luminal epithelial cells
of maternal endometrium of pig (Reed et al., 1996) and the
mRNA has been detected in horse and cow endometrium
during pregnancy (Badinga et al., 19<J4). It has been suggested
that SLPI acts to maintain the utefine-placental border in
these species and that expression is related to epitheliochorial
placentation. SLPI has not been detected in the endometrium
of mammals with haemochorial placentation (e.g. rat) (Badinga
et al., 1994) and previous studies have failed to detect the
protein in non-pregnant human endometrium (Casslen et al.,
1981; Franken et al., 1989), although SLPI has been found to
be present in uterine fluid (Casslen et al., 1981). Successful
human pregnancy demands that inflammatory responses in
the uterus are suppressed and, as an antibacterial and anti¬
inflammatory molecule, it seems probable that SLPI may
contribute to this. This study investigates the expression of
SLPI by human endometrium, decidua and trophoblast.
Materials and methods
Tissue collection
Endometrial biopsies were collected from women undergoing
gynaecological procedures for benign conditions. No attempt was
made to distinguish between subjects with normal menstrual loss and
undergoing a laparoscopic procedure for sterilization and subjects
describing heavy menstrual loss and undergoing investigation or
treatment (hysterectomy) for this subjective complaint. All women
reported regular menstrual cycles (25-35 days) and had not received
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any form of hormonal treatment in the 3 months preceding biopsy.
Biopsies were dated from the patient's last menstrual period (LMP);
histological dating according to published criteria (Noyes et al., 1950)
was consistent with the date of LMP. Furthermore, circulating sex
steroid concentrations were in keeping with the time in the cycle
during which the biopsy was collected. Serum was separated from
venous blood samples collected at the time of biopsy. Oestradiol and
progesterone concentrations were measured by radioimmunoassay.
The inter-assay coefficients of variation for the oestradiol and
progesterone assays were 11.0 and 9.0% respectively, while the intra-
assay coefficients of variation were 8.0 and 7.0% respectively.
Oestradiol concentrations were in the range 0^145 pmol/1 in the
proliferative phase; all progesterone concentrations were <6 nmol/1.
In the secretory phase, oestradiol concentrations were in the range
65-740 pmol/1; progesterone concentrations were >6 nmol/1 (with
the exception of two premenstrual samples).
In addition, endometrium was collected from women using a
levonorgestrel intrauterine system (LNG-IUS; n = 4) for contracep¬
tion and heavy menses. The LNG-IUS causes marked decidualization
of the endometrium (Critchley et al., 1998).
First trimester decidua were collected by curettage of the uterine
wall away from the site of implantation prior to suction termination
of pregnancy. Trophoblastic villi were also collected during the
procedure. Decidual parietalis (without trophoblast) was subsequently
confirmed by examination of haematoxylin and eosin-stained sections.
Tissue samples were collected in Roswell Park Memorial Institute
(RPMI) 1640 medium (Sigma, Poole, Dorset. UK); in addition,
endometrial biopsies were fixed in 10% neutral-buffered formalin
(NBF) overnight at 4°C, stored in 70% ethanol, and then embedded
in wax. Written informed consent was received from all patients prior
to biopsy collection and ethical approval was received from Lothian
Research Ethics Committee.
Tissue culture
All tissue was cultured for 24 h on sterilized polypropylene capillary
matting in RPMI 1640 (Sigma) supplemented with 10% fetal calf
serum (Mycoplex, PAA Laboratories, Teddington, UK), penicillin
(50 |ig/ml; Sigma), streptomycin (50 pg/ml; Sigma) and gentamycin
(5 pg/ml; Sigma). Endometrium and decidua were cultured in the
presence of oestradiol (10~8 mol/l). The culture medium was removed
after 24 h for subsequent inclusion in SLPI assays. Tissue was
weighed after incubation and all assay measurements were corrected
for weight.
Acid extraction of tissue
SLPI is an acid-stable molecule with a high isoelectric (pi) point and.
therefore, more soluble in weak acid solution. After 24 h culture,
tissue was acid extracted in the presence of 200 pi phosphate-buffered
saline (PBS) and 10 pi HC1 (1 N) for 10 min. Neutralization was
achieved by addition of 10 pi NaOFl (IN) and 50 pi Tris buffer
(1 mol/l; pH 7.2). Supernatant was collected for subsequent inclusion
in SLPI assays.
SLPI assay
SLPI was measured by an enzyme-linked immunosorbent assay
(ELISA). Assay plates (96-well; Nunc Maxi-Sorp, Gibco, Paisley,
UK) were coated with 0.025 pg/ml recombinant SLPI (R&D Systems,
Oxford, UK) in PBS and 1% 400 mmol/1 carbonate buffer. 100 pi
were added to each well. Plates were left for 60 min at room
temperature. Blocking was carried out with 400 pl/well blocking/
protecting solution [polyvinylpyrrolidone 2%, bovine serum albumin
(BSA) 5 mg/ml, preservatives, EDTA 5 mmol/I, Tris 50 mmol/1] for
30 min. Plates were washed with wash buffer (150 mmol/1 NaCl,
100 mmol/1 Tris, 0.05% Tween-20; pH 7-7.5). 150 pi of standard/
sample and 50 pi of anti-SLPI (R&D Systems); 2 pg/ml; diluted in
ELISA buffer (150 mmol/1 NaCl, 100 mmol/1 Tris, 50 mmol/1 Phenol
Red solution, 2 mmol/1 EDTA, 1 mmol/1 2-methylisothiazolone)
(Boehringer Mannheim, Lewes, UK). 1 mmol/1 bromonitrodioxane
(Boehringer Mannheim), 2 mg/ml BSA, 0.05% Tween-20; (pH 7.2)
were added to each well. A non-specific binding well (200 pi buffer
only) and two B0 wells (150 pi buffer; 50 pi anti-SLPI) were
included on each plate. Standards were added in triplicate and their
concentration range was from 50-0.098 ng/ml. Incubation was on a
plate shaker at room temperature for 2 h; and the plates were
then washed. 100 pl/well of peroxidase-labelled anti-sheep/goat
immunoglobulin G (IgG) Fab fragments raised in donkey (Boehringer
Mannheim; 1:1000 dilution of stock in ELISA buffer) were added.
Incubation was on a shaker as before and the plates were washed
again. 200 pi substrate (0.3 g/1 urea-hydrogen peroxide, 0.1 g/1
tetramethyl benzidine in 100 mmol/1 sodium acetate; pH 6) were
added to each well. After 2-10 min, wells were quenched with 50
pl/well 2 N sulphuric acid. Plates were read in a plate reader at 450 nm.
Immunohistochemistry
Tissue sections were dewaxed in histoclear (National Diagnostics,
Atlanta, Georgia, USA) and rehydrated in descending grades of
alcohol. Non-specific endogenous peroxidase activity was blocked by
treatment with 3% hydrogen peroxide (BDH Laboratory Supplies,
Poole, UK) in distilled water for 10 min at room temperature. All
tissue sections were subjected to a non-immune block with diluted
normal horse serum (Vectastain 4002; Vector Laboratories,
Peterborough, UK) for 20 min in a humidified chamber at room
temperature. Tissue sections were then incubated overnight at 4°C
with 50 pi of goat anti-SLPI antibody (1:400 in horse serum; R&D
Systems). In negative control sections the primary antibody was
substituted with goat immunoglobulin (R&D Systems). Sections
were then incubated with biotinylated horse-anti goat IgG (Vector
Laboratories) followed by an avidin-biotin peroxidase detection
system (both for 60 min at room temperature; Elite ABC 6101; Vector
Laboratories). The peroxidase substrate diaminobenzidine (DAB;
Vector Laboratories) was used to identify positive staining. Sections
were then counterstained with Harris's haemotoxylin (Pioneer
Research Chemicals Ltd, Colchester, UK), dehydrated in ascending
grades of alcohol and mounted from xylene in Pertex (Cellpath pic,
Hemel Hempsted, UK).
SLPI reverse transcription-polymerase chain reaction
(RT-PCR)
Tissue samples were immersed in Ultraspec (Ultraspec RNA Isolation
System, Biogenesis Ltd, Poole, UK), homogenized and RNA was
extracted as detailed in the manufacturer's protocol.
Decidual and endometrial RNA samples were reverse transcribed
using random primers with MgCL (5.5 mmol/1), dNTPs, random
hexamers (2.5 pmol/1). RNAase inhibitor (0.4 IU/pl) and multiscribe
reverse transcriptase (1.25 IU/pl; all from PE Biosystems, Warrington,
UK). The mix was divided into aliquots in individual tubes (8 pi/
tube) and template RNA was added (2 pl/tube of 100 ng/pl RNA).
Mineral oil was added and samples were incubated for 60 min at
25°C, 45 min at 48°C and then at 95°C for 5 min.
A reaction mix was made containing Taqman buffer, MgCL
(5.5 mmol/1), dATP (200 pmol/1), dCTP (200 p mol/l), dGTP
(200 mmol/1). dUTP (400 pmol/1), ribosomal 18S forward and reverse
primers and probe (all at 50 nmol/1), SLPI forward and reverse
primers (both 300 nmol/1), SLPI probe (200 nmol/1), AmpErase UNG
(0.01 IU/pl) and Amplitaq Gold DNA polymerase (0.025 IU/pl; all
































Figure 1. (a) Secretory leukocyte protease inhibitor (SLPI)
production by control endometrium (throughout cycle),
endometrium from levonorgestrel-intrauterine system users (LNG-
IUS), decidua and trophoblast (a'bP < 0.01). Numbers in the groups
are shown immediately above the error bars, (b) SLPI production
by control endometrium from the proliferative, early/mid-secretory
(ES/MS) and late secretory (LS) phases of the menstrual cycle
(a-bP < 0.0001).
separate tubes for each cDNA sample. 1 pl/replicate of cDNA was
added to each tube. After mixing 23 pi of sample was added to the
wells on a PCR plate. Each sample was added in triplicate. A no
template control (containing water) was included in triplicate. Wells
were sealed with optical caps and the PCR reaction run on ABI Prism
7700 using standard conditions.
SLPI primers and probe for quantitative PCR were designed using
the PRIMER express program (PE Biosystems). The sequence of the
SLPI primers and probe were forward: GCATCAAATGCCTGGAT-
CCT; reverse: GCATCAAACATTGGCCATAAGTC; probe (Fam
labelled): TGACACCCCAAACCCAACAAGGAGG.
Ribosomal 18S primers and probe were forward: CGGCTACC-
ACATCCAAGGAA; reverse: GCTGGAATTACCGCGGCT; probe
(Joe labelled): TGCTGGCACCAGACTTGCCCTC.
The concentrations of SLPI primers and probe used in the PCR




Figure 2. Secretory leukocyte protease inhibitor (SLPI) release
during acid extraction of control endometrium, decidua and
trophoblast (a bP < 0.05).
standard pool of RNA. Within assay variation of the PCR measurement
of SLPI in cDNA was calculated from six replicates.
A PCR using the above primers (but excluding the probe) was run
with identical conditions to the quantitative run. The product was run
on an agarose gel to demonstrate amplification of a single product.
Statistical analysis
Significant difference was determined by analysis of variance
(ANOVA) (Statview 3.0) and individual differences were assigned
using Fisher's protected least squares differences (PLSD) test.
Results
SLPI secretion by endometrium, decidua and
trophoblast
Decidua (n = 17) produces 4.7 ± 2.0 ng/mg of SLPL This is
significantly higher (P < 0.01) than secretion by either
endometrium or trophoblast which produce 0.4 ± 0.1 ng/mg
and 0.1 ± 0.04 ng/mg respectively. Endometrium from LNG-
IUS users produces 1.4 ± 1.0 ng/mg. This is similar to
production by control endometrium (Figure la).
SLPI secretion by endometrium increases in the late
secretory phase of the menstrual cycle. Secretion is 1.5 ±
0.2ng/mg at this time, compared with 0.2 ± 0.02ng/mg in the
proliferative phase and 0.3 ± 0.1 ng/mg in the early/mid-
secretory phase (Figure lb; late secretory compared with
proliferative and early/mid-secretory, P < 0.0001).
SLPI release from endometrium, decidua and tropho¬
blast during acid extraction
Endometrium releases 1185 ± 298% (of SLPI in control culture
medium) during acid extraction whereas decidua releases only
150 ± 43%. Release from trophoblast (210 ± 72%) is also
lower than from endometrium. (Figure 2; P < 0.05). This
suggests that the majority of SLPI produced by endometrium
is not secreted into the culture medium. The result from one
decidual sample was discounted from this analysis as the value
was 11805% (i.e. 94 SD from the mean of the other values).
Localization of SLPI in endometrium and decidua
Immunohistochemistry showed positive SLPI immuno-
reactivity in the glandular epithelium and secretions in endo-
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Figure 3. Immunohistochemical localization of secretory leukocyte protease inhibitor (SLPI) in human endometrium and decidua.
(a) Proliferative endometrium. No immunoreactivity is present, (b) Mid-secretory endometrium. Immunoreactivity is present in the epithelial
cells and secretions of the glands. No immunostaining is observed in the stroma, (c) First trimester decidua. SLPI immunoreactivity is
present in the glandular epithelium and secretions. Immunostaining is present in stromal cells, (d) Negative control (primary antibody
replaced with goat immunoglobulin at equimolar concentrations). Scale bars = 100pm.
metrial biopsies from the mid to late secretory phase.
Immunostaining was also present in the luminal epithelium of
some biopsies. The immunoreactivity was mainly localized to
superficial areas of endometrium. No stromal staining occurred
(Figure 3b). Very little SLPI was detected in proliferative and
early secretory phase biopsies (Figure 3a).
SLPI immunostaining was also present in the epithelial
cells of the glands and their secretions in decidual biopsies.
Immunoreactivity was also found in the stromal cells of some
decidua (Figure 3c).
SLPI RT-PCR
The accuracy of the quantitative PCR was tested by serial
dilution (to 64X dilution) of a pool of SLPI cDNA. The slope
of the line plotting the cycle number at which the curve
crossed a threshold (Ct) against dilution had a gradient <0.1 ACt
units/64 X dilution. Intra-assay precision of the PCR was
calculated as 9.7% (r.s.d). All data were obtained from a single
PCR run and related to a standard SLPI cDNA preparation
using the formula 2_AAQ which relates the ratio of 18S and
specific amplicon in the sample cDNA with that of the standard
preparation.
SLPI mRNA was detected in all samples tested. Decidua
contained 0.6 ± 0.3 of SLPI mRNA. This was greater
than both proliferative and secretory endometrium which had
0.2 ± 0.1 and 0.5 ± 0.2 respectively (Figure 4a; not significant).
Figure 4b shows that only one PCR product (representing
SLPI) is amplified by the SLPI primers.
Discussion
To our knowledge this is the first report describing detection
of SLPI in human endometrium and first trimester decidua.
Previously, immunohistochemistry has failed to detect SLPI
in human endometrium in either the proliferative or secretory
phase of the menstrual cycle. However, SLPI was found to be
present in uterine fluid and this was thought to be due to
diffusion from the cervix (Casslen et al., 1981). It now seems
likely that the source of this SLPI was endometrial glandular
epithelial cells. This is consistent with the production of SLPI
by epithelial cells at other mucosal surfaces such as lung.
SLPI has previously been detected in term decidua where it
was found to be localized to the large decidualized stromal
cells (Denison et al., 1999). In first trimester decidua, SLPI
was expressed mainly in the glandular compartment of the
tissue although some stromal cells did contain SLPI. This
suggests that as pregnancy progresses the site of SLPI produc¬
tion changes from the glandular epithelium to the stromal
cells. A similar change of location has been reported in the






1 2 3 4 5 6 7
Figure 4. (a) Amounts of secretory leukocyte protease inhibitor
(SLPI) mRNA in decidua and proliferative and secretory
endometrium, (b) Agarose gel of polymerase chain reaction (PCR)
products showing only one amplification product. Lanes 1-3 show
no template controls. Lanes 4-6 show replicate samples from one
patient containing SLPI. The product corresponds to the product
length expected for SLPI (-110 bp). Lane 7 contains PCR markers.
in the glandular epithelium in secretory endometrium but at
the time of menstruation and in decidualized tissue the receptor
is also present in stromal cells (Kohnen et al., 1998). It may
be that as glands become atrophied as decidualization progesses
it is necessary for the stromal cells to produce glandular
products in order to maintain decidual function. Trophoblast
was found to secrete very little SLPI and is unlikely to be a
major source during pregnancy.
In non-pregnant endometrium, SLPI secretion shows cycle
dependence with an increase in the mid to late secretory phase.
This suggests progesterone regulation of SLPI although it is
likely that this effect is indirect rather than a direct action of
progesterone on SLPI gene expression. For example, changes
to glandular morphology (e.g. increased surface area) occur
and there are variations in inflammatory mediator expression
under the influence of progesterone. Such effects may lead
to secondary changes in endometrium, e.g. increased SLPI
production. SLPI expression increases particularly in the late
secretory phase around the time of decidualization and
implantation and then increases further in decidua. The amounts
of mRNA present are consistent with the protein expression
pattern found. Leukocytes infiltrate the endometrium prior to
menstruation and may be responsible for the rise in SLPI in
the late secretory phase. However, this would be inconsistent
with the increased presence of SLPI in decidua. Additionally,
immunostaining suggested that the main source of SLPI
RRKPGKCPVTYGQCLMLNPPNFCEMDGQCKRDL KCCMGMCGKSCVSPVKA
RSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK
Figure 5. Comparison of secretory leukocyte protease inhibitor
(SLPI) (upper sequence) and human (3-defensin 1 (lower sequence)
amino acid sequence.
in endometrium is the glands. Decidualization may be a
contributory factor in SLPI production. LNG-IUS users have
endometrium which is decidualized due to the very high
local concentrations of progestogen (Pekonen et al., 1992).
Levonorgestrol-treated endometrium was found to produce
higher concentrations of SLPI than proliferative endometrium
but similar to those of late secretory endometrium.
Acid extraction of tissue was performed to ensure that
the SLPI values measured in culture medium were a true
representation of SLPI production by the tissue. Acid extraction
of tissue resulted in release of SLPI from endometrium at
concentrations much greater than those found during culture.
Decidua and trophoblast released similar amounts of SLPI
during culture and acid extraction. This suggests that SLPI
production by endometrium far exceeds secretion although
this may reflect in-vitro culture conditions. SLPI has been
found to bind to endometrial extracellular matrix (Reed et al.,
1997) and it may be that acid extraction is causing release of
bound protein.
As a potent neutrophil elastase inhibitor, SLPI may have a
role in the prevention of tissue degradation in the endometrium.
Neutrophils infiltrate the tissue during menstruation (Poropatich
et al., 1987) and may contribute to tissue breakdown. SLPI
could act to limit this although is seems unlikely due to: (i)
the superficial localization of the mediator; and (ii) the
increased release of SLPI in pregnant decidua.
It has been suggested that in mammals which have
epitheliochorial placentation, SLPI acts in maternal endo¬
metrium to maintain the integrity of the uterine-placental
border by preventing inappropriate trophoblast invasion
(Badinga et al., 1994). In humans, trophoblast cells invade
throughout the decidua and into the myometrium, so SLPI is
unlikely to regulate this invasion because of its localization
primarily in the superficial endometrium.
SLPI has been found to have antibacterial, antiviral and
antifungal effects and it has previously been suggested that its
presence in the cervix and the male genital tract (with high
concentrations in semen) protects these mucosal membranes
from insult (Ohlsson et al., 1995). Endometrial production of
SLPI could offer similar protection against infection of the
uterus around the time of implantation and during pregnancy.
Ascending infection is a major cause of premature labour, so
natural antibiotics are likely to be important in controlling
this. The location and expression profile of SLPI is consistent
with an antibacterial role during pregnancy.
The defensins are a group of proteins found to have
antibacterial, antifungal and antiviral actions. Defensin 5 and
P-defensin 1 have been identified in epithelial cells of the
endometrium and endocervix (Quayle et al., 1998; Valore
et al., 1998). In addition, defensin 5 expression was found to
be maximal in endometrium during the secretory phase of the
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cycle (Quayle et al., 1998). One area of the SLPI molecule
has 37% homology with the defensins and five or six cysteine
residues involved in disuphide bonding are conserved between
the proteins (Figure 5). Interestingly this area of homology
does not coincide with the /V-terminus of the SLPI molecule
which is thought to be involved in antibacterial activity
(Hiemstra et al., 1996). The similarities in protein sequence
and expression of SLPI and the defensins gives further support
to an antibacterial role for SLPI in endometrium.
Some bacteria secrete proteins which degrade SLPI implying
that without this breakdown SLPI would pose a risk to the
pathogen. Trichomonas vaginalis, a major pathogen of the
lower female genital tract, releases cysteine proteases which
degrade recombinant SLPI under assay conditions (Draper
et al., 1998). It has been reported that there may be an
association between irregular menstrual bleeding and the
presence of bacteria in the uterus (Kristiansen et al., 1987;
Moller et al., 1995). Our study does not attempt to distinguish
between patients with normal and heavy menstrual loss. Indeed,
all patients included in the present study reported regular
menstrual cycles. Further study is required to determine
concentrations of SLPI in endometrium during uterine infection
or in the context of aberrant menstrual bleeding patterns.
In addition to the antibacterial effects, SLPI also inhibits
the NFkB signal transduction pathway (Jin et al., 1997). This
is a major pathway involved in inflammatory response. SLPI
may have anti-inflammatory actions in decidua via inhibition
of NFkB. This would prevent inappropriate inflammatory
mediator expression during pregnancy.
In summary, SLPI has been detected for the first time in
human non-pregnant endometrium and first trimester decidua.
The most likely role of SLPI in this location is as a natural
antibiotic and anti-inflammatory molecule. Infection ascending
through the cervix could pose a threat to the implanting and
developing conceptus. Indeed, the presence of high concentra¬
tions of SLPI in decidua might be some compensation for the
immunosuppressive factors present in decidua of pregnancy.
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